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ABSTRACT 
Adipose tissue expresses high levels of angiotensinogen ( agt), the only known precursor 
of Angiotensin II (Ang IQ and we have previously shown that this hormone plays a paracrine role 
in regulation of adipocyte metabolism by increasing activity and gene expression of two key 
lipogenic enzymes, fatty acid synthase (FAS) and glycerol-3-phosphate dehydrogenase (GPDH). 
However, molecular mechanisms by which Ang II regulates an adipocyte lipogenic gene, namely 
FAS and transcription factors mediating this regulation are largely unknown. Furthermore, 
signaling mechanisms whereby Ang II induces adiposity need to be further explored. Accordingly, 
our studies were designed to investigate transcriptional regulation of FAS gene by Ang II and 
determine signaling mechanisms of Ang II leading to activate FAS gene transcription. We 
demonstrated that Ang II responsive element is an E box within adipocyte FAS gene and the 
adipocyte determination and differentiation factorl/sterol-regulatory element binding protein le 
(ADDl/SERBPl c) functions as a transcription factor mediating these actions. Ang II induced 
FAS transcription as well as ADDI gene expression in a glucose-dependent manner. Using 
immunoprecipitation and western blot analyses, we found that Ang II regulates adipocyte 
metabolism via activation of insulin signaling molecules including IR�, IRS, PI-3K and Akt. This 
signaling mechanism was mainly mediated by angiotensin receptor type 1 receptors (ATl )  and in 
part by angiotensin receptor type 2 receptors (AT2). Next, with agt knockout (agt-/-, KO) and 
transgenic (Tg-KO mice expressing agt exclusively in adipose tissue and Tg-WT mice 
overexpressing agt in adipose tissue) mouse models, we examined changes in adipose tissue 
metabolism in vivo and renal gene regulation in these mice and further dissected endocrine effects 
of adipocyte agt. We found that compared with those of WT mice, body weight gain and fat pad 
weight were lower in response to high fat diet in KO mice exhibiting hypotension and renal 
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abnormalities. Targeted expression of the agt gene only in adipose tissue {Tg-KO) partly rescued 
these phenotypes whereas agt overexpression in adipose tissue of transgenic mice (Tg-WT) was 
associated with increased epididymal fat pad mass and blood pressure. Subsequent western blot 
and renal gene expression analyses indicated that adipocyte agt participates in systemic blood 
pressure regulation at least partly by increasing renal agt and ATl receptor production in Tg-WT 
mice. Additionally, microarray data revealed that adipose tissue-specific agt restoration was able 
to correct altered expression of genes associated with blood pressure homeostasis and renal 
function in KO mice. In conclusion, Ang II plays a hypertrophic role in adipocytes by a 
paracrine/autocrine mechanism. Furthermore, adipocyte Ang II exerts endocrine effects on renal 
function and gene expression, thereby contributing to systemic blood pressure regulation and 
kidney homeostasis. This study may provide valuable approaches in treatments of obesity and 
obesity-associated metabolic alternations such as insulin resistance and hypertension. 
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PARTl 
INTRODUCTION 
1 
Angiotensin II (Ang rn, a main effector of the renin-angiotensin system (RAS), is an 
important regulator of vascular tone and electrolyte and water homeostasis and is locally 
synthesized in various tissues including adipose tissue (1 ). In addition to its classical function, 
increasing evidence has suggested putative roles of adipose RAS in the development of obesity, 
which is widespread and increasingly prevalent disease as well as may cause or exacerbate many 
health problems including insulin resistance, type II diabetes, and hypertension (2). Several 
epidemiological studies have reported positive correlations between plasma angiotensinogen (agt) 
levels, plasma renin activity (PRA) and plasma angiotensin-converting enzyme (ACE) activity 
with body mass index (BMI) in different human populations (3-12). Of note, a positive 
relationship between plasma leptin and agt levels in humans was observed and a similar 
relationship with plasma leptin was also described for plasma renin activity, indicating a positive 
association of systemic RAS with obesity ( 10, 12). Genetic studies have also demonstrated an 
association between the agt locus and obesity-related phenotypes in humans (13, 14). Especially, 
the AGT235T variant has been associated with body fatness in women (14). Moreover, a 
significant association of adipose agt expression with obesity has been illustrated. In obese 
humans, agt mRNA expression in subcutaneous and omental adipose tissues is strongly 
associated with increased body mass index and waist-to-hip ratio index (a index of central 
obesity) ( 15-17). The expression of other RAS component genes, renin and ACE in adipose tissue 
was also upregulated in obese subjects (18). This is also true in some animal models of obesity 
(19, 20). Agt secretion in adipose tissue from genetically obese mice (ob/ob and db/db mice) was 
higher than in lean control animals (21 ). A very recent study has reported that diet-induced 
obesity induces agt expression in a depot-specific manner (22). Of importance, multiple 
molecular and clinical studies have emphasized possible roles of RAS in insulin resistance and 
type II diabetes. Specifically, Ang II has been shown to interfere with insulin signaling pathways 
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at multiple levels in vascular smooth muscle cells (VSMC) (23-27). In support of negative effects 
of RAS on insulin sensitivity, the results of two recent clinical trials, Captopril Prevention Project 
(CPP) and Heart Outcomes Prevention Evaluation (HOPE), demonstrated that blockade of the 
RAS, beyond lowering blood pressure, prevent the development of type 2 diabetes (28, 29). Very 
recently, a clinical study has shown that RAS blockade improves insulin sensitivity with 
increased adiponectin plasma levels, insulin sensitizer (30). Moreover, the positive link between 
systemic RAS and obesity-related hypertension has been described in several epidemiological 
studies ( 4, 5, 10, 12). The effects of adipose RAS on obesity-induced hypertension have not been 
addressed until recently. Earlier data from study of Frederich et al. have suggested that changes in 
adipose agt expression contribute to changes in systemic blood pressure associated with fasting 
and refeeding (21 ). This mechanism provides a possible explanation for the refeeding 
hypertension models. Couple of years ago, availability of agt knockout and transgenic models 
provided mechanisms underlying involvement of adipose RAS in systemic blood pressure 
regulation; it was clearly shown that adipose tissue itself contributes to systemic agt 
concentrations. Agt knockout mice are hypotensive, lose large amounts of sodium from the 
kidney and have no detectable agt plasma levels (31-34). Adipose tissue specific reexpression of 
agt results in detectable plasma agt levels, blood pressure normalization and significant enhanced 
ability of sodium reabsorption (31 ). Overexpression of agt in adipose tissue leads to hypertension 
concomitant with elevated adiposity (31 ). Taken together, these observations indicate the close 
association of systemic RAS with obesity and obesity-associated complications. Especially, 
adipose RAS appears to be implicated in the development of obesity and obesity-associated 
insulin resistance and hypertension, although the precise mechanisms responsible for :functional 
roles of RAS in obesity and its related alternations are largely unknown. 
To date, the pivotal actions of Ang II in adipose tissue including growth, metabolism and 
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thermoregulation of brown adipose tissue have been demonstrated by our studies as well as others 
(35-37). Previous data from our lab have shown that Ang II controls fat mass via upregulating 
activities and gene expression of two key lipogenic enzymes, fatty acid synthase (FAS) and 
glycerol-3 phosphate dehydrogenase (GPDH) in human and murine adipose cells (37). In addition, 
Ang II has been demonstrated to increase gene expression and secretion ofleptin, a well-known 
adiposity marker, by adipocytes as well. However, molecular and signaling mechanisms 
underlying Ang II-induced adiposity remain unresolved. 
The purpose of this study was to define potential mechanisms by which Ang II induces 
adiposity and hypertension associated with obesity in a paracrine/autocrine manner. Accordingly, 
our studies were specifically designed to address the following aims: 
Aiml: Investigate the mechanisms by which Ang II regulates adipocyte lipogenic gene, 
FAS and transcription factors mediating this regulation. 
Aim 2: Investigate potential interactions of Ang II signaling with insulin signaling 
pathways. 
Aim 3: Investigate endocrine effects of adipose agt on changes in lipid metabolism in
vivo and renal gene regulation as well as systemic blood pressure regulation using agt knockout 
and transgenic mouse models. 
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A. OBESITY
Obesity is a complex and multifactoral disorder. Its onset and progression have been 
ascribed to genetics, lifestyle and endocrine disorders (1 ). Of note, obesity is a major health 
problem in developed countries and is rapidly becoming a significant health problem in 
developing countries. In the United States, obesity is reaching epidemic proportions: more than 
31 % of adults are clinically obese as defined by a body mass index (BMI) of 30 kg/m2 or higher 
and an additional 33% are overweight. In addition, the number of children and adolescents with 
obesity and type II diabetes has dramatically increased: 11 % of children and adolescents are 
overweight (1, 2). Obesity increases the risk for many disorders that are associated with high 
mortality and morbidity, including diabetes, hypertension, coronary heart disease, dyslipidemia, 
several forms of cancer and gallbladder disease (1 ). 
1. OBESITY AND MORTALITY
It has been reported that obesity-associated diseases cause more than 400,000 deaths 
annually in the United States alone. Previous data from the Nurses' Health study have 
demonstrated a J-shaped relationship between BMI and overall mortality (3). The lowest 
mortality was found among women with BMI of 19.0 to 26.9 kg/m2, but then mortality increased 
steadily as BMI levels rose above 27 kg/m2• Similarly, another cohort study has illustrated that 
obesity and overweight in adulthood are associated with large decreases in life expectancy and 
increases in early mortality (4). 
2. OBESITY AND MORBIDITY
Excessive adipose tissue, particularly caused by abdominal or upper-body obesity, has 
been associated with a number of chronic diseases: insulin resistance, hypertension, 
hyperlipidemia, diabetes, cancer, restrictive lung diseases, gout and degenerative arthritis. The 
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precise association between obesity and each above chronic disease remains poorly understood 
(1). 
2.1 Obesity and Insulin Resistance/Diabetes 
Obesity is associated with insulin resistance and type 2 diabetes. Insulin resistance, a 
defect in the response of muscle, adipose tissue and liver to insulin-mediated glucose transport, 
metabolism and storage, is a prediabetic status. Insulin resistance associated with obesity is 
manifested by decreased insulin-induced glucose transport and utilization in skeletal muscle and 
adipose tissue. These functional defects may be in part due to impaired insulin signaling 
pathways such as insulin binding to its receptors, receptor and insulin receptor substrate (IRS) 
phosphorylation and phosphatidylinositol 3-kinase (PI3K) activation, thus subsequently 
downregulating insulin-responsive glucose transporter, Glut 4 (5). Indeed, decreased expression 
ofIRS-1 and subsequently reduced PI3K activity in adipocytes are evident in obese humans (6). 
In morbid obesity, the expression of insulin signaling molecules is reduced in skeletal muscle (7). 
Additionally, diminished Glut 4 expression or impaired translocation, docking and vesicle fusion 
of Glut 4-containing vesicles is shown in skeletal muscle and adipose tissue of obese subjects (8). 
Further, one of the potential mechanisms for the signaling defects in obesity has been proposed. 
Increases in expression and activity of protein tyrosine phosphatase 1B (PTPlB) and src 
homology 2 domain-containing protein tyrosine phosphatase (SHP), which have shown to 
dephosphorylate the insulin receptor (IR) and IRS-1, were observed in adipose tissue and muscle 
of obese humans and rodents. Accordingly, the obesity-associated insulin signaling defect may be 
in part mediated by activation of these protein phosphatases (9, 10). However, mechanisms 
whereby increased fat mass induces insulin resistance in insulin-sensitive tissues, including liver 
and muscle, remain unclear. To date, two paradigms have been suggested to explain link between 
obesity and insulin resistance: ectopic fat storage syndrome and adipocyte-secreted factors. 
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2.1.1 Ectopic Fat Storage Syndrome 
Lipodystrophy syndrome is characterized by a decrease in adipose tissue mass and 
diabetes. Insufficient adipose tissue leads to excess energy storage as triglycerides in the liver and 
skeletal muscle, and consequently to insulin resistance and diabetes (11). Recently, transgenic 
animals that block adipose tissue development revealed lipid infiltration of skeletal muscle and 
fatty liver along with insulin resistance, glucose intolerance and diabetes (12, 13). The 
transplantation of adipose tissue back into lipoatrophic animals reverses the elevated glucose 
levels ( 14 ). In this context, obesity has been suggested to be another ectopic fat storage syndrome 
(15). Massive obesity also proceeds the progressive overaccumulation oflipid in nonadipose 
tissues including the liver, skeletal muscle and the pancreas, leading to impairment of functions, 
steatosis, and increased ceramide formation, which triggers nitric oxide-mediated lipotoxicity and 
ultimately lipoapoptosis, causing severe diabetes ( 16, 17). In contrast to lipodystrophic diabetes, 
adipose tissue stores are adequate or even large in these patients, reflecting that adipose cells fail 
to maintain their leptin-mediated liporegulatory effect on confining the storage of triglycerides to 
adipocytes. Current study has proposed that the lipid storage in the wrong places may result from 
increased fat cell size, which is highly associated with insulin resistance and the development of 
diabetes ( 18). The enlarged fat cells, a characteristic of obesity are indicative of a failure of 
proliferation and/or differentiation of adipocytes ( 18, 19). In other words, increased fat cell size 
represents the failure of the adipose tissue to expand and subsequently induces lipid accumulation 
in extra-adipose tissues like the liver, muscle and the pancreas, contributing to the development of 
diabetes. This was also supported by recent evidence demonstrating that single nucleotide 
substitutions in the peroxisome proliferator activated receptory (PP ARy) gene involved in adipose 
tissue development are associated with the development of diabetes (20). Additionally, cross­
sectional studies have presented the adverse effect of increased intracellular lipid in peripheral 
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nonadipose tissues on insulin sensitivity. The elevated myocyte lipid represses the activity of 
carnitine palmitoyltransferase-1 (CPT-1 ), a limiting enzyme of fat oxidation, and in turn enlarges 
the intracellular free fatty acid (FF A) pool, thereby leading to a vicious cycle of continuous 
deterioration (21 ). 
2.1.2 Endocrine Function of Adipose Tissue 
Adipose tissue functions as an endocrine organ that secretes several biological molecules 
that exert multiple endocrine effects. Several factors including tumor necrosis factor-a. (TNF-a.), 
adiponectin and resistin are associated with insulin resistance in obesity (22). 
TNF-a. is overexpressed in enlarged adipocytes from obese animals (23). TNF-a. inhibits 
lipogenesis and increases lipolysis, resulting in increasing mobilization of FFA, which are closely 
related to insulin resistance (24). TNF-a. signaling has been shown to impair insulin signaling, in 
part through serine phosphorylation oflRS-1 (25). This cytokine reduces Glut 4 gene expression 
thorough inhibition of CCAAT/enhancer binding protein a. (C/EBPa.) homodimerization which is 
required for transcriptional activity of GLUT 4 gene, consequently decreasing insulin-induced 
glucose transport (26, 27). Further supporting evidence derives from TNF-a. knockout studies 
demonstrating that TNF-a. inactivation improves insulin sensitivity (28). 
Adiponectin, also termed as Acrp30 and adipoQ, is a newly discovered plasma protein 
which is produced from adipocytes (29). Independent of body adiposity, circulating adiponectin 
levels are positively associated with insulin sensitivity as assessed with fasting insulin levels, 
hyperinsulinemic-euglycemic clamps or frequently sampled intravenous glucose tolerance tests 
(18, 30-32). In diabetic animals, reduced adiponectin expression and circulating levels correlated 
with insulin resistance (33). Decreased tyrosine phosphorylation of muscle insulin receptors is 
related to lower plasma adiponectin concentrations (34). Further, adiponectin administration 
reduces insulin resistance and improves glucose tolerance in mice with low adiponectin levels 
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resulting from lipoatrophy-or obesity-induced insulin resistance (29). Adiponectin decreases 
insulin resistance by reducing triglyceride content and increasing fatty acid oxidation in muscle 
and the liver. These insulin-sensitizing effects of adiponectin appear to be mediated by activation 
of AMP activated protein kinase (AMPK) (35, 36). In addition, thiazolidinediones (TZDs) of 
PP ARy agonist have shown to increase adiponectin expression in adipocytes, suggesting that 
adiponectin mediates anti-diabetic effects ofTZDs (37). 
Resistin is an adipocyte-derived hormone and has been suggested to potentially link 
obesity to diabetes (38). Resistin is expressed in white adipose tissue with higher levels in female 
gonadal adipose tissue and resistin mRNA levels have been reported to be markedly increased 
during 3T3-Ll and primary preadipocyte differentiation into adipocytes (39). However, resistin 
had inhibitory effects on adipose conversion, suggesting that resistin may be a feedback regulator 
in adipogenesis and thus signal to restrict adipose tissue formation (39). Genetic-and diet-induced 
obese mice showed markedly increased resistin levels in the circulation (38). Treatment of normal 
mice with recombinant resistin has been demonstrated to impair glucose tolerance and insulin 
action (38). In contrast to adiponectin, rosiglitazone treatment has been shown to decrease resistin 
mRNA and serum levels, thus improving insulin sensitivity (38). 
2.2 Obesity and Hypertension 
The increase in the prevalence of obesity is a global phenomenon associated with 
increased risk for the development of cardiovascular disease (40). Recent study has demonstrated 
that both systolic and diastolic blood pressure increase in a linear manner over the whole range of 
BMI or waist circumference, an index of visceral obesity (41). The National Health and Nutrition 
Examination Survey III (NHANES III) data also show that obesity increases the risk of 
hypertension. Respondents with a BMI of 30 kg/m2 or greater were twice as likely to have 
hypertension compared with non-obese subjects. Similarly, subjects with abdominal obesity, 
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defined by a waist circumference of at least 102 cm for men and 88 cm for women, were twice as 
likely to have hypertension ( 1 ). Of significance, an increase in blood pressure following a gain in 
body weight is associated with profound changes in cardiovascular-renal physiology, including 
high cardiac output, increased plasma volume, increased tubular sodium retention, 
inappropriately normal to total peripheral resistance, increased heart rate, activations of the 
sympathetic nervous system (SNS) and of the systemic renin-angiotensin system (RAS) (42). 
Although the mechanisms leading to these obesity-associated changes are not fully understood, 
alternations in renal mechanisms, increased sympathetic activity and systemic RAS activation 
seem to be especially important contributors to the development of hypertension in relation to 
obesity. 
2.2.1 Renal Mechanisms 
Animal models of obesity induced by high fat feeding have displayed renal structural 
changes including increases in renal weight largely attributable to augmented mesangial and 
capillary endothelial cell proliferation, elevated deposition of hyaluronate in the inner medulla 
and higher intrarenal lipid levels (43-46). Increased Bowman's capsule space area, glomerular 
basement thickening and increased focal formation of transforming growth factor� (TGF�) have 
also been observed (44). Of note, the alternations in renal structure result in increased intrarenal 
pressure. In fact, intrarenal pressure is about 10 mmHg higher in the kidneys of obese dogs than 
in those of lean dogs ( 4 7). The rise in interstitial fluid pressure of the kidney reduces medullary 
blood flow and causes tubular compression, consequently slowing tubular flow rate and 
increasing fraction tubular sodium reabsotption (47). Collectively, these obesity-associated 
changes in renal structure induce elevated tubular sodium absorption and a rightward shift of the 
pressure-natriuresis curve, ultimately raising arterial blood pressure. In addition to renal structural 
changes, the increase in renal sympathetic nerve activity has been suggested as a contributing 
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factor in obesity-related sodium retention ( 48, 49). Renal denervation has been demonstrated to 
attenuate sodium retention and hypertension associated with obesity (48). Consistently, combined 
systemic a- and J3-adrenergic blockade prevented the development of obesity-associated 
hypertension in rabbits fed a high-fat diet (49). 
2.2.2 Sympathetic Nervous System (SNS) 
SNS hyperactivity has been considered a hallmark of obesity-associated hypertension. 
Obese subjects have a higher peripheral tissue norepinephrine turnover and increased muscle 
sympathetic activity (50). Kassab et al. illustrated that the impact of sympathetic activation on 
kidney function is due to the activation of renal efferent nerves, when they studied dogs fed a 
high fat diet for five weeks: the kidneys with intact renal nerves retained almost twice as much 
sodium as the denervated kidneys (51 ). The mechanisms by which obesity activates the SNS are 
still unknown, but hyperinsulinemia, fatty acids, Angiotensin (Ang Iij, and hyperleptinemia are 
proposed as putative mediators (52). Commonly, circulating leptin increases proportionately with 
adiposity. Corica et al. reported that leptin plasma levels are higher in hypertensive than in 
normotensive obese women. This study showed positive association between plasma leptin and 
norepinephrine levels in obese but not lean subjects (53). This finding is in line with the 
observation in a cross-sectional study showing higher norepinephrine and leptin plasma levels in 
obese hypertensive volunteers than in age-and sex-matched obese normotensive participants (54). 
A study by Fogteloo et al. has further demonstrated that higher leptin levels associated with 
hypertension in humans appear likely to be due to increased secretion from adipose tissue rather 
than to impaired leptin clearance by the kidneys (55). Experimental studies by Paolisso et al. 
confirmed the possibility that increase in blood pressure associated with higher leptin levels is 
caused by an increase in SNS activity ( 56). Intracerebroventricular (ICV) administration of leptin 
has been shown to rapidly increase blood pressure, renal SNS activity and plasma catecholamine 
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levels (57). In addition, the stimulatory effects of chronic venous infusion of leptin on heart rate 
and blood pressure have been shown to be markedly enhanced by concomitant blockade of nitric 
oxide (NO) synthesis with L-NAME (58). Moreover, a recent study by Correia et al. suggested a 
new concept of selective leptin resistance. The leptin resistant state in obese agouti yellow mice 
could stimulate sympathetic outflow, thus elevating arterial pressure despite resistance to the 
weight-reducing effects of leptin. This finding indicates that there is a selective resistance to the 
metabolic actions of leptin but not to its sympathoexcitatory effects in obese mice (59). 
2.2.3 Adipose Tissue Renin Angiotensin System (RAS) 
Enhanced activity of systemic RAS has been reported in obese humans (60-63). 
Epidemiological studies have shown a positive correlation between angiotensinogen (agt) and 
plasma leptin levels, suggesting a direct contribution of adipose tissue to plasma agt levels (60). 
This notion is supported by recent agt knockout and transgenic studies showing that in Tg-KO 
mice reexpressing agt only in adipose tissue, circulating agt returned to detectable levels (-20% 
of levels in WT) and blood pressure was restored to the levels comparable to those seen in WT 
mice (64). Additionally, adipose tissue agt contributions to systemic agt levels seen in Tg-KO 
mice could explain the significantly elevated plasma renin activity (PP A) phenomenon in obese 
people despite their marked sodium retention and greater extracellular fluid volume; plasma 
concentration is close to the Michaelis constant of enzymatic reaction between agt and renin (52). 
In mature adipocytes, Ang II induces leptin gene expression and production, increases 
prostacyclin (PGl2) and prostaglandin E2 (PGE2) production and induces norepinephrine release 
in brown adipose tissue. It suggests that all of these mechanisms may account for the regulation 
of adipose tissue blood flow or systemic blood pressure. The earlier study from Soltis and Cassis 
provides evidence for functional role of perivascular adipose tissue RAS in vascular 
responsiveness. Contractile responses of adipose tissue-embedded aortic ring preparation to 
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electrical stimulation were increased compared with denuded aortic ring preparations. This effect 
was blunted by ATl receptor antagonist saralasin. Accordingly, increased vascular constriction 
appears to be most likely due to Ang II-stimulated norepinephrine (NE) release from adipose 
tissue, suggesting that perivascular adipose tissue locally modulates vascular reactivity, compared 
to large adipose tissue depots ( 65). In addition, the relationship among adipose tissue agt 
expression, hypertension and body weight has been investigated in several animal models and 
humans. Although studies have yielded inconsistent findings, positive correlation between agt 
expression in adipose tissue and BMI or waist-to-hip ratio in humans has been reported (66-68). 
Gene expression of other RAS components like A Tl receptor, ACE and renin in adipose tissue, 
was significantly increased in hypertensive obese individuals, suggesting potential association of 
adipose tissue RAS with obesity-associated hypertension (69). 
B. GENETICIS OF OBESITY
Obesity arises as results of numerous behavioral, environmental and genetic factors (70). 
Obesity is a complex trait, reflecting the effect of a network of genes. Evidence for genetic 
influences on obesity emerged in twin, adoption and family studies; 40-70% of the variation in 
obesity-related phenotypes such as BMI, sum of skinfold thickness, fat mass and leptin levels in 
humans is heritable (71 ). Although mutations of mouse obesity genes displaying a Mendelian 
inheritance pattern have been cloned, it is very rare in common human obesity (70). To date, two 
general approaches have been performed in the search for potential genes underlying common 
polygenic obesity in humans; 1) candidate genes approach focusing the search for specific obesity 
susceptibility mutations in genes selected on the basis of their known or presumed biological 
roles in energy homeostasis and 2) genome scanning approach to detect chromosomal regions 
showing linkage with obesity using inbred strains of mice and human population. These 
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approaches provide information for obesity gene map in humans and rodents and identifying 
quantitative trait loci {QTL) associated with obesity and human population with a genetic 
susceptibility to obesity (72). 
1. GENETICS OF HUMAN OBESITY
The role of genetic factors in common human obesity is complex, being determined by 
the interaction of several genes (polygenic), each of which may have relatively small effects. 
They are susceptibility genes and work in combination with each other as well as with 
environmental factors such as nutrients, physical activity and smoking (70, 72). Most of the 
syndromic forms of obesity like Prader-Willi, Achondroplasia, Angelman, Alstrom, Cohen, 
Bardet-Biedle, Fanconi Biekel, Borjeson Forssman Lehmann and Simpson-Golabi Behme! have 
been genetically mapped, but causative genes have not yet been isolated because of the extreme 
rarity of these mutations (73). Using the strategy focused on mutations in candidate genes that are 
homologous to murine genes known to be involved in energy balance and mutated, thus causing 
obesity in rodents, six different human obesity genes have been identified {Table 1 ): LEP, LEPR, 
proopiomelanocortin (POMC), proconvertase 1 (PCJ), single minded drosophila homolog 
l(SJMJ) and melanocortin 4 receptor (MC4R) (74-78). Significantly, except for SIMJ, all of the 
proteins encoded by these five genes are part of the same pathway regulating food intake in the 
brain. In human monogenic obesity, LEP, LEPR and POMC gene mutations are very rare and 
recessive form of obesity. On the other hand, the MC4R gene is the most prevalent obesity gene 
to date, being involved in 1-4% of very obese individuals (79). MC4R mutations generally 
segregate in families via an autosomal dominant mode of inheritance with variable penetrance 
(79). In some consanguineous pedigrees, MC4R mutations with relatively modest loss of function 
appear to be codominantly or even recessively associated with obesity. Further, the 
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Table 1. Single gene mutations for obesity from humans 
LEP Recessive Leptin I .Satiety hormone I .Early-onset obesity 
(mainly produced 2. Hyperphagia
by fat cells) 3. Hypogonatropic
2.lncreased energy hypogonadism 
expenditure 
LEPR Recessive Leptin I .Receptor of leptin 1. Massive obesity
Receptor 2. Growth retardation
POMC Recessive Pro- I .Decreased food I.Obesity
opiomelano intake 2.ACTH deficiency
-cortin 3. Altered pigmentation and
red hair 
PCJ Recessive Proprotein I.Conversion of l .Hyperproinsulinemia
convertase 1 POMC and 2.Early-onset obesity
proinsulin to a- 3.ACTH deficiency
MSH and 
insulin, respectively 
SIMI Recessive Single 1. SIMI is involved 1. Profound obesity
minded in paramentricular 2. Increased linear growth
Drosophila nucleus 3. Normal energy
homolog 1 development and expenditure 
neurogenesis 
MC4R Dominant Melacortin 1. Decreased food I .Mild severe and morbid 
or receptor 4 intake obesity 
Recessive 2. Hyperphagia
3. No effect on thyroid and
gonadal function 
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strategies of genetic linkage and association analyses have been performed to identify 
chromosome regions containing candidate genes underlying common polygenic obesity. 
Statistical probability of linkage is typically presented as a logarithm of the likelihood ratio for 
the linkage score (LOD). A number of DNA polymorphisms and susceptibility loci associated 
with obesity and related phenotypic traits have been identified over the whole genome (72). Thus 
far, genome-wide scans for obesity susceptibility genes have been performed in several 
populations of diverse e�nic background including Mexican American families, French 
pedigrees, Pima Indians and in White Americans. Loci at chromosome 2 and 8, as well as to a 
lesser extent, loci on chromosome 5 have been described to contribute to the genetic risk for 
obesity in humans (80). 
2. ANIMAL MODELS OF OBESITY
Several spontaneous single-gene mutations causing obesity have been identified in inbred 
mice. Mouse models of obesity having single-gene mutations include obese (ob), diabetic (db), 
fat (fat), tubby (tub) and yellow agouti (A>') mutant mouse strains (81-86) (Table 2). These models 
are very useful for elucidating genetic mechanisms underlying the development of obesity. For 
instance, agouti and/at mice provide models to investigate later onset and moderate obesity, in 
contrast with other monogenic obese mice characterized by early onset obesity. Tubby mice are a 
good model to study late onset obesity that is not associated with diabetes. In addition, numerous 
knockout and transgenic models resulting in the development of obesity have been generated. 
Studies on knockout and transgenic mice revealed additional genes causing body weight 
dysregulation by hyperphagia or changes in behavioral and metabolic responses (87, 88). Similar 
to human obesity which is polygenic and genetically heterogeneous, polygenic mouse models of 
obesity are unique resources to study the genetic effects on obesity caused by gene-gene 
interactions or gene-environment interactions. Using molecular markers (microsatellites, 
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Table 2. Single gene mutations for obesity from mouse models 
Obese (ob) Leptin 1. Satiety hormone 
(mainly produced by 
fat cells) 
Diabetes (db) Leptin receptor 
Fat (fat) 
Tubby (tub) 
Agouti 
yellow 
obese (AY) 
Carboxypeptidase E 
Tub protein 
Agouti signaling 
Protein 
2. Increased energy
expenditure 
I .Receptor of leptin 
I .Posttranslational 
processing of 
prohorrmone ( cleaves 
basic amino acids from 
C-terminal)
1. Transcription factor
I .Antagonist of 
melanocortin 
receptor 4 
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.. I/ 
I .Early-onset obesity 
2. Hyperphagia
3. Growth hormone
deficiency 
4. Decreased linear growth
1. Early-onset obesity
2. Diabetes
I .Late-onset obesity 
2. Infertility
3. Hyperglycemia
I .Late-onset obesity 
2.Retinal degeneration
3.Deafness
4.lmpaired infertility
1. Yell ow pigment
2. Late-onset obesity
3. Immune defect
4. Increased linear growth
5. Decreased infertility
restriction fragment length polymorphisms or single nucleotide polymorphisms) linked to 
segregation of quantitative obesity phenotypes (e.g. BMI, % of body fat, fat mass), 75 QTLs for 
multigenic obesity and 85 QTLs for body weight have been mapped in crosses between various 
mouse lines (80). One set of QTLs was mapped by their effects on high fat diet-induced obesity 
following crosses between the strains ARK/J and SWR/J. These QTLs appear to be active only 
under the environmental effects of a high-fat diet (30% fat) (89). Additional QTLs for obesity­
related sub-phenotypes (e.g. increased serum levels ofleptin and insulin) and influence of age and 
gender have also been identified (88). 
C. ROLE OF ADIPOSE TISSUE IN OBSITY
The primary role of adipocytes is to store triglycerides during periods of caloric excess 
and to mobilize this reserve when expenditure exceeds intake. Mature adipocytes possess the full 
complement of enzymes and regulatory proteins needed to carry out both lipolysis and de novo
lipogenesis. Of significance, white adipose tissue has been recently considered as an endocrine 
secretory organ. Adipose tissue lies at the center of a network of autocrine, paracrine and 
endocrine signals, thereby dynamically influencing systemic metabolism. Further, metabolic 
alternations in adipose tissue is associated with the development of obesity and obesity-associated 
metabolic syndromes (90). 
1. ORIGIN OF ADIPOCYTES AND ADIPOSE TISSUE
Despite the fact that the developmental origin of the adipose cells is still unknown, 
studies on multipoint stem cell lines have shown that adipocyte lineage derives from an 
embryonic stem (ES) cell precursor which is able to differentiate into the mesodermal cell types 
of adipocytes, chondrocytes, osteoblasts and myocytes (91 ). Development of adipose tissue 
occurs at different states in various species (92). In most spec�es, white adipose tissue (WAT) 
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formation begins before birth and rapidly expands postnatally. Although genes that commit 
progression from pluripotent mesodermal stem cells to the adipoblast stage of development have 
not yet been identified, it has been demonstrated that transcriptional factor GATA 
downregulation induces the transition of embryonic stem cells to adipocytes (93). In contrast to 
the initial steps of adipogenesis, transcriptional controls in late stages of adipogenesis ( conversion 
of preadipose cells to adipocytes) have been well established using preadipocyte cell lines (e.g. 
3T3-Ll, 3T3-F442 A and Ob 1771) which are already committed solely to the adipocyte 
lineage(94). 
Brown adipose tissue (BAT) develops earlier than WAT. With respect to morphology 
and physiology, BAT is distinct form WAT; they store lipid in multiple small droplets instead of 
a single large droplet, and BAT serves primarily to dissipate energy instead of storing it though 
the expression of uncoupling proteins (UCP) (94). BAT stores are not present in humans, 
although the expression UCP-1 in WAT reflects the presence of some BAT cells in WAT 
deposits (95). Additional evidence indicates a transition of BAT to WAT at birth (96). In spite of 
the fact that no transcription factors have been identified and specifically expressed in brown fat 
cells, PPARy and C/EBP have been described to be involved in a induction of brown 
adipogenesis in a similar fashion to white cell differentiation (94). Peroxisome proliferator 
activated receptor y coactivator-1 (PGC-1) was also shown to preferentially direct preadipocytes 
to a brown fat phenotype (97). 
Fat mass expansion occurs as a consequence of increased fat cell size, increased number 
of fat cells arising from differentiation of preadipocytes into mature adipocytes or both 
throughout life span (90). Several experimental studies have supported this notion. Studies of rats 
fed a high-calorie diet have shown that 3H-thymidine incorporates into new fat cells throughout 
adulthood (81 ). Adipocyte precursor cells from human adipose tissue can be fully differentiated 
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into mature adipose cells in vitro, (98). Further, Kras et al. have demonstrated that adipocyte 
acquisition is the result of preadipocyte proliferation, not stem cell recruitment, to become 
adipocytes (99). Especially, the development of hyperplastic adipose tissue has been implicated in 
the most severe forms of obesity (90). However, the relative contribution of adipose hypertrophy 
and hyperplasia to adipose tissue expansion and development of obesity remain still elusive. 
On the other hand, adipose tissue does not respond uniformly to stimuli that trigger lipid 
storage or mobilization, implying local depot-specific growth regulation. Indeed, recent studies 
have reported differential adipose tissue growth and its potential regulators in various adipose 
tissue regions (90, 100). For example, there is an inverse relation between the degree of SNS 
innervation and the propensity for increases in fat cell proliferation. The order of density of SNS 
innervation of adipose tissue depots from richest to poorest is mesenteric, epididymal, 
retroperitoneal and inguinal, but proliferative capacity and hyperplasic growth, from greatest to 
least, is just the opposite ( 100). The precursor cell population, perfusion capacity, innervation 
density and some hormones including insulin (hypertrophy inducer), androgen (proliferation 
promoter) and testosterone (proliferation promoter) could contribute to the site-dependent 
patterns of adipose tissue growth (90). 
2. PROCESS ADIPOCYTE DIFFERENTIATION
Adipocyte differentiation is the transition from undifferentiated fibroblast-like 
preadipocytes into mature round lipid-filled fat cells. The adipogenic program in preadipocyte 
cell lines consists of several sequential steps that have been well characterized (94 ). Briefly, the 
sequence of events that precedes terminal differentiation includes; 1) Growth arrest at confluence: 
when confluence is reached, cells arrest in the Go/G1 stage of the cell cycle. The step is required 
for the initiation of differentiation event 2) Clonal expansion: the process involves synchronous 
entry of all cells into S phase of cell cycle, leading to one or two rounds of mitosis. It occurs 
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when appropriate mitogenic or adipogenic stimuli ( e.g. methylisobutylxanthine (MIX) and 
dexamethasone (Dex)) are presented to the cells and is characterized by the expression of 
C/EBPP and C/EBP8 3) Terminal differentiation: this process is accompanied by an exit from the 
cell cycle. PPARy, C/EBPa and many of the adipocyte markers are expressed at this stage and 
the cells assume their characteristics rounded morphology and visibly accumulate lipid droplets 
(94). 
2.1 Transcriptional Regulation of Adipocyte Differentiation 
Adipose differentiation is the result of transcriptional remodeling that leads to activation 
of a considerable number of adipose-related genes. This process is controlled by various positive 
and negative signals changing the activity of a variety of transcription factors. In an early 
adipogenic process, the master transcription factor for adipocytic commitment of mesodermal 
stem cells remains unknown. Two transcription factors, twist and scleraxis, have been shown to 
be important for the formation of tissues ofmesodermal lineage. However, the roles of these 
factors in fat development are unknown ( 101, 102 ). Further evidence has shown that GA TA 2 and 
3 (zinc-finger DNA binding proteins) likely act as inhibitors ofpreadipocyte-adipocyte transition, 
and their inhibitory effects are mediated by inhibition of PP ARy. GATA 3-defiecient ES cells 
display an enhanced capacity to differentiate into adipocytes, indicating the role GATA as a 
determination factor in the transition of pluripotent stem cells to a preadipocytic lineage (93). 
Similarly, activation of wnt signaling has been reported to prevent preadipose-adipose transition 
(103). 
In a later stage of adipogenesis (preadipocyte-mature adipocyte), three transcription 
factor families, C/EBPs, PP ARs and adipocyte determination and differentiation dependent factor 
l(ADDl )/sterol regulatory element-binding protein 1 (SREBPl ), have emerged as critical 
adipogenic regulators (94). In the transcriptional cascade of adipogenesis, hormonal signals 
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initiate transient increases in expression of C/EBP� and C/EBPo. These factors stimulate the 
expression of PP ARy though the C/EBP binding site in the PP ARy promoter region and also 
induce C/EBPa via its transcription activation. ADDl/SERBPl , in addition to regulating genes 
important in fatty acid metabolism, increases the activity of PPARy, possibly through the 
production of the endogenous ligands. Activation of PPARy by ligands allows the differentiation 
process to proceed. Subsequently, the expression of C/EBPa is induced and C/EBPa also allows 
for the continued expression of PPARy once the levels of C/EBP� and C/EBPo have decreased 
after early transient expression. It is likely that both C/EBPa and PP ARy are important for 
maintaining the fully differentiated state (94). Recently reported FOXC2, a winged 
heli:x/forkhead transcription factor, has been shown to be implicated in adipocyte differentiation 
through the activations of PPARy, C/EBPa and ADDI/SREBPI genes (104). 
Of note, three key adipogenic transcriptional factors, C/EBP, PPARy and ADDl/SERBPl, 
are also responsible for the expression of many adipocyte marker genes. Accordingly, the 
adipogenesis is accompanied with complex changes in the expression of fat-specific genes. 
Lipoprotein lipase (LPL) is one of early genes expressed during differentiation process; its 
expression appears in the confluent stage of growth arrest (105). The expression ofC/EBP�, 
C/EBPo, PPARy and ADDl/SERBPl is also induced early in the differentiation program. PPARy 
expression is induced by transient expression of C/EBP� and C/EBPo genes. Following the 
expression of these early transcriptional factors, preadipocytes enter the terminal phase of 
differentiation (94). C/EBPa is expressed late in the adipogenesis, concomitant with decreases in 
C/EBP� and C/EBPo gene expression. Several adipocyte-specific genes associated with 
adipocyte function and phenotype are directly induced by PPARy, C/EBPa and ADD 1/SERBP I ;  
PP ARy activates the transcription of fatty acid transport protein (FA TP), phosphoenol-pyruvate 
28 
carboxykinase (PEPCK), adipocyte specific fatty acid binding protein (aP2) and acyl CoA 
synthase (ACS) genes; C/EBPa induces expression ofGlut4, UCPl, IR, and IRSl  genes; 
ADDl/SERBPl enhances fatty acid synthase (F AS) and acetyl CoA carboxylase (ACC) gene 
expression (94, 105). 
In addition, C/EBPa and PP ARy exerts antimitotic activity in the control of adipocyte 
differentiation (second and permanent period of growth arrest). This action is related to both a 
transcriptional effect and interaction with proteins involved in cell cycle control. PPARy 
activation leads to a loss of DNA binding activity of E2F/DP, a central transcription factor in the 
regulation of many genes involved in cell growth and differentiation (106). C/EBPa inhibits the 
growth of fibroblasts via a direct repression ofE2F/DP activity in vivo and in vitro (107, 108). A 
subsequent study has illustrated that C/EBPa interacts directly with the cyclin dependent kinases 
2 and 4, preventing cyclin binding and thus inducing growth arrest (109). Further, PPARy induces 
the expression of several cyclin-dependent kinase inhibitors such as p 18 and p2 l ,  and C/EBPa 
stabilizes p21 and thus inhibits adipocyte proliferation ( 110, 111 ). 
Recent gain-and loss-function studies on these adipogenic transcriptional factors have 
presented the profound impacts of these proteins on fat cell development. In vivo, invalidation of 
C/EBPf3 and C/EBPo genes impairs severely viability, but live double knockout mice (C/EBPW'­
and C/EBPo·'·) exhibited defects in adipocyte maturation despite normal expression of C/EBPa 
and PP ARy, suggesting that C/EBPf3 and C/EBPo can synergistically promote terminal adipocyte 
differentiation (112). The C/EBPa-null mice did not exhibit any subcutaneous inguinal WAT 
along with decreased UCP expression (113). Similarly, transgenic mice expressing a dominant­
negative bZIP protein under the control of adipocyte specific aP2 promoter, which induces 
inhibition of C/EBP transcriptional activity, exhibit a lipodystrophy phenotype, emphasizing the 
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importance of C/EBP proteins in adipogenesis in vivo (114). The ablation of the PPARy gene in 
mice results in placental-lethal phenotypes. A live PP ARy -1- pup by aggregation of two-celled 
PP ARy embryos with wild-type tetraploid embryo shows a lack of adipose tissue, proving that 
PPARy is required for fat cell development in vivo (115). Of interest, PPARy +I- mice were less 
prone to develop insulin resistance when fed a high fat diet than were their wild-type littermates, 
possibly owing to the reduced adipocyte size and decreased production ofTNFa and fatty acids 
in the heterozygotes (116). Surprisingly, ADDl/SERBPl-null mice were normal without 
alternations in their adipose mass and the levels of lipogenic genes. It was suggested that this may 
be due to the presence of a low level of SERBP2 in fat, which compensated for the lack of 
SREBPl ( l  17). Overexpression of ADDl/SERBPl in fat tissue in vivo has been demonstrated to 
result in mice with severely compromised levels of fat; these animals have fatty liver to 
compensate for reduced adipose mass (118). 
2.2 Modulator of Adipocyte Differentiation 
Adipocyte differentiation is modulated by several hormones, cytokines and growth 
factors (94, 105). 
2.2.1 Inducer of Adipogenesis 
Insulin and insulin-like growth factor (IGF) stimulate adipogenesis, and ras and 
Akt/protein kinase B(PKB) have been suggested to play as mediators in the stimulatory effects of 
these hormones on adipocyte differentiation (119, 120). Glucocorticoids and Dex (a synthetic 
glucocorticoid) induce preadipocyte differentiation (98). Dex was shown to increase adipogenic 
activity through increasing expression of C/EBP and transcriptionally repress preadipocyte factor 
1 (pref-I), which is a negative regulator of adipogenesis and is found in preadipocytes (98, 121). 
Retinoic acids (R A) i� physiological concentrations promote the transition of OB 17 preadipocyte 
into mature adipocytes (122). However, pharmacological doses of R A  inhibit adipogenesis (123). 
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An intracellular secondary messenger, cAMP promotes adipogenesis and its stimulatory effect 
was demonstrated in MIX application; MIX inhibits phosphodiesterase concurrent with 
stimulating adenylyl cyclase via blocking protein Gi and thus accumulates intracellular cAMP. 
Thus, MIX triggers fat cell differentiation via increasing cellular cAMP accumulation (98). 
Mechanistically, cAMP-activated transcription factor, cAMP response element binding protein 
(CEBP) has been shown to mediate cAMP-enhanced adipogenesis (124). One of the 
prostaglandins, PGI2 is an endogenous ligand for PPARy thereby leading to adipogenesis in a 
PP ARy-mediated manner. Alternatively, PGI2 promotes preadipocyte differentiation by 
increasing cAMP (125). Recent studies on the differential effects of long chain fatty acids (e.g. ro-
6 vs ro-3) on adipogenesis have illustrated that polyunsaturated fatty acids (PUF A) of the ro-6 
series are more adipogenic both in vitro and in vivo compared with their ro-3 counterparts. ro-6 
arachidonic acids induce adipocyte development via prostacyclin-activated protein kinase A 
(PKA) pathways, which upreguate C/EBPl3 and C/EBP8 gene transcription (126). 
2.2.2 Inhibitor of Adipogenesis 
TNFa suppresses fat cell differentiation through downregulation of C/EBPa and PP ARy 
genes (98). Several growth factors including epidermal growth factor (EGF), TGFa and TGFl3 
have been shown to inhibit adipogenesis in various preadipocyte cell lines and primary rat 
preadipocytes (127). This inhibitory effect on adipogenesis is likely to be mediated through 
activation of mitogen-activated protein kinase (MAPK). This kinase and JNK MAPK directly 
serine phosphorylate PPARy 2 and thus inhibit its adipogenic activity (128). In 3T3-Ll cells, 
prostaglandin F2a (PGF2a) exerts its inhibitory effects on adipogenesis in a FP receptor­
dependent manner. FP receptor stimulation causes a transient increase in intracellular calcium, 
activation of calcium/calmodulin-dependent protein kinase (CaM kinase) and an increase in DNA 
synthesis associated with the inhibition of differentiation (129). CaM kinase has been shown to 
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repress differentiation. However, the precise role of CaM kinases in this process remains to be 
clarified (130). 
3. METABOLISM OF ADIPOSE TISSUE
The adipose tissue is the major store of lipids. These stores are constitutively remodeled 
by control of lipogenesis and lipolysis. The adipose tissue is primarily responsible for the 
conversion of excess dietary carbohydrate to triglycerides, a process known as lipogenesis ( 131, 
132). This process includes enzymes of glycolysis, fatty acid biosynthesis, and triglyceride 
synthesis. 
FAS and ACC play central roles in de novo lipogenesis ( 131 ). ACC catalyzes acetyl CoA 
into malonyl CoA and is a rate limiting enzyme in de novo fatty acid biosynthesis (132). ACC is 
primarily regulated via a short-term allosteric effectors or covalent modifications. Hormonal and 
nutritional manipulations influence the activity of this enzyme (131 ). FAS catalyzes all the 
reactions in the conversion of acetyl-CoA and malonyl-CoA to palmitate by the action of its seven 
active sites (131, 132).Unlike ACC, FAS activity has been shown to be regulated at the 
transcriptional levels; cis-and trans- acting factors. FAS concentration is exquisitely sensitive to 
nutritional and hormonal status in lipogenic tissues such as liver and adipose tissue ( 131 ). FAS 
transcription was undetectable in the lipogenic tissue of fasted mice and was dramatically induced 
upon refeeding of a high carbohydrate, fat-free diet (133). Recent studies have reported that the 
binding of SREBP-1 to a sterol response element (SRE:-150) is mediated by refeeding-induced 
FAS promoter activation. Upstream stimulatory factor 1 (USF-1) binding to the -65 E box is 
necessary for SREBP binding and activation of the FAS promoter in in vivo context (134). 
Changes in nutrient intake bring changes in circulating glucose, which in turn signal the secretion 
of hormones, insulin and glucagon. Glucose and insulin induce FAS promoter activity 
dependently and independently. Glucose directly activates the FAS gene trough a glucose 
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response element (GRE, the first intron of the FAS gene) (135). Alternatively, rather than glucose 
itself, glucose-6-phosphate and its metabolites have been described as a mediator in glucose­
induced FAS transcription regulation (136). By using adipocytes in culture and transgenic mice 
expressing the reporter gene driven by the FAS promoter, the cis-acting insulin response element 
(IRE, E box) that mediates insulin regulation of the FAS promoter was defined. In addition, USF 
and SREBP (the basic helix-loop-helix leucine family of transcription factors) have been 
presented to be key players in such regulation through both in vivo and in vitro studies. USF-1 
and-2 that bind to the -65 E box are required for insulin-mediated transcriptional activation of 
FAS gene(137, 138). ADDl /SREBP-1 was also shown to be involved in induction of this gene by 
insulin though binding to the E box (-65/-60) (139). Of note, glucose was definitely required in 
insulin-induced FAS transcription mediated by both USF and ADD-1/SERBP-1 (140, 141). 
Further, using specific inhibitors and expressing various signaling molecules, the cellular 
signaling pathway was defined. Insulin regulation of the FAS promoter is mediated by PI3K and 
Akt/ PKB, a downstream effector of PI3K signaling pathway in adipocytes (142). Other 
hormones such as T3, glucagon and Ang II also influence activation of the FAS promoter. The 
inhibitory effect of glucagon on FAS expression is mediated by cAMP and a cAMP-response 
element (-149/+68) has been identified in the FAS gene (143). In addition, the -99/-92 region of 
the FAS promoter was recognized as a core region for cAMP responsiveness (143). Mutation of 
this box has been shown to prevent cAMP-mediated inhibitory effect on the FAS gene as well. T3 
has been demonstrated to enhance FAS expression. FAS promoter region contains two thyroid 
response elements (TRE):TREl (-870/-650) and TRE2 (-272/-40) (144). Ang II has been reported 
to increase FAS transcriptional activity via an E box, and this stimulatory effect of this hormone 
was dependent on ADDl/SERBPl and glucose in 3T3-Ll adipocyte cells (145). Agouti 
stimulates FAS transcription in a Ca +2 -dependent mechanism. An agouti/Ca +2 -response element (-
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435/-415) within FAS gene has been identified (146). Additionally, Moon et al. have recently 
examined in vivo and in vitro the specific FAS promoter elements implicated in PUF A 
suppression. They found that the promoter region required for PUF A suppression in vivo is 
located in the -150 sterol response element (SRE) where SREBP functions and the -65 E Box 
which contributes to PUFA suppression of the FAS promoter, at least in vitro (147). 
Hormone-sensitive lipase (HSL ), the rate-limiting enzyme of intracellular triglyceride 
hydrolysis, is a major determinant of fatty acid mobilization in adipose tissue. Adipocyte lipolysis 
is also subject to hormonal and neuronal regulation (148). Catecholamines are considered as 
major stimulators while insulin is accepted as the most important physiological inhibitor of 
catecholamine-induced lipolysis. SNS activation induces the release of catecholamines, which 
triggers an elevation of cAMP concentration that activates PKA, resulting in the phosphorylation 
ofHSL and the perilipins (148). Thus, phosphorylation of these proteins dramatically increases 
lipolysis. By contrast, insulin exerts its antilipolytic actions by inducing phosphorylation and 
activation of the phosphodiesterase type 3B (PDE3B), resulting in a decrease in cAMP levels and 
concomitant decrease of PKA activity (148). Molecular mechanisms underlying activation of 
lipolysis have been provided. On stimulation of the adipocytes, PKA-mediated phosphorylation 
triggers the translocation of HSL from the cytoplasmatic compartment to the surface of the lipid 
droplets (149). Perilipins, which is located on the surface of the lipid droplets in adipocytes and 
precludes HSL binding to lipid droplets in resting cells, are phosphorylated and probably relieve 
the restraint and allow the translocation of phosphorylated HSL to the lipid droplet ( 150). 
Compelling evidence for this barrier role of perilipins has recently been reported (151 ). In 
nutritional regulation of HSL, prolonged fasting in rats induces HSL transcription, protein and 
enzyme activity, collectively elevating basal lipolysis activity (152). Of importance, in vivo and
in vitro studies have presented that catecholamine-induced lipolytic effects as well as antilipolytic 
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effects of insulin are blunted in obese subjects, thereby contributing to considerable increases in 
the net adipocyte lipolytic rate of obese subjects compared to lean individuals (153). The altered 
lipolysis of catecholamine could be attributed to a decreased number of �2 adrenergic receptors, 
changes in the functional balance between a.2- and �-adrenergic receptors, or postreceptor 
alterations. Other studies have provided evidence that this impaired lipolytic action of 
catecholamines was due mainly to reduced HSL activity (154). A dysfunction in lipolysis due to 
impaired HSL expression and a decrease in enzyme activity could precede the actual 
development of obesity. Furthermore, a marked resistance to the lipolytic effect of noradrenaline 
in adipocytes was also observed in type II diabetic subjects who were characterized with elevated 
FFA levels, due to a decrease in the number of �2-adrenergic receptors (155, 156). 
4. FUNCTION OF ADIPOSE TISSUE
Adipose tissue is actively involved in cell function regulation through a complex network 
of endocrine, paracrine and autocrine signals that influence the response of many tissues 
including the hypothalamus, liver and skeletal muscle. Adipocyte-secreted biological molecules 
have been shown to be implicated in obesity and obesity-related metabolic alternations including 
insulin resistance, diabetes and hypertension (Table 3) (22). 
D. ROLE OF ANGIOTENSIN II IN OBESITY
1. SYSTEMIC RENIN ANGIOTENSIN SYSTEM (RAS)
1.1 Overview 
Ang II, a vasoactive hormone, is the active component of the RAS. Ang II is a 
multifunctional peptide hormone that not only controls blood pressure homeostasis but also 
regulates cardiovascular and renal functions. Ang II is produced systemically via classical or 
circulating RAS and locally via tissue RAS (157). The classical pathway of RAS is composed of 
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Table 3. Adipocyte-associated biological factors 
, MoleculJ '.i,. Function 
�· 
' 
·"'"''' 'i, 
Adipocyte- Leptin Signals to the brain about body fat stores 
secreted Regulation of appetite and energy expenditure 
Proteins TNFa. Interferes with insulin receptor signaling and is a possible 
causes of the development of insulin resistance in obesity 
IL-6 Implicated in host defense and in glucose and lipid 
metabolism 
PAl-1 Potent inhibitor of the fibrinolytic system 
Tissue Factor Maior cellular initiator of the coagulation cascade 
Agt Precursor of angiotensin II and regulator of pressure and 
electrolyte homeostasis 
Adipsin Possible link between the activation of the alternative 
complement pathway and adipose tissue metabolism 
ASP Influences the rate of triacylglycerol synthesis in adipose 
tissue 
Adipophilin May be a specific marker for lipid accumulation in the cells 
Adiponectin Associated with insulin sensitivity 
PGl2, PGF2a. Implicated in regulatory function such as inflammation and 
blood clotting 
TGFf3 Regulates a wide variety of biological responses including 
proliferation, differentiation, apoptosis, and development 
Resistin Associated with insulin resistance 
Receptor Main effects ofreceptr,r'activati.on on adipacyte:�ettdiollsm 
t � 
,, o/ m 
White Leptin (OB-R) Stimulation of lipolysis 
adipocyte Autocrine regulation of leptin expression 
receptors Insulin Inhibition of lipolysis and stimulation of lipogenesis 
Induction of glucose uptake and oxidation 
Prostaglandin Strong antilipolytic effects (PGE2) 
Modulation of preadipocyte differentiation (PGF2a. and 
PGI2) 
TNFa. Stimulation of lipolysis, Regulation of leptin secretion, 
Potent inhibition of adipocyte differentiation, involvement in 
development of insulin resistance 
IL-6 LPL activity inhibition, induction of lipolysis 
Angil Increase lipogenesis, Stimulation of prostacyclin and PGE2 
by mature fat cells, interaction with insulin in regulation of 
adipocyte metabolism 
(31,(32, (33 Stimulation oflipolysis, Induction ofthermogenesis, 
Reduction ofleptin mRNA levels 
a.I Induction of inositol phosphate production and PKC 
activation 
a.2 Inhibition of lipolysis 
PPARy Induction of adipocyte differentiation and insulin sensitivity 
PAR/PXR Regulation of adipocyte differentiation 
Vitamin D Inhibition of adiPocvte differentiation 
VLDL Binding and internalization ofVLDL particles 
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Rl/tr,mces 
. � . ''.' 
(82, 158) 
(159, 160) 
(161) 
(162) 
(22) 
(163) 
(164) 
(164) 
(165) 
(166) 
(161) 
(167) 
(38) 
Referejft;n 
,!1� 
(22, 168) 
(22) 
(22) 
(26, 169) 
(161) 
(163, 170) 
(171) 
(171) 
(171) 
(172) 
(173) 
(174) 
(175)
a sequential reaction of two critical enzymes that convert hepatic-derived precursor agt into Ang 
II. The first enzyme, renin, is secreted from juxtaglomerular (JG) cells in the kidney and splits a
specific leucine-leucine peptide bond in circulating angiotensinogen, resulting in the formation of 
decapeptide angiotensin I. Biologically inactive angiotensin I (Ang I) is then carried via the blood 
to the lung, where the second enzyme, angiotensin converting enzyme (ACE), removes two 
amino acids from the carboxy terminus of angiotensin I to generate the active octapeptide Ang II 
(176). ACE is a monomeric, membrane-bound, zinc-and chloride-dependent peptidyl dipeptidase 
anchored on the endothelium of the lung that degrades bradykinin and is involved in the 
biosynthesis of different neuropeptides such as substance P. In addition to renin and ACE­
dependent pathways of Ang II formation, the existence of non-renin and ACE pathways have 
been also demonstrated (177, 178). Ang II can be formed via several non-renin and non-ACE 
enzymes including chymase, kallikrein, cathepsin D, cathepsin G, tissue plasminogen activator 
and tonin. Alternatively, Ang I can be processed into heptapeptide Ang 1_7 by neural 
endopeptidase (NEP). Unlike renin and agt, which have relatively longer plasma half-lives, Ang 
II is degraded by angiotensinases to angiotensin III (Ang III), angiotensin IV (Ang 3_8, Ang IV) or 
Ang 1_7 within few seconds. Circulating Ang II and agt-derived bioactive peptide fragments are 
dispersed to the target tissues of body, where they can exert diverse physiological effects via their 
interactions with specific angiotensin receptors, such as ATla, ATlb, AT2 and AT4, which 
induce different signal cascades (176). The well-known biological actions of Ang II such as 
vasoconstriction, antinatriuresis and cell proliferation are mediated via the classic ATl 
receptor(l 76). Paradoxically, other Ang II-mediated effects, including cell death, vasodilation and 
natriuresis are mediated by AT2 receptor activation. Currently, the physiological functions of 
Ang II-derived peptides have been intensely investigated in different cell types. Ang III has been 
shown to signal via both AT I and AT2 receptors with a similar affinity to that of Ang II. Ang III 
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appears to have a key role in the brain RAS. It participates in the central control of blood pressure 
and the release of vasopressin. Ang IV regulates renal blood flow and facilitates memory 
retention and retrieval via AT4 receptors (179). Ang 1_7 promotes vasodilatation, antiproliferation 
and apoptosis possibly through interacting with A Tl and AT2 receptors (Fig 1 ). 
1.2 Angiotensin Receptors: Structure and Distribution (Table 4) 
Ang II exerts its effects via at least two plasma membrane receptors: ATl and AT2 (180, 
181 ). Most of the physiological actions of Ang II are mediated via the AT 1 receptors. Ang III is a 
full agonist at A Tl receptors and binds with high affinity at AT2 receptors. Ang IV and Ang 1_7 
display lower affinity for A Tl and AT2 receptors. AT4 receptor, a novel Ang IV receptor, was 
recently purified and identified by mass spectrometry as insulin-regulated amino-peptidase 
(IRAP), a transmembrane-anchored metallopeptidase that co-translocates in vesicles with GLUT4 
to the cell surface in response to insulin (182). Very recently, Santos et al demonstrated that Ang 
1_7 mediates vasodilatory actions by direct interactions with the G-protein-coupled receptor Mas in 
mouse kidneys, suggesting Mas as a functional receptor for Ang 1_7 although a specific Ang 1_7 
receptor has not been cloned(183). Additionally, an AT3 receptor has also been identified in 
cultured mouse neuroblastoma cells, but not yet characterized (176). 
1.2.1 ATl and AT2 receptors 
Both receptors belong to the seven transmembrane spanning G-protein-coupled receptor 
family (176). The receptors comprise extracellular, transmembrane and carboxyl-terminal 
domains; the extracellular loop and the transmembrane domain play an important role in Ang II 
binding whereas carboxyl-terminal domain is the cytoplasmic and regulatory site, often 
containing sites for phosphorylation and cellular trafficking. Like most G-protein-coupled 
receptors (GPCR), the ATl receptor, but not the AT2 receptor, undergoes Ang II-stimulated 
internalization. The internalized receptors are either trafficked to lyzosome (degradation) or 
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Fig. 1 Scheme of the systemic RAS. The diverse biological effects of active peptides (Ang II, Ang III 
and Ang 1•7) that are derived from Ang I and the principal enzymes involved in their production are 
illustrated, including the possible sites of action of the human homologue of ACE (ACEH or ACE2). The 
angiotensin AT 1 and A T2 receptors, which are G-protein-coupled receptors ( GPCRs ), have been cloned 
and characterized in detail. The AT4 receptor has recently been identified as insulin-regulated 
aminopeptidase (IRAP), a membrane-bound enzyme and AT1•7receptor has not been cloned. AP, 
aminopeptidase; CP, carboxypeptidase; NEP, neural endopeptidase (neprilysin) 
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Table 4. Properties of angiotensin receptor subtypes 
,, ., Characteristic! ,., A'Il tl ��,AT2 
!/ ��
· 
':if-14 ", 
·�" 
:;. ;,. ,, ). ., . :, ., 
Affinity· Ang II>Ang III>Ang I Ang III> Ang IV 
Ang II>Ang I 
Selective antagonists 
Losartan (DuP753), PD121981, Divalinal-Ang IV 
CGP4627 PD123319, 
DuP532, EXP3174, PD124125, 
L158809 CGP42112A 
SK1F108566 PD 123177 
Coupling to G-protein YES (Gi, Gq, Ga) YES (Gi ?) NO 
Signal transduction 
Increase Ca +2 and IP3 Decrease cGMP Tyrosine 
phosphorylation 
Decrease cAMP Increase 
Increased prostaglandins Increase Ca+2 in
prostaglandins kidney 
Tyrosine 
Tyrosine dephosphorylation 
phosphorylation 
Structure 
359 amino acids 3 63 amino acids Trimer ( a,p,y) 
Seven transmembrane Seven 
domains transmembrane 
domains 
Internalizations YES NO YES(?) 
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dephosphorylated and recycled to the cell surface. A Tl and AT2 receptors, with - 32  % amino 
acid sequence homology are single copy genes found on chromosome 3 and X, respectively. In 
rodents, the two distinct subtypes (A Tl a and A Tl b) of A Tl receptor share 94 % similarity and 
are pharmacologically indistinguishable but are differentially expressed and regulated. ATI 
receptors are antagonized by biphenylimidazoles such as losartan whereas 
tetrahydroimidazopyridines such as PD 123319 specifically block AT2 receptors (176). 
Northern blot and RT-PCR analyses have identified mRNA for ATl receptor in most 
Ang II target tissues (176). ATl receptors are expressed in blood vessels, the adrenal cortex, liver, 
kidney and brain. In rats and mice, AT 1 a is the predominant receptor in most organs whereas 
A Tl b is most abundant in the adrenal and pituitary glands. A T2 receptors are ubiquitously 
expressed in human fetal mesenchymal tissues. However, the expression of the receptors rapidly 
declines at birth. In adults, A T2 receptor expression is detectable in pancreas, heart, kidney, 
adrenals, brain and vasculature (184). After vascular and cardiac injury and during wound healing 
and renal obstruction, AT2 receptors are reexpressed in adults, suggesting a possible role of AT2 
receptors in tissue remodeling, repair, growth and development (176). 
1.2.2 AT 4 receptors 
In contrast to the other angiotensin receptors associated with G proteins, AT4 
receptor/IRAP is a type II membrane-spanning protein and a member of the Ml family of zinc­
dependent metallopeptidases (185). Besides the endogenous ligand Ang IV, other peptides like 
LVV-hemorphin-7 (the endogenous globin fragment) are also capable of binding and activating
AT4 receptors (185). AT4 receptor signals via its homodimers: 1) the intracellular amino­
terminus contains multiple serine/threonine residues indicative of phosphorylation and two 
dileucine internalization motifs 2) the single transmembrane-spanning region is connected to an 
extracellular domain containing N-linked glycosylation sites and a putative cleavage site. Three 
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isoforms of AT4/IRAP are synthesized from a single gene on chromosome 5 (176). The binding 
of angiotensin IV to the AT 4 receptor is insensitive to both losartan and PD 123319, but is 
selectively inhibited by the peptide antagonist divalinal-Ang IV (186). High levels of AT4/IRAP 
are expressed in heart, placenta, skeletal muscle, kidney and small intestine whereas lower 
expression is found in brain, liver, testes, colon and spleen (185). 
1.3 Physiological Function of Systemic RAS 
Ang II, a physiologically active effector of circulatory RAS, controls blood pressure, 
body fluid homeostasis and cardiovascular homeostasis primarily due to its potent vasoconstrictor 
actions. The mechanisms of blood pressure regulation by Ang II are well-established. In addition 
to its documented vasoconstrictive effects, growing evidence has shown that Ang II may play a 
central role in cardiovascular and renal diseases. Overactivity of the RAS has been implicated in 
the development of various cardiovascular diseases, such as hypertension, congestive heart failure 
and renal insufficiency (176) 
1.3.1 Regulation of Blood Pressure 
Circulating Ang II is a main regulator of systemic and local blood pressure, as well as 
electrolyte and fluid homeostasis. It acts through its vasoconstrictive effects on the vascular 
system and by promoting renal sodium and water absorption in the kidneys in both acute and 
chronic manners (187). 
1.3.1.1 Short-term Regulation 
In the vascular system, Ang II constricts the capillary arterioles, leading to an increase in 
total peripheral resistance. Ang II enhances the peripheral effector cell response to noradrenalin 
and has a positive inotrophic effect on the heart due to an increase of calcium-ion influx during 
the plateau phase of action potential. In the central nervous system, Ang II stimulates sympathetic 
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nervous activity, thus inducing peripheral resistance which contributes to increasing body blood 
pressure (187). 
1.3.1.2 Long-term Regulation 
In its chronic actions, Ang II regulates blood pressure through direct effects in the 
kidneys and indirect effects mediated through its interactions with other hormones such as 
aldosterone and vasopressin. Ang II directly causes contraction of mesangial cells and 
constriction of the afferent and efferent arterioles in the glomerulus and thus reduces blood flow 
in the kidney. The sum of these changes reduces the glomerular filtration rate (GFR). This 
decreased GFR results in decreasing formation of urine and increasing sodium and water 
retention, thereby elevating extracellular volume and blood pressure. In addition to its GFR 
regulation, Ang II augments proximal tubular sodium and bicarbonate reabsorption primarily by 
enhancing tubular sodium transporter activities (e.g. increasing Na+/ H+ exchanger, Na+/HCO- co­
transporter and Na+/K.+ ATPase activities) and changes in starling forces (187). Ang II indirectly 
stimulates the synthesis and secretion of aldosterone in the adrenal gland, the release of 
vasopressin (antidiuretic hormone) in the pituitary and the sensation of thirst and salt appetite in 
the brain ( 187). 
1.3.2 Regulation of Gene Expression 
Independent of its vasopressor effects, Ang II directly causes cellular phenotypic changes, 
growth and migration and regulates the gene expression of growth factors, extracelluar matrix 
components and cytokines in renal mesangial, endothelial and vascular smooth muscle cells 
(VSMC) (176). These actions are proposed to participate in the pathophsiology of cardiac 
hypertrophy and remodeling, vascular thickening, thrombosis and glomerulosclerosis ( 188). 
Ang II induces expression of the several proto-oncogenes in human and rat vascular 
smooth muscle cells, including c-fos, c-jun, and c-myc. The study of Chen et al has shown that 
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Ang II induces vascular c-fos gene expression in a protein kinase C (PKC)- and Ca 2+ -dependent
manner (189). Ang II increases the expression and production of several growth factors such as 
insulin-like growth factor-I (IGF-1 ), platelet-derived growth factor A chain (PDGF-A), basic 
fibroblast growth factor (FGF) and adhesion molecules such as intracellular adhesion molecule-I 
(ICAM-1) and vascular cell adhesion molecule-l (VCAM-1) as well as chemotactic factors such 
as monocyte chemoattractant protein (MCP-1)(188). In vascular smooth muscle and mesangial 
cells, Ang II, time and dose dependently increases TGF-p mRNA, which is associated with 
increase in mRNA for matrix proteins fibronectin and collagen type 1 (190). Ang II also 
stimulates expression and production of cytokine TNF-a in renal tissue( 191 ). Additionally, Ang 
II enhances levels and activity ofplasminogen activator inhibitor-I (PAI-1) in vascular smooth 
muscle, mesangial, endothelial cells, thereby influencing fibrinolysis, extracellular matrix 
turnover, degradation and regulation of cell migration ( 192, 193). Consistently, Ang II and its 
metabolites such as Ang III and IV promote PAI-1 production and release by human fat cells in a 
ATl receptor-mediated manner, suggesting a potential prothrombotic effect of Ang II in human 
adipose tissue (194). 
Ang II is a powerful mitogen for many cells types. Ang II stimulates transition from the 
G0-G1 phase in the cell cycle, which leads to increased DNA synthesis and to mitogenesis in 
combination with other growth factors (195). In adrenal cortical cells and human preadipose cells, 
Ang II increases cell cycle regulatory protein cyclin D 1 expression and cyclin DI -dependent 
kinase activity, thus promoting cell cycle progression (196, 197). Additionally, Ang II 
upregulates transcription of genes for later markers of adipocyte differentiation such as FAS and 
leptin as well as expression of adipogenic transcription factor, ADD 1, indicating a significant role 
of Ang II in adipose growth and development (145, 198). 
44 
1.4 Regulation of Systemic RAS Components 
The rate-limiting step in the cascade of enzymatic events that make up the circulating 
RAS is the first step, the cleavage of agt by renin. The plasma agt micromolar range (-1 µM) 
whereas the affinity of renin for its substrate (Km) is about 1.25 µM in humans, indicating that 
the agt concentration is a determinant of Ang I production in vivo ( 199). Accordingly, like the 
classical controller of plasma renin activity (PRA), agt availability is important in circulating 
RAS activation. Evidence from clinical studies has noted that ACE activity is also a rate-limiting 
factor that influences the activity of RAS. Treatment with ACE inhibitors (such as captopril) has 
been clinically shown to significantly reduce blood pressure (200). In addition, a relationship 
between RAS component polymorphisms and essential hypertension has been reported previously. 
Genetic background has been shown to highly influence the activity and expression of RAS. Thus, 
it appears that genetic factors can be a critical determinant in circulating RAS activity (201 ). 
1.4.1 Angiotensinogen (agt) 
The human agt gene contains five exons and four introns, which span 13 kb and is 
located on chromosome lq42-3(202). In term of exon number, size and splicing sites, the agt 
gene belongs to the serpin (serine protease inhibitor) superfamily. Human agt protein is a globular 
glycoprotein with a molecular mass between 55 and 65 kDa, depending on its state of 
glycosylation (203). Despite the unknown function of glycosylation in humans, it has been shown 
that the glycosylation status influences the agt clearance rate in rats; the more highly glycosylated 
form is secreted faster by the liver and eliminated more rapidly by the kidney than is the less 
glycosylated form (203). Mature agt contains 453 amino acid residues (-50kD): the first ten 
amino acids correspond to Ang I and the other larger portion corresponds to des(AngI)agt. 
Plasma agt concentration reflects mainly hepatic agt synthesis since agt is constitutively released 
from hepatocytes. The plasma and tissue agt concentrations both contribute directly to the 
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circulating amounts of Ang I and Ang II, ultimately influencing the degree of RAS activation 
(176). Agt synthesis and secretion are regulated by several hormone factors. In its transcriptional 
regulation, some of the cis- and trans- regulatory elements of promoter regions of agt gene have 
been identified. 
Evidence from in vivo and in vitro experiments has demonstrated that glucocorticoids 
( especially dexamethasone ), estrogens, Ang II and thyroid hormones all increase the synthesis 
and release of agt from hepatic and nonhepatic cells (204 ). Agt production is mainly regulated by 
controlling gene transcription, although it has been shown that Ang II posttranscriptionally 
regulates agt gene expression by increasing the stability of agt mRNA (205). It has been found 
that the transcriptional cis elements, angiotensinogen-gene activating element 1 (ACEl, from -
3 39 to-139), AGE2 (from -96 to -52) and AGE3 (-6 to +22) of the proximal promoter of agt gene 
have pivotal roles in the regulation of hepatic angiotensinogen production in vivo (206). Novel 
transcriptional factors such as angiotensinogen gene-activating factor (AGF) 1 to 3 have been 
identified and regulate agt expression levels in human hepatocytes (207). The agt expression is 
tightly controlled through the actions of a multihormone-inducible enhancer (from -615 to -4 70). 
Glucocorticoids stimulate agt transcription by binding directly to the glucocorticoid receptor 
( GR) which is translocated into the nucleus to interact with glucocorticoid receptor element 1 
(GREl: from -548 to -570) and glucocorticoid receptor element 2 (GRE2 : from -472 to -477) 
within the agt promoter (208,209). Cytokine TNF-a induces agt transcription by nuclear factor­
KB (NF-KB) transcription factor which binds to acute-phase response element (APRE: 5' to the 
transcriptional state site), which is the binding site for C/EBP (210,211). The critical core 
promoter region of agt gene has been analyzed. A ubiquitously expressed nuclear factor, hAG 
core promoter binding factor 1 (AGCFl), binds to hAG core promoter element 1 (AGCEl: from -
25 to -1) which appears to play a major role in activating agt transcription. Several natural 
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variants of agt gene have been detected in this regulatory region. A variant in the proximal 
promoter of the agt, an adenine instead of a guanine six nucleotide upstream from transcription 
initiation site, A at (-6) has been suggested to be causally related to a genetic predisposition to 
essential hypertension (212). 
1.4.2 Renin 
Renin is encoded by a single gene and renin mRNA is translated into the preprorenin. In 
JG cells, preprorenin is converted into mature and active renin by a series of proteolytic cleavages 
and glycosylation (213). Stored active renin is released from JG cells by an exocytic process 
involving stimulus-secretion coupling. Plasma renin depends on 1) transcriptional control of the 
renin gene;2) posttranscriptional control at the mRNA level;3) posttranslational processing of the 
preprorenin protein, and;4) the uptake of renin into vesicles and its release (214, 215). 
With regard to the regulation ofrenin transcription, two enhancer regions have been 
identified that markedly increase renin synthesis. In the renin enhancer, cAMP responsive 
elements and several important transcription factors (retinoid acid receptor, RAR/retinoid X 
receptor RXR), E box proteins USF1/USF2 and Hox/Pbx have been found (215,216). Vitamin 
D3 and its receptor have been suggested as a negative regulator of renin expression (217). This 
was also supported by clinical observations that there is an inverse relationship between plasma 
vitamin D3 levels and plasma renin activity as well as with blood pressure. Vitamin D3 
supplementation has been shown to lower blood pressure in hypertensive subjects (218). 
In addition to transcriptional regulation in renin expression, posttranscriptional control at 
the renin mRNA level has been demonstrated. In particular, cAMP has been known as an inducer 
of renin synthesis via prolonging its mRNA half-life (213 ). More recently, the studies from 
Skalweit et al have identified several RNA-binding regulatory proteins (hnRNP Kand El, 
Dynamin, Nucleolin, Y-Boxl and MINT homologous protein) involved in 3'-untranslated regions 
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{UTR)-mediated control of renin mRNA stability and also illustrated that cAMP-based renin 
mRNA stabilization is accompanied by upregulation of these renin mRNA binding proteins (219). 
Renin release from the kidney· JG cells is affected by several systemic and intrarenal 
factors (213). Systemic factors include sympathetic nerves (stimulator), circulating Ang II 
(inhibitor), blood pressure (inhibitor) and salt balance (inhibitor). Intrarenal factors are renal nitric 
oxide and prostaglandins which stimulate renin secretion (213). At the cellular level, renin 
secretion is controlled by classic signaling systems, including cAMP, Ca2+/PKC and cGMP 
pathways (213). While cAMP and Ca2+ /PKC appear to be direct antagonists in the regulation of 
renin secretion, cGMP plays a more versatile role by directly inhibiting renin secretion via protein 
kinase GU (PKGII) and by indirectly stimulating renin secretion via inhibition of cAMP 
degradation (220) Renin metabolic clearance rate (MCR) in plasma has been shown to be 
decreased by elevated agt concentration. The studies pointed out that higher agt concentration 
increases agt-renin complex stability and thus elevates PRA, thereby increasing blood pressure 
independent ofrenin secretion and Ang II-mediated feedback (220). Interestingly, the studies of 
Nguyen et al have implicated renin receptor as an important cofactor in PRA since it increases the 
catalytic efficiency of agt cleavage by receptor-bound renin, thus facilitating Ang II generation 
and action on a cell surface (221 ). 
1.4.3 ACE 
The ACE gene produces two mRNA species from tissue-specific promoters and two 
isoforms of ACE (222). The ubiquitous somatic ACE and the sperm-specific germinal ACE have 
identical enzymatic activity. ACE converts Ang I into Ang II and inactivates two vasodilator 
peptides, bradykinin (BK) and kallidin (176). ACE exists as soluble and membrane-bound forms 
but most of ACE is membrane-bound (222). ACE2 (an ACE homolog, ACEH) has recently been 
identified in humans that differs from ACE in specificity and physiological roles (223). ACE2 
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cleaves a single residue from Ang I, generating Ang 1_9 and a single residue from Ang I I  to 
generate Ang 1_7• ACE2 has been shown to play as a critical regulator of cardiac function (224). 
Pharmacological stimulators and pathological conditions modulate ACE expression and 
secretion (200, 225-228). Several agents, such as cAMP analogues and calcium ionophore 
A23187 have been shown to induce ACE secretion from cultured bovine endothelial cells (225, 
226). ACE secretion was also increased by glucocorticoid hormone on cultured endothelial cells 
and VSMC (227). Fibroblast growth factor increases ACE gene expression in cultured rat aortic 
smooth muscle (RA SM) (228). Pathophysiologic conditions such as hypertension and heart 
failure induce an increase in tissue ACE activity. Additionally, ACE insertion (!)/deletion (D) 
polymorphism has been shown to influence plasma ACE level; subjects with the D allele have 
higher plasma ACE levels and blood pressure than subjects with the I allele (200). 
1.5 Signaling Mechanisms of Angiotensin Receptors 
1.5.1 Overview 
The interaction of Ang II with A Tl and A T2 receptors activates a complex series of 
intracellular signaling events (176). The physiological functions of ATl receptors are 1) cell 
growth and proliferation 2) vasoconstriction and 3) salt and water retention. A Tl receptor­
induced effects are mediated via complex and interacting signaling pathways involving 1) 
stimulation of phospholipase C (PLC)/ PKC and Ca +i mobilization 2) activation of phospholipase 
D (PLD)/phospholipase A2 (PLA2) 3) activation ofMA PK/signal transducers and activators of 
transcription (STAT)/ Janus kinase (JAK) and 4) transactivation ofreceptor tyrosine kinases such 
as epidermal growth factor receptor (EGFR), insulin growth factor receptor (IGFR) and platelet­
derived growth factor receptor (PDGFR) (Fig 2). By comparison, the cell signaling pathways 
involved in A T2 receptor activation are not fully clarified but appear to involve G protein-
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Fig. 2 Signal transduction mechanisms and physiological effects mediated by the ATJ receptor. 
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dependent and independent pathways. Current evidence has elucidated four major signal 
transduction cascades induced by AT2 receptor activation: 1) activation of the phosphotyrosine 
phosphatase and protein dephosphorylation 2) regulation of BK-nitric oxide (NO)-cyclic 
guanosine monophosphate ( cGMP) system 3) stimulation of PLA2 and release of arachidonic acid 
(AA) and 4) sphingolipid-derived ceramide (Fig 3). Functionally, the AT2 receptor exerts 
vasodilatory, antihypertrophic and proapoptotic effects, which antagonize the A Tl receptor­
mediated physiological actions. Like AT2 receptors, Ang IV-activated AT 4 receptors may 
oppose the effect of AT 1 receptor by modulating renal blood flow, inhibiting tubular Na+ 
reabsorption and blocking cardiac hypertrophy. The initial events that characterize the 
intracellular signaling mechanisms of the AT4 receptor are presently unknown, although 
downstream target genes (c-Fos, c-Jun, PAI-1) have been found (176). 
1.5.2 Signaling Mechanisms of A Tl Receptors 
AT 1 receptor expression is physiologically and hormonally regulated in a transcriptional 
or posttranslational-dependent mechanism. The expression of ATl receptors is tissue-specific. 
Ang II downregulates the expression of vascular AT 1 receptors by a negative feedback 
mechanism (176). Recent studies have provided evidence that AT2 receptor is a natural 
antagonist of A Tl receptor in a ligand-independent manner. A T l/ AT2 receptor 
heterodimerization increases structural stability of A Tl receptors and thus diminishes its 
sensitivity to Ang II. Overexpression of AT2 receptors decreases A Tl receptor expression (229). 
Like GPCR signaling cascades, AT 1 receptors interact with different G protein isoforms 
including Gq/11, Gi and Ga12 and Ga13 which couple to distinct signal cascades. One of the 
earliest events triggered by Ang 11-ATl receptor stimulation is a rapid, PLC-dependent hydrolysis 
of phophatidylinositol-4,5-bisphophate. PLC activation results in the production of 1,4,5-inositol 
51 
ATIR,ap•r � II 
Fig. 3 Signal transduction mechanisms and physiological effects mediated by the AT2 receptor. 
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triphosphate (IP3) and diacylglycerol (DAG), which are involved in Ca+2 mobilization from the 
sarcoplasmic reticulum (SR) and stimulation of PKC, respectively (230). Increased 
intracellular Ca+2 induces VSMC contraction, whereas PKC activation regulates intracellular pH 
through the Na+II-r exchanger and induces voltage-opening Ca+2 channel activation on plasma 
membrane via phosphorylation, thereby leading to cellular contraction (231,232). 
Ang II-induced PLD activation induces the formation of phosphatidic acid and 
subsequent generation of DAG which is the physiological activator of PKC and is also a source of 
arachidonic acid production. Earlier studies reported that molecular mechanis� coupling A Tl 
receptors to PLD were independent ofGq and Gi proteins (176). These observations are 
supported by studies from Ushio-Fukai et al, which has illustrated that A Tl receptor activation of 
PLD is mediated by Ga12 and G�y subunits, Src and RhoA (233). ATl receptor-stimulated PLD 
signaling has been implicated in vascular contractility, cardiac hypertrophy and VSMC 
proliferation. These effects have been revealed to be mediated via phosphatidic acid (PA) and 
other PLD metabolites (234), which affect vascular generation of superoxide anion by activating 
NAD(P)H oxidase (233), stimulate tyrosine kinases and Raf/Ras, and regulate intracellular Ca +2 
signaling (235). 
Ang II activates PLA2, which is responsible for the release of arachidonic acid from cell 
membrane phospholipids. Released arachidonic acid (AA) is metabolized by cyclooxygenases, 
lipoxygenases or cytochrome P450 oxygenases to many different eicosanoids in vascular and 
renal tissues. PLAi-derived eicosanoids have been recognized as important regulators in vascular 
and renal mechanisms of blood pressure regulation (236). ATl receptor-induced activation of 
vascular PLA2 in response to Ang II is dependent on intracellular Ca +2 and Ca +2-calmodulin­
dependent protein kinase II and MAPK (237). On the contrary, in renal epithelial cells, Ang II­
evoked PLA2 stimulation has been shown be mediated via AT2 receptors and a Ca+2-independent 
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mechanism (238). Ang II-generated eicosanoids through PLA2 activation have been demonstrated 
to modulate vascular contraction and growth possibly via MAPK and redox-sensitive 
pathways(236).Vasorelaxant prostaglandins such as PGI2 and PGE2 attenuate Ang II-mediated 
vasoconstriction in vascular tissues whereby thromboxanes are involved in Ang II-activated 
contraction (236). Lipoxygenase-derived eicosanoids appear to facilitate Ang II-elicited 
vasoconstriction in VSMC. Lipoxygenase inhibitors decrease the vasoconstrictor effect of Ang II 
and attenuate blood pressure in spontaneously hypertensive rats (SHR) (236). 
A Tl receptor-Gi coupled signaling inhibits adenylate cyclase in several Ang II target 
tissues including liver, kidney and adrenal glomerulosa, thus decreasing formation of the 
vasodilator cAMP and consequently inducing vasoconstriction (176). Further, the early event of 
AT 1 receptor signaling is also associated with stimulation of non-receptor tyrosine kinase 
phosphorylation including JAK, Src family kinase, Ca+2-dependent and redox sensitive tyrosine 
kinases (e.g. proline-rich tyrosine kinase, PYK.2), focal adhesion kinase (FAK), p130Cas, PI3K 
and MAPK. These processes are linked to mitogenic-and inflammatory-like characteristics of 
Ang II (176). 
Ang II rapidly activates c-Src in VSMC. Src plays a pivotal role in A Tl receptor-induced 
activation of PLC-y and IP3 formation. Src has also been associated with A Tl -induced 
stimulation of PYK.2 and extracellar signal regulated kinase (ERK) as well as activation of other 
downstream proteins including JAK2, ST A Tl and adaptor protein, She (239). Studies on VSMC 
from human resistance arteries suggested an important role of Src in the regulation of Ang II­
induced Ca +2 mobilization (240). Further, the studies of Sayeski et al have illustrated that c-Src 
activation is required for Ang II-induced activation of p130Cas which is important in cytoskeletal 
reorganization, focal adhesion formation and cell migration (241 ). 
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Similar to classical cytokine receptors, A Tl receptors also activate JAK2 and TYK2, 
member of the JAK family in VSMC, cardiac myocytes, and renal mesangial cells, which may 
partly explain the cytokine-like actions of Ang II in mediating cardiovascular remodeling (242). 
Mechanically, ATl receptor-derived messengers (Ca+2, DAG, PKCo) signal to JAK2 through
PYK2 in VSMC. The JAK2 phosphorylation in response to Ang II is also associated with 
Gq/PLC pathways (243). In other studies in RASM cells, Schieffer et al proposed a distinct 
pathway for Ang II-induced JAK2 activation. Ang II-stimulation of the ATl receptors increases 
JAK2 activity via G�-subunit association (244). The ATl receptor activated by Ang II induces 
rapid tyrosine phosphorylation of JAK.2 and subsequently the phosphorylation of its substrates 
ST AT proteins, which are transcription factors and are involved in mRNA expression of early 
growth response genes such as c-fos, c-jun and c-myc (245). Using electroporation techniques 
with anti-ST AT proteins, Marrero et al demonstrated an essential role of ST AT proteins in Ang 
II-induced cell proliferation, but not to other growth factors (245). Further evidence has revealed
that NADPH oxidase-generated 02- is required for ATl receptor activation of the JAK/STAT 
cascade participating in Ang II-induced inflammation in RASM cells. This study implies 
additional functional roles of the Ang II-stimulated JAK/STAT signaling pathway (246). 
Ang II promotes cell migration and changes in cell shape and volume in FAK-dependent 
signaling pathways (247). It has been shown that Ang II-activated FAK results in its translocation 
to sites of focal adhesion with extracelluar matrix and phosphorylation ofpaxillin and talin, 
which may be involved in the regulation of cell morphology and movement (248). Previous 
studies have reported that Ang II /ATl receptor-mediated stimulation of PYK2 (also called 
F AK2) is implicated in the regulation of ion channel, cell adhesion, motility as well as mitogenic 
and hypertrophic reactions (248). This PYK2 activation was associated with Fyn (Src family 
member). Alternatively, other studies have demonstrated that PYK2 accounts for Ang II-induced 
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EGFR transactivation, leading to stimulation of ERK cascade (Ras/Raf/MEK/ERK.). ATl 
receptors activate tyrosine phosphorylation of PYK2 which increase c-Src phosphorylation. 
PYK2 associated c-Src activation induces the direct recruitment of Grb2/Sos complex for ERK 
activation (249). In endothelial cells, Ang II-induced tyrosine phosphorylation of PYK2 was 
regulated by a Yes tyrosine kinase (Src family member) and a tyrosine phosphatase SHP-1 (250). 
The study by Tang et al has emphasized that PYK2 functions as an important mediator in protein 
tyrosine kinase-mediated contractility when stimulated with Ang II in rat VSMC (250). 
Pl3K, characteristically associated with tyrosine kinase receptors, influences cell survival, 
metabolism, cytoskeletal reorganization and membrane trafficking (251 ). In VSMC, Ang II has 
been shown to stimulate activity, phosphorylation and migration of PI3K by ATl receptors, 
leading to DNA synthesis and proliferation (252, 253). PI3K inhibition by wortmannin and LY 
294002 abolished Ang II-stimulated hyperplasia in cultured rat VSMC, implicating a regulatory 
role in VSMC growth. Further, Akt/PKB has been identified as a PI3K downstream target in Ang 
II-activated VSMC (253). However, the cellular mechanisms whereby the ATl receptor mediates
activation of PI3K-dependent Akt/PKB remain unclear. Further elucidation of the mechanisms of 
ATl receptor-mediated PI3K activation in hypertrophy ofmesangial cells has revealed 
arachidonic acid/redox-dependent and PI3K-independent pathways, suggesting that reactive 
oxygen species (ROS), a critical factor in the development of cardiovascular diseases, may be an 
important component of Ang II-mediated growth (254). A very recent study has pointed out that 
Akt/PKB is necessary for Ang II-ATl-induced hyperplastic actions and this effect is mediated by 
a Gq protein-dependent Ca+2-dependent pathway in RASM cells (255). In addition, Ang II­
activation of PI3K/Akt has also been implicated in the prevention of cell apoptosis through 
inhibition of caspases (253). Despite the mitogenic effect of PI3K in Ang II target tissues, the 
exact role of PI3K in Ang II signaling has not yet been established. 
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Ang II differentially activates the major members of the MAPK family, ERKI/2, c-Jun 
N-terminal protein kinase (JNK) and p38 MAPK at various intracellular levels via ATI receptor
mediation (256, 257). Ang II-stimulated ERKI/2 is associated with increased expression of the 
early response genes like c-fos, c-myc and c-jun involved in DNA synthesis, cell growth and 
differentiation and cytoskeletal organization(258). Src, Ras-protein kinas C-( (PKC-l;) and PI3K 
have been identified as upstream linker molecules ofERKI/2 stimulation (258). In addition to 
these upstream modulators, Ang II-induced oxygen radicals have been shown to induce 
phosphorylation ofERKI/2, which is responsible for enhanced p27kipt protein (an inhibitor ofGi 
phase cyclin-dependent kinase) expression and cellular hypertrophy, implicating an essential role 
of reactive oxygen species (ROS) in ERK phosphorylation in response to Ang II in renal 
proximal tubular cells (259). In addition to ERK activation, Ang II activates JNK/Stress activated 
protein kinase (SAPK), which control VSMC growth by promoting apoptosis or inhibiting 
mitogenesis via p21-activated kinase (aPAK) (260). Following phosphorylation, JNKI/2 
translocate to the nucleus to activate transcription factors such as c-Jun and activating 
transcription factor 2 (A TF-2). It appears that Ang II exerts growth-facilitative effects via 
ERKI/2 activation as well as growth-inhibitory effects mediated via JNK/SAPK stimulation 
(261). Ang II also phosphorylates vascular p38 MAPK, which is associated with inflammatory 
responses, apoptosis, arterial remodeling in hypertension and cellular stresses including heat and 
osmotic shock (262). A recent study has observed that Ang II-induced p38 MAPK activation 
along with ERKI/2 activation is required for hypertrophic action mediated by ATl receptors in 
VSMC (262). Ang II-induced ROS also play a role as second messenger in this signal cascade 
(262). 
Significantly, it has become apparent that mitogenic responses to the ATI receptor are 
mediated by activation of receptor tyrosine kinase (R TK), even though it does not directly bind to 
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R TK (261 ). Two major possible mechanisms of Ang II-induced EGFR and/or PDGFR 
transactivation have been proposed; 1) tyrosine kinase ( c-Src/PYK2) or JAK mediation and 2) 
ROS mediation. Ang II-induced EGFR transactivation has been shown to require Ca+2, Ca+2-
sensitive tyrosine kinases (PYK2 and Src) and linker proteins such as Grb2/Sos complex, which 
promotes tyrosine receptor dimerization and, subsequently ERK activation, ultimately leading to 
VSMC hyperplasia (249). EGFR transactivation also participates in the signaling pathway of Ang 
II-stimulated c-fos gene expression, DNA synthesis, and protein synthesis (263). Previous studies
have provided strong evidence of a key role for ROS (e.g. H202) in ERK.1/2 and p38 MAPK 
activation by Ang II and growth factors (264). Similarly, other studies have demonstrated that 
ROS mediate EGF-induced phosphorylation of its receptor as well as PDGF stimulation of STAT 
tyrosine phosphorylation (265, 266). Further study provided direct evidence that the 
transactivation of PDGFR by Ang II required activation of RAS as a second messenger (267). 
Alternatively, the studies from Prenzel et al have demonstrated another mechanism for cross-talk 
between GPCR and RTK. Requirement of a metalloproteinase mediated cleavage of pro-heparin 
binding (HB)-EGF (a ligand ofEGFR) for GRCR-induced EGFR transactivation has been 
reported. Further, metalloproteinase was activated by Ca +i or PKC leading to formation of active 
HB-EGF, suggesting a plausible mechanism of Ang II-induced transactivation mediated by 
metalloproteinase (268). A similar process was found in insulin-like growth factor l(IGF-1) 
transactivation with Ang II in VSMC (269). However, the role of this mechanism in RTK 
transactivation by Ang II is still unclear as some studies failed to observe inhibition of Ang II­
mediated EGFR transactivation by metalloproteinase inhibitor (261 ). Like EGFR transactivation, 
Ang II-transactivated PDGFR has been reported. PDGFR transactivation by Ang II has been 
shown to be a Ca+2 independent and redox-sensitive mechanism (261). However, the exact 
mechanism by which ROS mediated this mechanism is still unknown. Collectively, the A T l  
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receptor-induced signal transduction cascade is mainly mediated through phospholipids, non­
receptor tyrosine kinase phosphorylation and receptor tyrosine kinase transactivation, leading to 
cell proliferation, growth and vasoconstriction in a variety of cells. 
1.5.3 Signaling Mechanisms of AT2 Receptors 
Although the regulation of A T2 receptor is poorly understood, A T2 receptor expression 
may be controlled at the transcription, post-transcription (mRNA stability) and translation levels 
(176). AT2 receptor expression is upregulated by sodium depletion and is suppressed by Ang II 
and growth factors such as PDGF and EGF. Interestingly, growth factors like insulin and IGF 
upregulate AT2 receptor expression. Currently, much less is known about the intracellular 
mechanism of AT2 receptors. However, recent studies have demonstrated that its signaling 
pathways are associated with serine and tyrosine phosphatases, NO, PLA2 (prostaglandins) and 
cGMP (176). 
Current evidence indicates that AT2 receptor stimulation leads to activation of various 
phosphatases, especially serine/threonine phosphatase 2A (PP2A), protein tyrosine phosphatase 
{PTP), MAP kinase phosphatase 1 (MKP-1) and SH2-domain-containing phosphatase 1 (SHP-1 ), 
resulting in the inactivation of MAPK, especially ERK.1/2 and consequently inhibition of growth 
in different types of cells (176). Earlier studies have demonstrated that AT2 receptor stimulation 
antagonizes the growth-stimulatory effect via A Tl receptors. A T2 receptor activation in cultured 
rat neonatal cardiomyocytes and fibroblasts inhibited A Tl receptor-dependent growth (270, 271 ). 
Further reports have elucidated that AT2 receptor activation inhibited growth factor-induced 
ERK.1/2 activities through dephosphorylation of serine/threonine phosphate by PP2A or MKP-1 
in cultured rat neurons. The activation of PP2A by AT2 receptors has been shown to be 
associated with Gai proteins. These findings suggest that A T2 receptor activation involves 
antiproliferative/antigrowth effects (272). Consistently, growth-inhibitory effects by AT2 receptor 
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activation have also been reported in cultured coronary endothelial cells, VSMC and PC 12W 
cells (176). In addition to AT2 receptor-mediated inactivation of ERK.1/2 via PP2A, an 
alternative tyrosine kinase phosphatase-dependent pathway was observed in growth-suppressing 
effects of AT2 receptor activation. Growth factor-induced ERK.1/2 activities were attenuated by 
AT2-induced tyrosine kinase phosphatase, SHP-1. The inhibitory effect was mediated by non­
Gi/Gq pathways (273). Interestingly, the study by Dulin et al provided evidence that AT2 
receptors increased ERK.1/2 phosphorylation by PLAi-dependent release of Arachidonic acid 
(AA) and cytochrome P450-dependent production of epoxy derivatives of AA in renal proximal 
tubule epithelial cells (274). Additional evidence of AT2-dependent MAPK cascade activation 
mediated by AA was demonstrated in kidney epithelial cells. Ang II/AT2's activation ofp21ras 
has been shown to be mediated by the Shc/Grb2/Sos complex and AA(275). The MAPK cascade 
activation by Ang II in the kidney has been suggested to be responsible for the AT2-induced 
natriuretic effect. Further, AT2 receptor-stimulatory effects on differentiation were reported in 
neuronal NG108-5 cells, PC12W cells and VSMC. Neuronal differentiation by Ang II/AT2 
receptors was mediated by a decrease in p21 ras activity, together with an increase in MAPK 
activity (276). A subsequent study from the same group has also reported that AT2-mediated 
neuronal differentiation occurs through an increase in NO production(277). These findings were 
confirmed by another study on VEGF-induced endothelial cell differentiation. They found that 
the MAPK cascade was activated the by NO/cGMP pathway (278). Very recently, the same 
group of researchers has examined whether Rap 1 ( a small guanine nucleotide-binding protein of 
the Ras family )/B-Raf ( a neuron-specific member of the Raf family of kinases) may involve Ang 
II-induced MAPK activities participating in the morphological differentiation of NG 108-15 cells.
They found that the AT2 receptors of Ang II induce differentiation ofNG108-15 cells in cAMP­
independent and Rap 1/B-Raf-dependent manners (279). An A T2 receptor-mediated proapoptotic 
60 
effect has been observed in R3T3, VSMC and PC12W cells. The mechanism by which AT2 
receptor promotes apoptosis has been demonstrated to be associated with ERK inactivation 
mediated by bcl-2 dephosphorylation via MKP-1 and SHP-1 _activation (280). Recently,
ceramides, which are possible caspase 3 and phosphatase activators have been proposed to be 
mediators in AT2 receptor-stimulated apoptosis (281). Like ATI transactivation with RTK, a 
recent study has shown that AT2 activation cross-talks with the insulin signal cascade and thus 
induces apoptosis in Ang II-responsive cells (176). 
In addition to A T2 receptor's apoptotic effect, A T2 receptor activation influences 
neuronal cell activity via modulating ion channel activity. Kang et al showed that AT2 receptor 
stimulation increased neuronal delayed rectifier K+ current through Gi protein and PP2A 
activation (282). In non-differentiated NG 108-15 cells, AT2 receptors mediate inhibition ofT­
type Ca +2 currents via activation of a tyrosine phosphatase (283 ). Neuronal membrane ionic 
current changes by AT2 receptors may result in hyperpolarization of membranes that suppress 
cellular activities stimulated by depolarization. 
It has been shown that AT2 receptors activate PLA2 and stimulate AA and prostaglandin 
generation, which are linked to AT2 receptor-induced vasoactive effects. The study by Kohout et 
al has demonstrated that the AT2 receptor-mediated release of arachidonic acid upregulates ion 
transporter system (Na+/H+ exchanger and Na+/HCO- symporter system), which influences pH in 
cardiac cells leading to heart contractility (284). Recently, AA has been documented as a second 
messenger in A T2 receptor-induced activation of p21 Ras in renal tubule epithelial cells (275). AT2 
receptor-dependent production ofPGI2 was reported in differentiated adipocytes Ob 1771 in 
culture. PGI2 facilitates differentiation of undifferentiated Obi 771 cells in a coculture system by 
a paracrine-dependent mechanism. This action was blocked by PD 1231771, but not the AT 1 
receptor antagonist losartan, suggesting that prostacyclin production is dependent on AT2 
61 
receptor activation (285). However, the mechanism involved in this signaling pathway remains to 
be defined. In the kidney, the A T2 receptor has been shown to stimulate the conversion of renal 
PGE2 to PGF2a and subsequently increase the production ofvasodilator prostanoids, 
contributing to its vasodilatory actions (176). 
Moreover, AT2 receptor was subsequently shown to mediate vasodilation via stimulation 
of the BK-NO-cGMP pathway in the vasculature and kidney. In aortic VSMC, the AT2 receptor 
causes intracellular acidosis by inhibition of an amiloride-sensitive epithelial sodium channel, 
thus activating kininogenase, which cleaves BK from intracellularly stored kininogen. The AT2 
receptor-induced BK release triggers the formation NO/cGMP in a paracrine manner to promote 
vasodilation and natriuresis thus leading to antihypertensive effects (286,287). Collectively, the 
AT2 receptors exert an anti-ATl receptor effect in VSMC, PC12W cells and neuronal cells. In 
response to Ang II, A T2 receptor-induced antigrowth, vasorelaxation, sodium excretion, 
differentiation and apoptosis are mediated by inhibition of ATl receptor or RTK-mediated 
MAPK via activation of various phosphatases (protein dephosphorylation), stimulation ofBK­
NO-cGMP pathway and release of prostaglandins in G protein-dependent and-independent 
manners. 
1.5.4 Signaling Mechanisms of AT4 Receptors 
AT 4 receptor is new Ang-receptor type that has recently been discovered and 
characterized that preferentially binds to Ang IV. AT 4 receptor stimulation by Ang IV is 
suggested to mediate both peripheral and central actions. To date, intracellular signaling 
mechanisms of AT4 receptors remain largely unknown. Peripherally, Ang IV has been shown to 
elicit a vasodilatory effect by increasing renal blood and flow and natriuresis in an AT4 receptor­
dependent manner. In a related study, Patel et al have noted that the vasodilatory effects of AT4 
receptors in response to Ang IV may be attributed to Ang II-induced NO effects (288). The study 
62 
by Handa et al has found that Ang IV acts on tubular epithelium to inhibit sodium transport via a 
decrease in Na+-K+ ATPase activity without changes of mean arterial pressure (MAP), GFR and 
urine volume, thereby contributing to natriuretic action of AT 4 receptors in the kidney (289). 
Additionally, the activation of the renal AT 4 receptor has been reported to result in increased 
PAI-I expression in proximal tubule cells and an increase in intracellular calcium signaling 
activity in mesangial, proximal tubule and distal/collecting duct cells. Further, AT4 receptor 
activation has been shown to inhibit DNA and protein synthesis in chick cardiocytes, thus 
blocking hypertrophy of cardiac cells (176). Interestingly, in the brain, Ang IV/AT4 receptor 
stimulation has been demonstrated to activate c-fos expression and facilitate learning and memory 
processes (176). 
1.5.5 Cross-talk between Ang II and Insulin Signaling Systems 
1.5.5.1 Overview 
As mentioned above, Ang II and Ang II-derived biologically active products of RAS 
have a vast range of actions throughout the body. Importantly, the A Tl or A T2 receptor 
activations in response to Ang II have been documented to negatively or positively cross-talk 
RTK signaling in a variety of cells, thus contributing to Ang II's divergent effects related to 
health and cardiovascular diseases (176). Several lines of evidence have demonstrated cross-talk 
between Ang II and insulin signaling systems, emphasizing an association between hypertension 
and insulin resistance which are risk factors for cardiovascular diseases (290, 291 ). 
Epidemiological studies have shown that hypertensive individuals are more likely to become 
diabetic than normotensive ones (292). 
Additionally, it has been suggested that pharmacological inhibition of RAS, as with ACE 
inhibitors and A Tl receptor antagonists, has beneficial effects on both hypertension and insulin 
resistance (293). This suggests a role for RAS in the regulation of insulin action, even though 
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results of experimental and clinical studies on the effect of A Tl receptor antagonists on insulin 
sensitivity have been conflicting. Some studies show no influence on insulin sensitivity and 
others demonstrate an improvement of insulin sensitivity (293,294). In support of positive effects 
of ATl antagonists on insulin sensitivity, Umeda et al demonstrated that ATl receptor 
antagonists improve insulin sensitivity in hypertensive animals with insulin resistance. However, 
the mechanism underlying this effect is unknown (295). Recently, Sharma et al proposed a 
mechanism for prevention of diabetes by RAS blockade. Inhibition of RAS promotes recruitment 
of preadipocytes which are sensitive to insulin because Ang II has been shown to act as an 
antiadipogenic substance in human adipose tissue. This induces redistribution of lipids from 
muscle and other tissue to adipose tissue, subsequently resulting in improved insulin sensitivity 
(296). Additionally, Henriksen et al have reported that A Tl receptor antagonism improves insulin 
resistance due to the effect on skeletal-muscle glucose uptake associated with an increase in 
GLUT4 protein expression (297). 
On the other hand, it has been observed that hyperinsulinemia and insulin resistance 
participate in the pathogenesis of hypertension (298). In this context, it has been described that 
hyperinsulinemia is closely associated with reduced renal sodium excretion and stimulation of the 
SNS (299). Insulin has direct effects on blood vessels modulating vascular tone via alterations in 
NO and cytosolic Ca +2 levels (300). The growth promoting effects of insulin have been proposed 
to be the most critical factors in increased cardiovascular risk (301). The different forms of 
insulin like IGF and proinsulin have also been shown to be involved, along with insulin, in 
vascular growth stimulation and atherosclerosis (301). Further, insulin activates the vascular RAS 
via stimulation of agt or Ang II production and upregulation of AT 1 receptor expression, thus 
resulting in enhanced cell growth of VSMC on stimulation with Ang II. These results provide 
evidence that the action of insulin on blood vessels, especially its effects on cell growth, is 
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mediated through activation of RAS components (302, 303).Very recently, Harte et al showed 
that insulin increases agt expression and production in human abdominal subcutaneous 
adipocytes in a dose-dependent manner, suggesting that hyperinsulinemia in obesity may be a 
contributing factor in obesity-associated hypertension (304). 
Consequently, potential interplays between insulin and the RAS (e.g. combined effects of 
insulin and the RAS) may account for the pathogenesis of hypertension/atherosclerosis and 
insulin resistance/diabetes. 
1.5.5.2 Insulin Signaling Systems 
Insulin is a key hormone implicated in wide biological effects on metabolism, cellular 
growth and differentiation. Insulin stimulates the synthesis and storage of carbohydrates, lipids 
and proteins in insulin-sensitive tissues such as fat, liver and muscle by promoting glycogen and 
protein synthesis and lipogenesis while inhibiting glycogenolysis, protein breakdown and 
lipolysis (251 ). Insulin resistance or deficiency is a defect in the response of muscle, adipose 
tissue and liver to insulin-mediated glucose transport, production of metabolism, and storage, 
thereby resulting in elevations in fasting and postprandial glucose and lipid levels. Insulin 
resistance is also linked to other common health problems such as obesity, diabetes, 
hyperlipidemia, hypertension and atherosclerosis. The pathophysiology of insulin resistance may 
be ascribed to impaired insulin signaling including insulin binding to its receptor, receptor 
phosphorylation and kinase activity, phosphorylation oflRS, activation of PI3K and subsequent 
down-regulation ofGLUT4 (major insulin-responsive glucose transporter) (251). 
Binding of insulin to the extracellular a-subunit of the IR leads to IR 
autophosphorylation and subsequently tyrosine phosphorylation oflRSs. Phosphorylated IRS-1 
and IRS-2 act in turn as docking proteins, recruiting and activating divergent signaling molecules, 
including those in the Ras-Raf-MAPK and PI3K pathways. The PI3-K pathway triggers several 
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cellular responses such as I) glucose transport 2) glycogen synthesis 3) protein synthesis 4) 
antiapoptosis and 5) gene expression while the Ras-Raf-MAPK pathway is important for 
mitogenic effects of insulin (Fig 4) (251). 
To date, two signaling pathways for insulin-stimulated glucose transport have been 
proposed in most insulin-responsive cells: the classic-PI3K-dependent pathway and the proposed 
PI3K-independent, alternative pathway (251). In classic PI3K-dependent pathway, the activated 
IR catalyzes IRS tyrosine phosphorylation, leading to recruitment of downstream effectors, the 
most important for glucose transport being PI3K. Akt/PKB 
and the atypical PKC isoforms have been both implicated as PI3K-induced Ptdins (3,4,5)P3 
effectors involved in GLUT4 translocation (251). In a parallel pathway, the Cbl-associated 
protein (CAP)-Cas B-lineage lymphoma (Cbl) dimeric complex is recruited to the IR, and Cbl is 
also tyrosine phosphorylated by IR kinase. The CAP-Cbl complex is recruited to lipid raft 
domains in the plasma membrane, and phosphorylated Cbl assembles a signaling complex 
consisting of the scaffolding protein CrklI, the guanine nucleotide exchange factor C3G, and the 
small GTP-binding protein TCIO. Activation of TC IO is proposed to mediate insulin-stimulated 
actin rearrangement which seems to be important in GLUT4 translocation to the plasma 
membrane (251) (Fig 5). 
1.5.5.3 Interactions between Ang II and Insulin Signaling Systems 
In view of the pivotal association between insulin resistance, hypertension and 
cardiovascular disease, several groups have explored the interactions between Ang II and insulin­
signal transduction using both in vivo and in vitro systems (305-310). Several lines of evidence 
have revealed that positive or negative cross-talk between Ang II and insulin signaling occur at 
several different levels of these two hormone response pathways in muscle and heart tissues. 
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Fig. 4 Multifunctional actions of insulin signal transduction. Insulin is the most potent anabolic 
agent known and exerts its numerous effects on insulin-responsive cells through two main signaling 
pathways, A (PI3K pathway) and B (MAPK pathway). Two signaling pathways regulate diverse functions 
including metabolic activity, growth, and differentiation (251). 
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Fig. 5 The mechanisms of insulin-stimulated glucose transport in insulin-sensitive tissues such 
as muscle and adipose tissue. It is likely that at least two signaling pathways (e.g. classic PI3K­
dependent pathway (A) and altemative-PI3K-independent pathway (B)) are required for the stimulation of 
Glut 4 translocation in response to insulin (25 I). 
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An earlier in vivo study from Saad et al. has shown that Ang II stimulates IRS and its associated 
PI3K activations in rat heart in vivo. This effect occurred at l min after Ang II infusion and was 
mediated in an AT I receptor-dependent manner (311 ). In a related study, Du et al. examined 
cross-talk between G-protein coupled and tyrosine kinase receptors in RASM cells. Consistent 
with previous findings, western blot analysis showed that Ang II ( lO0nM, 5mins) caused a 
marked increase in IRS-I and IGF IR� chain tyrosine phosphorylation (269). Both studies have 
suggested additional Ang II signaling pathways which may interact with insulin signaling 
pathways. The study by Ali et al. has illustrated that protein tyrosine phosphatase ID (PTP-ID) is 
a second mediator in the interaction of Ang II with insulin. The VSMC stimulation by Ang II was 
shown to induce tyrosine phosphorylation of IRS-I, PTP-1D and complex formation of PTP-ID 
with IRS-I docking protein (312). Conversely, the study by Velloso et al has suggested potential 
mechanisms for negative relationship between Ang II and insulin signaling systems in rat heart. 
They found that Ang II stimulated IRS-I and IRS-2 phosphorylation and IRS-l/p85 and pl 10a
associations but inhibited PI3K enzyme activity, along with increased JAK2 phosphorylation in 
an ATI receptor-mediated pathway. In this study, JAK2 may account for Ang-induced IRS-1/2 
activations. In spite of the fact that Ang II treatment stimulates IRS activation and IRS- l/PI3K 
docking, it has been shown that Ang II attenuates insulin-induced PI3K activation via Ang II­
induced serine phosphorylation of p85, thus inhibiting insulin signaling pathways (305). 
Additional mechanisms for inhibitory effects of Ang II on insulin signaling were proposed by 
Foli et al. They demonstrated that Ang II suppressed insulin signaling in VSMC at multiple steps 
(e.g. Ang II-induced IR�, IRS-I and p85 serine phosphorylation), suggesting that Ang II may 
contribute to insulin resistance in the vasculature (307). Subsequently, in vivo and in vitro studies 
from the same group have strongly supported their previous findings that Ang II negatively 
regulates insulin signaling via the PI3K pathway although Ang II exhibits opposing effects on IR 
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and IRS phosphorylation. These effects also were mediated via the AT l receptors but not AT2 
receptors in intact rat heart (306). In addition to acute effects of Ang II on insulin signaling, 
Ogihara et al have recently investigated the chronic in vivo effects (12-day infusion of Ang II) of 
Ang II on insulin signaling in insulin-sensitive tissues and the role of ROS in these effects (308). 
Chronic Ang II infusion into normal rats induced hypertension and insulin resistance. This Ang II 
action was mediated by activation of early insulin-signaling steps (IR/IRS/PI3K pathway) in fat, 
liver and muscle tissues which contrasts with earlier findings, suggesting that the sites where Ang 
II impairs the insulin signal pathway are possibly located in downstream from PBK. Treatment 
with tempol (a stable spin trap of superoxide, ROS inhibitor) in these mice was shown to improve 
insulin resistance seen in Ang II-infused rats via increasing glucose uptake in soleus muscle tissue. 
This indicates that ROS may plausibly inhibit the downstream pathways of PBK activation and 
thus mediate Ang II-induced insulin resistance (308). In addition to ROS-mediated negative 
interactions of Ang II with insulin, Fukuda et al demonstrated that Ang II impaired insulin 
signaling in VSMC from SHR in a MAPK/ A Tl receptor-dependent manners (309). Likewise, in 
a very recent study, Carvalheira et al. examined whether Ang II directly interacts with insulin 
signaling through MAPK and PI3K pathways in cardiac tissues of control and obese Zucker rats. 
The results have revealed that Ang II elicits an inhibitory effect on insulin signaling at the level of 
PI3K/Akt pathways via ATl receptor activation while Ang II has stimulatory effects on insulin 
signaling at the level ofIRS/Grb2 association and ERK.1/2 activations in an ATl receptor­
independent manner in hearts of obese Zucker rats. These findings suggest that imbalanced 
interactions of Ang II and insulin signaling may play roles in development of cardiovascular 
abnormalities observed in insulin resistant states, as in obese Zucker rats (310) (Fig. 6). 
Furthermore, cross-talk of A T2 receptors with the insulin signaling pathways in 
regulating cell growth and proliferation has been reported recently. AT2 receptor activation 
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Fig. 6 Proposed interactions be-tween Ang II and insulin signaling transduction. 
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inhibited insulin-induced ERK2 activity and cell growth via impairment in the early event of 
insulin signaling pathways, implying a possible role of A T2 receptor in insulin-sensitive tissues 
and/or pathology of proliferative diseases(313). In a related study, AT2 receptor-induced 
apoptosis was mediated by negative cross-talk with insulin-induced PI3K/Akt pathways and 
activation of protein tyrosine phosphatase (SHP-1) in PC12W cells where AT2 receptors are 
predominantly expressed. Thus, Ang II displays apoptotic effects through previously reported 
MAPK inactivation as well as functional trans-inactivation of insulin signaling pathways in an 
A T2 receptor-dependent manner (314) 
Altogether, Ang II plays a critical role in hypertension-associated insulin resistance, in 
part by its ability to differentially modulate insulin signaling pathways. However, the mechanisms 
that link Ang II-dependent hypertension with insulin resistance have not been fully elucidated. 
1.6 Genetic Manipulation of Systemic RAS 
Transgenic mice are created to overexpress a protein of interest either systemically or a 
cell specifically via random integration of the transgenic gene construct into the genome. In 
contrast, the inactivation of a target gene in knockout mice generally is accomplished by inserting 
a region of nonsense DNA, typically a selectable marker encoding antibiotic resistance, via 
homologous recombination into the target gene (315). Depending on the targeting 
constructs' design, the mutagenic process can result in transcription inhibition of the target gene 
or the generation of a transcript encoding a defective protein. Recently, the use of the cre-loxP 
recombinase system has provided a tool to induce the knockout of a gene in a specific tissue and 
under temporal control (315, 316). 
Many factors contribute to the development of essential hypertension, including 
environment, diet, daily stress and genetics. Although several single gene disorders causing high 
blood pressure have been identified, the genetics of essential hypertension are much more 
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complicated. The transgenic and knockout strategies have been useful tools to evaluate the 
genetics of essential hypertension and to identify pathways regulating blood pressure(3 l 7). 
1.6.1 Knockout Animal Models (Table 5) 
As mentioned previously, apart from the classic action of the RAS in the control of 
arterial pressure, RAS is a key player in the regulation of kidney function and structure under 
basal conditions and in response to various hormonal and environment factors; RAS regulates 
GFR, in part through the tubuloglomerular feedback mechanism and its direct constrictor actions 
on renal arterioles, as well as is involved in mature formation of the papilla and glomerular 
structure, thereby increasing proximal tubular sodium reabsorption. The pivotal roles of RAS in 
the kidney function were also supported by the results from RAS knockout studies (187). 
Subsequent studies on tissue specific RAS knockout via the use of cre-loxP recombinases have 
confirmed essential roles of RAS in cardiac and renal development via its growth-promoting 
effects. Of interest, the significance of RAS in brain structure and blood brain barrier (BBB) 
function has been suggested. Accordingly, genetic manipulation of major components of RAS 
genes in a tissue-specific manner has provided new insights into additional physiological 
functions of the tissue RAS (316, 318). 
1.6.1.1 Angiotensinogen (agt) 
The agt encodes the major substrate for the RAS. A critical role for the RAS in renal 
development has been described (319,320). Surprisingly, the results from the reports on agt 
inactivation were that mice appear normal at birth and have normal organs including the kidneys, 
indicating that the RAS is not essential for embryonic development (321,322). 
However, their survival in the perinatal period is reduced. Further, surviving adult Agt..;. 
mice have marked renal structural and vascular abnormalities. These vascular changes were not 
seen in other organs (322). Agt knockout mice elicited loss of GFR autoregulation in response to 
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Table 5. Genetic manipulation of RAS (Knockout mouse models) 
)ii ,,,(jenotype }fl! ., <;haf�cteristics of Phenotyp1,.r; � -{' , .. ;, . .. _.,J/:- :( . . 
Monogenic Agt ·t- 1. Postnatal mortality 2. Hypotension 3. Renal
knockout structural abnormalities 4 Renal dysfunction
models 5 .decreased body weight 6.Reduced fat mass
7. Increased locomotor activity 8.Resistance to high-
fat induced obesity
Renld ·1• 1. Altered kidney morphology
2. Sexually dimorphic hypotension
Ren le ·1• 1. Low blood pressure
2. Marked renal structural abnormalitv
Ren 2·1· 1. Normal blood pressure
2 Normal kidney morphology
ACE"'+ (a single copy 1. Normal blood pressure
deletion) 
ACE 1 (both sACE and 1. Hypotension 2. Renal structural abnormalities
tACE null) 3. Impaired renal function 4. Male infertility
5.Reduced hematocrit and hemoglobin
ACE2·1• 1. Normal blood pressure 2. Normal kidney function
3 .impaired cardiac function
Agtr la-1- 1. Moderated hypotension 2. Normal cardiac and
vascular development 3. Reduced ischemia-induced
angiogenesis 4. Reduced Ang II-induced remodeling
Agtr 1 b-1• 1. Reduced blood pressure
2. Reduced dipsogenic effect of Ang II
3. Decreased response to epinephrine
Agtr 2·1• 1. Slight increased blood pressure 2. Hypersensitivity
to Ang II-mediated vasoconstriction 3.Normal renal
function 4. Behavioral changes (decreased
spontaneous movement and impaired drinking
response) 5. Decreased cardiac hypertroohv
Double Agtrla·1-/Agtrl b·1• l .Smilar to phenotypes of Agt and Ace deficient mice
knockout 
models 
B2·1·1 ACE"1• 1. Hypertension 2. increased sensitive to Ang II
ACE"1·1 ACE2·1• I .Similar to phenotypes of ACE4 mice 
Tissue- Agt·1-(Liver-specific 1. No pressor response
specific deletion of Alrt) 
knockout ACE2·1-(Tissue null) 1. Hypotension
models 2. Abnormal renal structure
3. Reduced hemoglobin level and hematocrit
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changes in sodium intake and hypoplastic renal papilla, inability in preservation of glomerular 
size in response to extracellular fluid changes and arterial wall thickening. Several lines of 
evidence have demonstrated abnormalities in the regulation of renal RAS genes and proteins of 
overt hypotensive Agt-1- mice (323,324). Further, we and other illustrated additional 
characteristic phenotypes of agt knockout mice; reduced body weight, decreased fat mass, 
increased locomotor activity and resistance to high fat diet-induced obesity (325). In addition to 
renal dysfunction in these mice, the decreased density in granular layer cells of the hippocampus 
and an impaired blood brain barrier (BBB) function were reported in Agt-1- mice (326,327). 
Numerous studies on agt null-mutant mice have confirmed that RAS is essential for normal blood 
pressure maintenance. In supporting of importance of systemic RAS in blood pressure regulation, 
studies on transgenic mice lacking only hepatic agt pointed out that extrahepatic-derived agt is 
not a significant source of the circulating pool of agt (328). 
1.6.1.2 Renin 
In contrast to most other species which only have a single renin gene (Ren-1 c), other 
strains such as 129 and DBA contain two renin genes (Ren-1 d and Ren-2). Ren 2-dificent mice 
showed normal blood pressure, plasma renin activity, and normal kidney morphology, perhaps 
due to compensation by the other remaining renin gene. Although Ren-1 d knockout mice 
exhibited altered kidney morphology, complete absence of juxtaglomerular cell granulation and 
sexually dimorphic hypotension, phenotypes observed in these mice were much less severe than 
those seen in agt and ace knockout mice (329,330). Recently, mice completely lacking renin 
(Ren-1 c) have low blood pressures and marked renal structural abnormalities, similar to those 
seen in agt knockout mice, indicating a dependence of these phenotypes on the generation of Ang 
II. Interestingly, these knockout mice did not have the abnormal granular cell layer in the
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hippocampus seen in agt knockout mice, suggesting that a non-renin enzyme ( cathepsin D) is 
capable of producing angiotensin peptides in the brain of these animals (331 ). 
1.6.1.3 ACE 
There are two ACE isoforms which are encoded by the same genetic locus but are 
regulated by two different promoters: somatic ACE (sACE) and testis ACE (tACE). The majority 
of enzyme is bound to the tissue such as vascular endothelium. The tissue-bound form of the 
enzyme is cleaved to produce a soluble form of the enzyme that circulates in plasma. Deletion of 
a single copy the Ace gene have been demonstrated to have no effect on basal arterial pressure, 
suggesting that arterial pressure is not influenced by partial decreases in Ace gene expression 
(332). In contrast, the phenotype of Ace-I-mice lacking both sACE and tACE (termed ACE.I) is 
similar to that of Agt _,_ mice, with prominent hypotension, vascular hyperplasia, atrophy of the 
renal papillae, and impaired renal function, male infertility (332-335). The sperm-specific 
expression of transgenic germinal Ace in Ace·'·male mice restored fertility without curing their 
other abnormalities (336). Using gene targeting, mice exhibiting one-third normal plasma ACE 
levels but no measurable ACE activity associated with tissues such as the lung or the kidney were 
generated (termed ACE.2). These mice have a truncated ACE protein that circulates in the plasma, 
hypotension and abnormally thickened renal arteriolar walls, similar to those of ACE. I knockout 
mice. Interestingly, they did not develop characteristic atrophy of the renal papilla, suggesting the 
tissue and plasma forms of ACE differ in their contribution to the regulation of blood pressure 
and renal structure. Further, these studies strongly supported the concept that the tissue-bound 
ACE is essential for the control of blood pressure and the structure and function of the kidney. 
Both ACE. I and ACE.2 knockout mice exhibited reduced hematocrit and hemoglobin levels, 
suggesting a direct role of the RAS in erythropoiesis. Recently, Cole group created new mice that 
selectively express ACE in the liver but lack all ACE within vasculature (termed ACE.3). These 
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mice were indistinguishable from their WT mice, suggesting that the circulating ACE in plasma 
presumably due to enzymatic release from hepatocytes can compensate for the absence of the 
endothelial ACE enzyme (337). Mice expressing ACE limited to the kidney were created by 
using a kidney androgen-regulated protein promoter (termed ACE.4). The mice displayed 
profound reduction of sACE but retained normal tACE expression. The phenotypes of these mice 
are nearly identical to those of the ACE. I (null) mice: marked decreased blood pressure, impaired 
urine concentrating ability, renal morphological defects, and a decreased hematocrit (338). 
Additionally, double knockout mice lacking both bradykinin B2 receptor (B2R) and ACE also 
exhibited nearly identical phenotypes of ACE.4 mice, suggesting that the ACE inactivation 
develops the phenotypes independently ofbradykinin (339). 
Homologs of ACE have recently been described, one of these, ACE2 (also referred to as 
ACER) shares more than 40 % homology at the protein level with the catalytic domains of ACE, 
and its expression appears to be limited to heart, kidney and testis (223, 340, 341 ). Studies on 
mice with targeted disruption of the ACE2 have demonstrated that ACE2 is a critical regulator of 
cardiac function. In comparison with Ace knockout mice, these mice displayed normal blood 
pressure and no altered kidney function (224). Of note, impaired cardiac function (e.g. left 
ventricular failure) concomitant with elevated plasma Ang II, was observed in these mice whereas 
neither Ace -t- nor Agt -/- null mice developed any overt heart disease. This congestive heart 
failure phenotype was rescued in double mutant mice that are deficient in both ACE and ACE2 
(224). On the other hand, in the distinct lines of ACE2-deficient mice, different phenotypes have 
been reported (223). The differences in phenotypes observed have been explained by different 
genetic backgrounds or different assessments in each study. 
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1.6.1.4 Angiotensin receptors 
The Ang II-induced vascular effect is primarily mediated by ATl receptor. Homologous 
recombination has been used to generate mice lacking the type la receptor for Ang II (342-346). 
Agtrla-deficient mice were moderately hypotensive but exhibited normal cardiac and vascular 
development. Their renal structure was intact except for hypertrophy of the juxtaglomerular 
apparatus and modest mesangial expansion. They lacked the atrophy of the renal inner medulla 
observed in Agt -1- and Ace_,_ mice but had a renal concentration defect, impaired TGF response 
and a stepwise reduction in resting blood pressure associated with loss of Agtr-1 a expression. 
This confirmed that the AT 1 a receptor plays an important role in blood pressure homeostasis. In 
addition, physiologic roles of ATla receptor on cardiac growth have been investigated by loss-of­
function studies (AT la knockout mouse models). Of interest, pressure overload-induced cardiac 
hypertrophy was observed in mice lacking A Tl a receptor, suggesting that A Tl-mediated Ang II 
signaling is not essential for the development of pressure overload-induced cardiac growth in vivo
(347,348). Matsusaka et al. characterized the mode of action of Ang Hin cardiac remodeling 
using Agtr-la null mutant chimeras. They found that compared to Agtr-la null mutant chimeras, 
control chimeras had more extensive cardiac fibrosis, most prominently in perivascular regions in 
repose to Ang II, indicating that Ang II is involved in cardiac remodeling through ATl receptor 
signaling pathways (349). Further, Sasaki et al. provided evidence for regulatory roles of A Tl a 
receptor in ischemia-induced angiogenesis. Agtr-la knockout mice displayed decreased 
angiogenesis and fewer well-developed collateral vessels in response to hindlimb ischemia 
compared to WT mice. These homozygous mutant mice had decreased infiltration of 
inflammatory mononuclear cells in their ischemic tissue with concurrent reduced expression of 
MCP-land VEGF genes (350). 
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Less was known about function of the A Tl b receptor. Agtr-1 b null mice have phenotypes 
indistinguishable from those of their WT mice (351,352). Direct roles of ATlb in blood pressure 
control and vascular response to Ang II have been suggested by studies on Agtr-l a-1· animal 
models. Agtr-l a  null mice displayed a modest pressor response to Ang II infusion. This response 
to Ang II was not affected by sympatholytic agents and chronic administration of losartan caused 
further reduction of systemic blood pressure, indicating that in the absence of the dominant 
angiotensin receptor (ATla ), ATlb could contribute to the regulation ofblood pressure (344). 
Further, the function of the ATlb receptor in the brain was defined by examining the differential 
response to Ang II in Agtr 1 a-/· mice and Agtr 1 b"1" mice. The results from this study have shown
that Ang II mediates its CNS effects on blood pressure control via mainly the ATla receptor 
while the dipsogenic effect of Ang II is mediated by ATlb receptor (353). In contrast with the 
phenotypes seen in homozygous mutant mice of Agtr-1 b, the homozygous, doubly mutant mice 
(Agtrla-1·; Agtrl b-1-) showed virtually identical phenotypes to the Agt and Ace deficient mice, 
indicating that major biologic functions of endogenous Agt are mediated by the Agtrla receptors. 
The mice have significantly reduced postnatal survival, reduced body weight gain, diminished 
growth, very low baseline blood pressure, renal vascular changes and marked hypoplasia of the 
renal papilla. Interesting features in the double knockout mice are that they responded normally to 
another vasoconstrictor, epinephrine, and following administration of an ACE inhibitor, their 
blood pressure increased paradoxically. This suggests that this may be a result of disruption of the 
AT2 receptor signaling pathway in theses mice (352, 354). 
The AT2 receptor has served as a counter-regulator of the ATl receptor. AT2 receptor­
deficient mice displayed a slight elevation in resting blood pressure and hypersensitivity to Ang 
II-mediated vasoconstriction. Even though these animals exhibited no apparent abnormalities in
either the kidney, the brain or the adrenal gland, they had behavioral changes with decreased 
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spontaneous movements and impaired drinking responses (355,356). Recently, Gross et al. 
defined potential mechanism for elevated blood pressure seen in AT2 receptor knockout mice. 
They performed pressure-natriuresis-diuresis experiments. These mice exhibited rightward shift 
of pressure natriuresis, failure in medullary blood flow increase in response to the elevated renal 
perfusion pressure and increased renal vascular resistance along with an increment in renal AT 1 
receptor gene expression. These alterations in renal mechanisms lead to modification in renal 
sodiwn handling, thereby contributing to the development hypertension in these animals (357). 
With ATl receptor, the role of the AT2 receptor in cardiac hypertrophy has also been studied. Of 
interest, recent reports using AT2 knockout mice have suggested that this receptor is necessary 
for hypertrophy induction by in vivo pressor overload or Ang II infusion. This effect was 
mediated by a reduced phosphorylation of p70s6k, which plays a pivotal role in cardiac
hypertrophy (358, 359). 
1.6.2 Transgenic Animal Models (Table 6) 
With other genetically manipulated animal models (gene targeting), the use of transgenic 
mouse models has become important tools to unravel the complex interplay of genetic and 
environmental influences causing essential hypertension in humans (316) 
1.6.2.1 Angiotensinogen (agt) 
Numerous studies in genetic animal models have provided several lines of evidence on a 
critical role of circulating agt in the pathogenesis of hypertension. In gene targeted mice, arterial 
pressure and plasma agt levels have been shown to vary proportionally with the number of 
functional copies of the mouse agt gene (321 ). Transgenic mice overexpressing rat Agt gene in 
liver and brain developed hypertension (360). The dependence of blood pressure on agt levels is 
analogous to what has been found in hwnans with increased circulating agt contents (361). 
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Table 6. Genetic manipulation of RAS (Transgenic mouse models) 
Ii, i> f;,· :.i j{ iGtfnotype ·· .·• ; ) I> 1t Chiiratteristicso.f PheniJ�oe it 'Ii: 
Overexpression Agt ( 1-4 copies) 1. Increased 8mmHg per gene copy with
Transgenic plasma agt levels 35 % (lcopy) of WT,
models 124% (3copy) of WT, 145% (4 copy)
ofWT
Agt overexpression in liver and brain I .Hypertension 
R+/A+ (human agt and renin 1. Chronic Hypertension 2. High Ang II
overexpression in brain) plasma concentrations 3. Altered
baroreflex activity 4. Cerebral arteriolar
hypertrophy
Agt overexpression in adipose tissue 1. Hypertension 2, Increased body
weight
3. Increased fat mass 4 .Partially rescue
abnormal renal function and structure.
Cardiomyocyte overexpression 1. Massive hyperplasia of arterial
Of A Tl receptor myocytes
2. Perinatal mortality
Brain overexpression of A Tl 1.  Enhanced cardiovascular sensitivity
2. Normal blood pressure
mRen-2 overexpression 1. Hypertension
2. Altered heart rate
ACE (1-3 copies) I .No changes in blood pressure
Tissue-specific Agt restoration in multi-tissue {MT- I .Partially rescue abnormal renal
transgenic Agt+1-/Agt-/-; MT-AGT/KO) function and structure
models 2. Restored blood pressure
Kidney -specific expression of Agt 1. Overproduction of renal Ang II
(using proximal tubule specific production 2. Hypertension 3. Not able
promoter) to rescue kidney abnormalities
Adipose-specific expression of Agt 1. Increased systemic Ang II 2. Partially
rescue abnormal renal function and
structure 3. Restored blood pressure
4. Increased fat mass
Brain-specific restoration of Ang II 1. Hypertension 2. Partially rescue
abnormal renal function and
development 3.Increased sympathetic
nerve 4. Salt preference
5. Increased drinking intake
ACE3·1-(Liver- specific expression of 1. Normal
ACE ) 
ACE4"1"{Kidney specific expression 1 Similar to phenotype of ACEI 
of ACE) 
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With another genetic animal model of hypertension, double transgenic mice harboring both 
human renin and agt (R+/A J, potential mechanisms of hypertension and hypertension-associated 
diseases (e.g. inflammation, renal necrosis and fibrosis, vascular hypertrophy) have been 
investigated. These animals exhibit high plasma Ang II concentrations, altered baroreflex activity, 
cerebral arteriolar hypertrophy, impaired endothelial function and chronic 
hypertension (362-364). In a separate series of studies, Davisson's group has presented possible 
mechanisms of hypertension in these transgenic mice. The results from the studies demonstrated 
that increased brain RAS activity in these animals augments local Ang II production and 
subsequently Ang II-mediated ATI receptor activation stimulates vasopressin (antidiuretic 
hormone) secretion, collectively elevating blood pressure (365). In addition, Didion et al. have 
recently demonstrated the mechanisms responsible for endothelial dysfunction observed in R+/A + 
mice. The mechanism of this impairment was mediated by production of an endothelium-derived 
contracting factor produced by the cyclooxygenase pathway (364). 
Subsequent studies on several different double transgenic models, which were developed 
using tissue or cell-specific promoters (KAP for proximal tubule; albumin for hepatocytes; GF AP 
for glia in the central nervous system; synapsin I for neurons in the central nerve system; aP2 for 
adipocytes) have provided numerous insights into the functionality of the local tissue RAS (64, 
366-369). Various transgenic studies have pointed out the importance of brain Ang II in the
regulation of blood pressure and electrolyte balance. In particular, chronic overproduction of Ang 
II locally in the brain of transgenic mice have been shown to induce sympathetic nerve activity, 
drinking intake, salt preference and salt intake, thereby leading to hypertension (367,368). These 
effects are ATl receptor-dependent. Notably, a significant effect of brain RAS on blood pressure 
was independent of endocrine RAS, indicating that brain RAS per se plays a role as a determinant 
in systemic blood pressure regulation. In addition to brain RAS, the significance of renal RAS in 
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renal function and development as well as blood pressure homeostasis has also been appreciated 
with studies in kidney-specific models (specific targeting of RAS overexpression in the kidney 
and specific targeting of kidney RAS ablation). These transgenic mice exhibited overproduction 
of intrarenal Ang II and chronic hypertension. Mechanically, renal RAS increased blood pressure 
of these transgenic animals without increasing systemic Ang II levels, which was also observed in 
brain-specific models (370). Along with reports on other tissue-specific RAS models, studies 
from Davisson et al.' s group have clarified the function of the proximal tubule RAS (3 70). They 
demonstrated that human agt expression only in proximal tubule was not able to rescue renal 
abnormalities seen in agt null mice but elevated systemic blood pressure. In comparison with 
renal RAS effects, systemic expression of human agt and renin genes has been shown to partially 
rescue renal defects. Brain-specific restoration of Ang II and rat agt expression exclusively in 
adipose tissue prevented altered renal function such as hydronephorosis in agt knockout mice. 
Taken together, this suggests that renal RAS is an important regulator of arterial pressure and 
non-renal tissue RAS plays a significant role in renal function and development (64, 369). Of 
clinical relevance, the potential mechanisms of renal RAS-induced hypertension (e.g. alteration in 
sodium or fluid homeostasis) appear to be a common underlying mechanism causing high blood 
pressure in a number of human genetic syndromes (371,372). Recently, adipose tissue-specific 
models of rat agt gene using aP2 promoter were created by Massiera et al's group (64). Using 
these transgenic models, in vivo paracrine and endocrine effects of adipose RAS have been 
elucidated. The lipogenic effects of adipose RAS reported previous studies in vitro were 
confirmed by these transgenic studies. In this context, another study demonstrating that 
expression of both transgene human and endogenous mouse agt genes in visceral fat depots (e.g. 
omental, reproductive and perirenal fats) was significantly increased by a high fat diet provided 
evidence for a key role of adipose RAS in diet-induced obesity (373). Of significance, agt 
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overexpression in adipose tissue contributes to the development of hypertension via elevated 
systemic agt levels (presumably increased plasma Ang II concentrations). In contrast with 
mechanisms accounting for brain RAS or renal RAS-induced hypertensive effect, adipose RAS 
effect on blood pressure appear to be in part mediated by endocrine RAS. In addition, restoration 
of agt only adipose tissue was able to prevent renal anomalies seen in agt-deficient mice, 
suggesting that adipose RAS play a significant role in renal function and blood pressure 
homeostasis in an endocrine manner (64,325). 
Further, with respect to functionality of human agt gene variants highly associated with 
the development of hypertension, Sigmund et al. have recently developed two different 
transgenic mice targeting a single copy of each human agt haplotypes to the mouse hypoxanthine 
phosphoribosyl transferase (HPRT) locus (-6A/235Thr (AT) and -6G/235Met (GM)). This study 
revealed that AT and GM haplotypes of the human agt have no effect on gene expression of agt, 
but regulate the cardiovascular system (e.g. heart weight ) and the control of blood pressure 
differently; A small but significant increase in BP and relative heart weight was demonstrated by 
mice carrying the GM haplotypes (374). 
1.6.2.2 Renin 
To evaluate the role of an overexpression renin gene in the pathogenesis of hypertension, 
several investigators established transgenic models expressing the mouse Ren-2 gene (mRen-2) 
(375). Mullins and Ganten created transgenic rat models expressing the mRen-2 gene; three 
transgenic lines termed TGR (mRen-2) 25, 26 and 27 were derived (376). Of note, the fulminant 
hypertension developed in the TGR (mRen-2) 27 animals has been suggested to be partially 
dependent on the expression of the trans gene in the brain. Crossbreeding with transgenic rats 
carrying a brain-specific deficiency of agt led to the blunt of the central Ang II generation in 
TGR (mRen-2) 27 and thus a significant reduction in blood pressure in the TGR (mRen-2) 27 
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animals (377). In addition, these transgenic mice displayed inversed circadian blood pressure 
rhythm and altered heart rate. Further studies by Morimoto et al showing that human renin 
transgene is expressed in brain area relevant for cardiovascular and fluid homeostasis supports 
direct involvement of brain RAS activation in the development of hypertension (378). 
1.6.2.3 ACE 
Krege et al. 's group studied the effect of quantitative changes in ACE gene function on 
blood pressure regulation using transgenic mice having from one to three copies of ACE gene. 
The one to three ACE copy mice did not show any significant changes in blood pressure although 
there was a linear relationship between ACE gene copy number and serum ACE activity (379). In 
contrast with previous observations, subsequent study has recently described an inverse 
relationship between the number of ACE gene copies and arterial pressure response to dietary 
NaCl, suggesting that ACE may become a more important regulator in arterial pressure (380). 
1.6.2.4 Angiotensin receptors 
Thu et al. generated transgenic mice harboring with 2, 3 or 4 copies of Agtr-la gene to 
determine the physiological effects of quantitative variation of A Tl receptor gene expression. In 
contrast with previous studies showing that deletion of AT 1 a receptor gene decreases arterial 
pressure in a copy-dependent manner, the results of this study have demonstrated that the impact 
of enhanced AT 1 receptor expression on blood pressure was blunted by systemic compensations 
and altered other gene expression (kallikrein and aldosterone) involved in cardiovascular 
regulation (381). In addition to the effect of the ATl on blood pressure, the role of ATl receptor 
in cardiovascular homeostasis has been illustrated using transgenic mice with CNS-targeted A Tl 
receptors (neuron-specific enolase (NSE) promoter-A Tl ). Interestingly, brain-specific 
overexpression of A Tl a receptor has been shown to enhance cardiovascular sensitivity 
(baroreflex sensitivity) to intracerebroventricular (ICV) Ang II concomitant with normal blood 
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pressure. These phenotypes seem to contradict earlier findings; activation of central AT 1 a 
receptor was responsible for increased blood pressure in various genetic and experimental models. 
Of interest, blockade of the central A Tl receptor with ICV losartan injection significantly 
diminished basal blood pressure and increased heart rate in these mice, suggesting that central 
AT 1 a receptors involve maintenance of basal blood pressure in part mediated by resetting 
baroreflex sensitivity. Also, this A Tia action in the brain may prevent hypertension in these 
animals (382). Further, transgenic mice overexpressing the ATla receptor in the myocardium 
using the alpha-myosin heavy chain gene ( a-MHC) promoter were generated to explore other 
noncardiovascular-related functions of Ang II in heart (355, 383, 384). Earlier studies have 
reported that transgenic mice overexpressing the mouse A Tl receptor in cardiomyocytes 
displayed massive hyperplasia of arterial myocytes at birth but died perinatally due to bradycardic 
heart failure despite normal systolic blood pressure and the heart rate (384). Consistently, 
different strain of transgenic mice overexpressing human AT 1 receptor only in heart also 
developed similar but less severe phenotypes (385). In contrast with pronounced cardiac changes, 
cardiac hypertrophy and remodeling as well as enhanced mortality seen transgenic animals ( a­
MHC-ATI R), no cardiac morphological alterations were observed in transgenic mice 
overexpressing AT2 under the control of the same a-MHC promoter (355). Collectively, this 
implies that Ang II can directly induce classical features of cardiac hypertrophy, remodeling and 
failure via its myocardial ATI receptor. On the other hand, mechanisms accounting for the anti­
AT 1 actions of the A T2 receptor such as vasodilation, cell differentiation and apoptosis have 
been proposed in several transgenic mice. Mechanically, expression of the AT2 receptor 
exclusively in the vasculature has been shown to induce activation of kinin system, thus causing 
vasodilation (3 86). Cardiac-specific overexpression of AT2 receptor resulted in attenuated 
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response to ATI receptor-mediated chronotrophic and pressor effects (e.g. decreased ATI­
induced MAPK) (387). 
2.LOCALRAS
2.1 Overview 
Along with endocrine RAS, the whole or partial RAS system exists in many tissues 
including the brain, heart, kidney and pancreas. Recently, the focus has shifted from the classical 
role for RAS to an autocrine/paracrine role in specific tissue function; tissue RAS may either 
potentiate systemic function or have entirely separate activities meeting the specific needs of 
these individual tissues. These local systems are regulated at many levels ranging from the 
synthesis of renin to the dimerization of angiotensin receptors. Regulation of local RAS occurs in 
multiple tissues and, as a result, tissue concentrations of Ang II and the concentration of other 
RAS components and their active metabolites vary in each tissue independently of the circulating 
system. Further, therapeutic interventions involving ACE inhibitors and angiotensin receptor 
antagonists have shown to be likely to provide benefit at least in part through the interruption of 
local systems (388,389). Accordingly, understanding the biological function of the multiple 
RASs may help the development in novel therapeutic strategies in the treatments of hypertension 
and hypertension-associated diseases 
2.2 Physiological Function of Local RAS 
2.2.1 Brain 
Ang II actions in the central nerve system include arterial pressure regulation, promotion 
of thirst behavior and salt appetite, regulation ofvasopressin secretion and sympathetic outflow, 
modulation of the sensitivity of the arterial baroreflex, thermoregulation, blood brain barrier 
function and memory mechanism (318). 
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2.2.2 Heart 
Renin, agt ACE and Ang II receptors are all present in the myocardium. The 
accumulating evidence has demonstrated hypertrophic actions of cardiac Ang II on 
cardiomyocytes; RAS blockade (e.g. ACE inhibitors or ATI receptor antagonists) prevent or 
decrease left ventricular hypertrophy independently of blood pressure. Of importance, cardiac 
RAS has been implicated in the remodeling of the myocardium after myocardial infarction as 
well as i'i directly involved in the development of cardiac fibrosis by induction of growth and 
fibrosis-related genes (388). 
2.2.3 Kidney 
All of the components of the RAS are present within the kidney and specifically, renin, 
agt and ACE mRNA are localized in a site-specific manner within the kidney. Most of the 
intrarenal agt mRNA and protein is localized in the proximal tubule and then directly secreted 
into the tubule lumen, where Ang I may be formed by renin or renin-like enzymes. ACE is 
located in on the proximal tubule cell brush border. In the interstitium, Ang II levels are 1000-
fold higher than those in plasma, indicating that most of the intrarenal Ang II is formed within the 
kidney. Renal agt mRNA and protein biosynthesis are stimulated by Ang II; Ang 11 may 
autoamplify the activation of the intrarenal RAS. Intrarenal Ang II participates in renal function 
( e.g. sodium handling and water metabolism) and renal development. Collective evidence from 
the angiotensin receptor knockout mouse model has elucidated that the AT 1 receptor but not the 
AT2 receptor plays a critical role in renal development (388). Additionally, in vitro Ang II 
induces hypertrophy or hyperplasia of various renal cell types, mainly proximal tubular cells and 
mesangial cells ( 17 6) 
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2.2.4 Pancreas 
Emerging data have revealed the potential influence of pancreatic RAS on growth and 
free radical generation. Moreover, exogenous Ang II induced a marked vasoconstriction, which 
could delay the first phase of insulin release in response to glucose. These findings concluded that 
the pancreatic RAS may play a pivotal role in regulating islet blood perfusion, thereby, affecting 
insulin release by the islet cells. The significance of a local pancreatic RAS has been emphasized 
in view of therapeutic implications in diabetes, pancreatitis, cystic fibrosis as well as pancreatic 
cancer (388). 
3. ADIPOSE TISSUE RAS
With other local tissue RAS, paracrine and endocrine effects of RAS in adipose tissue 
which hosts all RAS components have widely been investigated. Ang II has been elicited be a 
pivotal physiological regulator in adipocyte metabolism; adipocyte hypertrophy and adipogenesis. 
Accordingly, it has been suggested possible roles of Ang II in pathophysiology of obesity (170). 
However, functional studies on adipose RAS have yielded some conflicting results (e.g. Ang II 
roles in adipogenesis and angiotensin receptor-mediated functions). In particular, recent findings 
revealing that Ang II inhibits adipocyte differentiation in human adipose tissue supports a new 
concept that its antiadipogenic effect may lead to fat redistribution into liver and muscle cells, 
thereby contributing to the development of diabetes in obesity (170). Of note, in vivo data on 
endocrine effects of adipose tissue agt using agt knockout and transgenic mice have currently 
provided convincing evidence for the contribution of adipose Ang II to the development of 
hypertension in obesity (64). 
3.1 Expression and Production of RAS Components 
Agt gene expression has been identified in murine adipose cell lines, rat adipose tissue 
and human adipose tissue. The presence of adipose agt mRNA was first detected in periaortal 
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brown adipose tissue (BAT) and other adipocytes (390). Subsequently, the detection of agt 
mRNA in several rat adipose tissue depots and brown adipose tissue as well as agt secretion from 
cultured fat pads were demonstrated (391-393). In humans, agt expression has been shown in 
adipose tissue, in primary cultured adipocytes and in differentiating preadipocytes (163, 394-396). 
Of note, agt expression and secretion have been demonstrated to be differentiation-dependent and 
thus serve as a late marker of adipocyte differentiation (92, 397). 
Renin mRNA expression in humane adipocytes and its increased expression during 
human preadipocyte differentiation were recently reported (396). Studies on hormonal regulation 
of RAS demonstrated the expression of renin and other RAS components in subcutaneous 
adipocytes isolated from both lean and obese patients (69). In contrast with this finding, studies 
by Faloia et al observed no detection in renin mRNA or protein expression in adipose tissue of 
either lean or obese normotensive subjects (398). In rodents, renin activity was detected in 
isolated rat BAT even after bilateral nephrectomy (399). Consistently, later studies in a 
comparative gene expression of RAS components in rat adipose tissue revealed the detection of 
agt, renin, and A Tl receptor expression in mature adipocytes ( 400). However, Harp et al. found 
no renin mRNA expression but was able to measure Ang I activity in adipose tissue (401). 
Several reports have described ACE expression and activity in human preadipocyte and 
adipocytes. Further, stronger ACE expression was found in human visceral than in subcutaneous 
adipose tissue (394-396, 402). On the other hand, ACE gene was found in only in the stromal­
vascular cells of the rat (400). In preadipocyte cell line (3T3-F442A), no ACE and its isoforms 
was found (403) 
Ang I, Ang II and Ang II-derived biological active peptides such as Ang III, Ang IV and 
Ang 1_7 have been shown to be present in rat BAT than WAT (399,404,405). Ang II is also 
found in conditional media of 3T3-Ll cells and primary human preadipocytes (406). Further, 
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functional studies with differentiated human preadipocytes suggested that Ang II is endogenously 
formed by these cells (194, 407). 
Collectively, the discrepancies in adipose RAS component presence of humans and 
rodents may be in part attributable to differences in cell types and age of animals. In addition, 
another possibility is that enzymes other than renin and ACE can form Ang I from agt or Ang II
from agt in adipose tissue or enzyme like neprilysin can degrade Ang II in adipose tissue. In 
supporting of this notion, few studies have demonstrated the presence of cathepsin G, chymase 
and cathepsin Din human adipose tissue (395). Neprilysin was also found in rat adipose tissue 
and human stromavascular cells ( 408, 409). Of interest, in human adipocytes, renin binding 
protein gene expression was detected. This enzyme was known to function as a renin inhibitor 
(410,411). Accordingly, modulation of renin activity in adipose tissue by this protein possibly 
contribute to some controversy on the presence of RAS components in fat tissue 
Similarly, confusing findings have also been shown in Ang II receptors in adipose tissue. 
Along with northern and western analyses, functional and pharmacological studies have 
illustrated the presence of angiotensin receptors (A Tl and AT2). A Tl receptor was detected in 
adipocyte membrane from rat epididymal fat tissue, BAT and human subcutaneous and visceral 
adipose tissues whereas A T2 receptor was also present in human preadipocytes and adipocytes 
and murine clonal cell line including 3T3-Ll and Obl 771 cells (197,285, 412-415). Higher 
density of AT 1 receptor was particularly observed in epididymal adipocytes of adult Sprague 
Dawley and obese Zucker rats compared to those of retroperitoneal, mesenteric and interscapular 
adipose tissues (413,414). In humans, the expression of ATl mRNA was higher in visceral than 
subcutaneous adipose tissues, but no difference in total Ang II binding between depots was 
reported (67). On the other hand, the contradictory results on mouse angiotensin receptors have 
been described. The presence of AT 1 a receptor in adipose tissue of adult mice was found by the 
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study from Burson et al ( 416). Subsequent studies have also demonstrated the expression of A Tl 
receptor in 3T3-Ll adipose and preadipose cells (163, 198, 285, 417). Ofnote, available data 
including our results have suggested that A T2 receptor is a primary receptor for paracrine 
functions of Ang II in murine adipose cell lines (198, 285). By contrast, recent results have 
described A Tl as a being primary receptor type in fully differentiated adipose cells; A Tl protein 
expression was maintained but protein levels of A T2 was diminished during differentiation of 
3T3-Ll preadipocytes (417). However, in humans, increased AGTR2 and decreased AGTRl 
gene expression were observed during in vitro differentiation of human preadipocytes (170,415). 
Possible explanations for the controversy have been suggested to be due to variance in receptor 
activity depending on species or strains, developmental stage and nutritional and hormonal states. 
3.2 Regulation of Adipose RAS Components 
Adipose RAS is controlled by a variety of factors including hormones, nutrients, 
sympathetic nerve activity, salt intake and pathophysiological conditions such as hypertension 
and obesity with its own distinct regulatory system (170). The confusing results have been 
obtained in adipose RAS regulation; species differences and various experimental conditions 
could in part explain these variations (170). 
3.2.1 Hormone and Nutrition 
Agt production is directly regulated at its transcriptional levels ( 205). In murine clonal 
cell lines, the expression level of agt mRNA was very low in preadipocytes but was increased 
during adipocyte differentiation(l 70). Several studies have identified differentiation specific 
elements (DSE) within agt promoter region and its corresponding binding protein (DSEBP) in 
hormonal differentiation of3T3-Ll adipose cells (418,419). Agt gene in Ob 1771 preadipocytes 
was upregulated by long-chain natural and non-metabolized fatty acids (known as PP AR natural 
ligands) and their stimulatory effects were abolished by actinomycin D (transcription inhibition) 
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(420). In addition, peroxisome proliferators such as rosiglitazone (a PPARy activator) and 
bromopalmitate (a PPARo activator) have also been elicited to activate agt gene (420). Together, 
this raises a possibility that PP AR mediates fatty acid-induced agt expression even though PP AR 
responsive elements have so far not been identified within mouse agt promoter region. Of interest, 
unlike hepatic agt gene, agt gene expression in rat adipose tissue was regulated by fasting or 
overfeeding; fasting reduces agt gene expression whereas overfeeding increases mRNA level of 
agt ( 421 ). Glucose also influences expression of agt gene. Plasma high glucose in the presence of 
an insulin clamp increased adipose agt expression in both lean and obese rats ( 422). However, agt 
expression in 3T3-L cells was not changed by glucose treatment (163). Intriguingly, studies from 
Hart et al have recently reported that insulin dose-dependently increases protein level of agt in 
isolated human abdominal fats (304). Consistently, in 3T3-Ll adipocytes, insulin-stimulatory 
effect on agt expression was obtained while in other murine cell lines, repressed agt gene 
expression by insulin was observed (163,423). Hyperinsulinemia with euglycemia also decreased 
adipose and hepatic agt mRNA levels of lean animals (422). Glucocorticoid has been shown to 
increase agt expression in murine preadipocyte cell lines and rat adipose tissue (69,424). Other 
hormones such as estrogen, triiodothyronine and Ang II, which was described as activators of 
hepatic agt mRNA, had no effect on Ob 1771 cells ( 425). In human adipocytes, Ang II has been 
shown to negatively regulates agt at the transcriptional levels (69,425,426). Also, SNS 
contributes to modulate agt expression (163). The agt expression in adipose tissue of Sprague 
Dawley rats was increased in response to bilateral nephrectomy or treatment with ACE inhibitor 
(enalapril) but no change in agt mRNA level was observed by sodium restriction (392,393). 
Adipose agt is also regulated by aging; agt gene expression was higher in adipocytes from 
younger rats but no differences in aging-associated agt expression was observed in obese Zucker 
rats ( 401 ). In addition to agt gene regulation, mechanisms responsible for agt secretion by 
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adipocytes have been recently elucidated. In epididymal adipocytes isolated from obese Zucker
rats, agt was constitutively released from the intracellular stores whereas in Ob 1771 adipocytes, 
agt production rather than storage affect agt secretion (420,425,427). 
3.2.2 Obesity and Hypertension 
Overall hormonal and metabolic alterations accompanying obesity, obesity-associated 
insulin resistance and hypertension could affect the expression and secretion of adipose RAS 
components. A decrease in adipose agt expression was observed in obese Zucker rats and viable 
yellow (A vy) mice whereas other genetic mice (ob/ob mice, db/db mice,fa/fa rats) exhibited 
increased agt formation in adipose tissue (163,421,428). Further studies in agt secretion and 
expression inf a/fa rats have supported the concept that increased agt secretion is closely 
associated with the onset of adipose tissue hyperplasia and stimulation of hypertrophy (429). 
They found that agt protein levels and secretion per cell number were significantly increased in 
adipocytes from obese fa/fa rats, compared to those of lean rats even though these elevations were 
independent of cell size ( 429). By contrast, another study demonstrated that obesity-associated 
hypertrophic adipocytes contribute to an increase in adipose agt expression. This was mediated by 
altered cholesterol distribution, which is a feature characteristic ofhypertrophic adipocytes (430). 
In obese humans, agt gene expression in subcutaneous and omental adipose tissues has been 
shown to be highly associated with increased body mass index (BMI) and waist-to-hip ratio 
(index of central obesity) (66-68). A positive relationship between agt secretions by isolated 
adipocytes and adipocyte volume has observed in obese subjects (170). 
In addition to modulation of adipose agt in obesity, the impacts of systemic blood 
pressure on adipose RAS components have been delineated. Epidemiological studies have 
demonstrated that hypertensive or obese hypertensive subjects exhibited decreased or unchanged 
adipose agt gene expression compared to normotensive controls while A Tl receptor, renin and 
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ACE genes in abdominal subcutaneous adipocytes was exclusively expressed in hypertensive 
obese women (69,398). Linkage among obesity, hypertension and RAS gene polymorphisms (agt, 
ACE, A T l  and AT2) has been found in several populations. In agt polymorphisms, agt promoter 
variants composing an A/G polymorphism at-217 are associated with hypertension (431). In 
addition, the DD allele of the ACE gene was closely related to abdominal adiposity and 
hypertension (432).Another study has recently illustrated female-specific association between the 
AT2 receptor C4599A polymorphism and hypertension in Japanese populations (433). 
3.3 Physiological Roles of Adipose Tissue RAS 
3.3.1 Autocrine/Paracrine Effects of Adipose Tissue RAS 
3.3.1.1 Brown Adipose Tissue (BAT) Function 
Brown adipose tissue plays a critical role in cold-thermogenesis, is capable of formation 
of Ang II (434). The thermogeic function of BAT is primarily mediated by norepinephrine (NE) 
release from sympathetic nerve densely innervating this tissue. Ang II has shown to increase 
evoked [3H]-NE release from rat BAT following electric field stimulation. During cold
acclimation, endogenous Ang II production and A T l  receptor density were elevated in rat 
intrascapular BAT (ISBAT) independent of systemic RAS (434). Further, Ang II-induced [3H]­
NE release was enhanced in cold-exposed rats compared to controls. These changes in NE 
turnover by cold exposure were completely prevented by treatment with losartan, suggesting 
potential role of Ang II in stimulating thermogenesis in BAT. In subsequent studies, decreased 
content of Ang II but increased NE activity by Ang II in ISBA T was observed in young obese 
Zucker rats. Conversely, in old Zucker animals, elevated Ang II content and decreased local SNS 
neurotransmission by Ang II were observed (435). 
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3.3.1.2 Adipose Tissue Growth and Differentiation 
Agt expression is differentiation-dependent; spontaneous differentiation also increases 
agt mRN A levels while dexamethasone, which potentiates adipocyte differentiation, enhances 
expression of adipose agt (397,420). Recent microarray data from 3T3-Ll cells have also 
addressed that adipose agt expression was higher levels in 3T3-Ll cells after several days of in
vitro differentiation (436,437). Earlier studies on co-culture of adipocytes and preadipocytes 
revealed adipogenetic effect of Ang II in Ob 1771 cells. This effect was PGI2-and AT2 receptor­
dependent (285). Further studies using microdialysis technique have confirmed that Ang II­
induced adipocyte differentiation is mediated by PGI2. In vivo and ex vivo rat epididymal fat pads 
with Ang II or prostacyclin exposure resulted in an increase in stromavascular cells undergoing 
adipogenesis and this effect was abolished by aspirin (inhibition of PG synthesis) (438). Study by 
Crandall et al. demonstrated mitogenic effects of Ang II, suggesting involvement of Ang II in 
early stages of adipocyte differentiation. Stimulation of human preadipocytes with Ang II resulted 
in an acceleration of the GI-phase of the cell cycle and increased expression of the cell cycle 
regulator cyclin D1(197). Taken together with the observation of differential expression of Ang II 
receptors during adipogenic conversion, these findings may suggest that in rodents and humans, 
Ang II exerts its adipogenic effects via interacting with different signaling pathways; Ang II 
promotes adipocyte hypertrophy by an adipogenic factor, prostacyclin in A T2-dependent 
mechanisms and induces hyperplasia in adipose cells by upregulation of cyclin D 1 gene through 
A Tl receptor activation. In contrast with its stimulatory effects on adipogenesis, Janke et al. 
elicited inhibitory action of Ang II in differentiation of human preadipocytes (407). Ang II 
inhibited insulin-induced differentiation and this effect was blocked by treatment of ATl receptor 
antagonist. Consistently, co-culture studies showed that mature adipocytes prevent preadipocyte 
differentiation in an AT I-dependent manner ( 407). On the basis of these results, they proposed a 
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possible mechanistic link between hypertension and insulin resistance; inhibition of preadipocyte 
recruitment by Ang II may result in lipotoxicity, thereby leading to the development of diabetes 
(407). Other study demonstrating that Ang II induces the formation of PAI-1, which inhibits 
cluster formation of human preadipocytes also support antiadipogenic effect of Ang II (194,439). 
3.3.1.3 Adipose Tissue Metabolism 
In addition to Ang II' s adipogenic actions in a paracrine manner, influences of Ang II on 
lipogenesis and lipolyisis in adipocytes have been studied (170). Previously, physiological 
concentration of Ang II significantly increased activity and gene expression of two key lipogenic 
enzymes, FAS and GPDH as well as ob gene activation concomitant with elevated triglyceride 
storage in 3T3-Ll cells and human adipocytes. Ang II-induced lipogenic effect was mediated by 
AT2 receptor (198). Specifically, ADDI and glucose was involved in FAS promoter activity by 
Ang II. In addition, Ang II stimulated production ofleptin (a adiposity marker) independent of 
prostacyclin (adipogenic effector) in human and murine adipose cells (440). Ofnote, several 
studies have illustrated lipolytic effects of Ang II through a pressor-independent mechanism. 
Infusion of Ang II at a pressor dose into the rats caused weight loss and reduction of adipose 
tissue mass over the course of one week, with concurrently marked changes in levels of 
circulating IGF-1 and its binding proteins. This weight-loss effect was predominately ascribed to 
decreased food intake and was prevented by blockade of ATl receptor (441). The successive 
study has demonstrated that infusion of Ang II for 7 days into rats reduces weight loss compared 
to vehicle-infused controls in a dose-related manner. This response paralleled with site-specific 
reduction of white adipose tissue, alternation of plasma leptin levels and elevation in abdominal 
surface temperature (442). Collectively, long-term systemic infusions of Ang II led to its lipolytic 
effect and this impact was primarily mediated by decreased food intake and increased energy 
expenditure with metabolic alternations. In contrast, in humans, both Ang II infusion at 
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subpressor or pressor doses for short-terms and blockade of Ang II formation had no effect on 
whole lipolysis and lipid oxidation rate (443). Of interest, further studies have demonstrated local 
actions of Ang II on lipid and carbohydrate metabolism and blood flow of human adipose tissue 
in a site- and tissue-specific manner. Perfusion of Ang II dose-dependently decreased local blood 
flow, lipolysis and glucose uptake and this effect was more pronounced in the femoral fat depots 
than the abdominal fat depots ( 444 ). Boschmann et al. examined specific effects of interstitial 
Ang II on metabolism and local blood flow in muscle and adipose tissues. Interstitial Ang II 
stimulated lipolysis in a dose-dependent manner along with a minimal effect on local blood flow 
of human adipose tissue whereas in the muscle, this hormone dose-dependently inhibited lipolysis. 
This finding indicates that interstitial Ang II modulates metabolism in a tissue-specific fashion 
( 445). Taken together, Ang II regulates adipose tissue metabolism with changes in local blood 
flow in a site-and species-specific manner. 
3.3.2 Endocrine Effects of Adipose Tissue RAS 
In addition to functional roles of Ang II in a paracrine mechanism, with agt knockout and 
transgenic mouse models, endocrine effects of adipose Ang II have been investigated (64, 325, 
446). Agt knockout mice exhibited altered adipose tissue development including adipocyte 
hypotrophy and marked decreased lipogenesis with the resultant reduction of fat mass as well as 
increased locomotor activity. Body weight was considerably decreased in agt homozygous mutant 
mice compared to WT mice and this effect was mainly due to reduction in fat mass, especially 
epididymal fat pad weight with no changes in other Ang II-responsive organs. Fat mass reduction 
in KO mice was related to adipose tissue hypotrophy with a parallel decrease in FAS enzyme 
activity. Of note, KO mice were resistant to high fat diet-induced weight gain despite maintained 
FAS activity in adipose tissue (325,446). They also generated two transgenic mouse models 
using an aP2 adipocyte-specific promoter; Tg-KO mice exclusively expressing agt in adipose 
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tissue and Tg-WT mice overexpressing agt in adipose tissue and investigated potential role of 
adipose agt in systemic blood pressure regulation. Tg-WT mice displayed body weight gain with 
dramatically increased fat mass, confirming in vitro lipogenic role of Ang II in adipocytes. 
Further, overexpression of agt in adipose tissue was able to raise blood pressure level by -16% 
concurrent with elevated circulating agt level by-20% compared to control mice, suggesting a 
potential mechanism responsible for obesity-induced hypertension; adipose tissue agt increases 
whole body blood pressure by activation of endocrine RAS. Tg-KO mice showed increased fat 
mass, restored renal morphology and function and blood pressure along with increased plasma agt 
concentrations (20 % of WT). Additionally, microarray-based data demonstrated that 
reexpression agt only in adipose tissue was able to correct altered expression of genes including 
ion channel and transporter, RAS components and Ang II signaling molecules seen in KO mice 
(325). Altogether, this indicates that adipose tissue agt plays pivotal roles in renal function and 
arterial pressure regulation. 
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PART III 
ANGIOTENSIN II RESPONSIVE ELEMENT IS THE INSULIN RESPONSIVE 
ELEMENT IN THE ADIPOCYTE FATTY ACID SNYTHASE GENE: ROLE OF 
ADIPOCYTE DETERMINATION AND DIFFERENTIATION FACTOR 1/STEROL 
REGULATORY ELEMENT BINDING PROTEIN lC 
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This manuscript has been published in similar form with co-authors Dugail I, Standridge M, 
Claycombe K, Chun J, Moustaid-Moussa N. in Biochem J 357:899-904, 2001. 
My primary contribution to this paper is to conduct experiments. 
A.ABSTRACT
We have previously shown that angiotensin II (Ang II) increases the expression of the gene 
encoding adipocyte fatty acid synthase (FAS). Here we investigate the mechanism responsible for 
increased FAS gene transcription by Ang II. We demonstrate that Ang II increased luciferase 
activity by 3-fold in 3T3-Ll adipocytes transfected with fusion constructs linking the FAS 
promoter to the luciferase reporter gene. Interestingly, we mapped the Ang II regulatory 
sequences to the insulin-responsive region (E box) in the proximal FAS promoter. The E box 
alone was able to mediate Ang II responsiveness when linked to a heterologous promoter. 
However, this response was lost when mutations that abolished the binding of the E box to its 
transcription factors were introduced. Using adenoviral overexpression of a dominant-negative 
form of adipocyte determination and differentiation factor 1 (ADDI), a transcription factor that 
binds to the insulin-responsive E box, we demonstrated that ADD 1 was required for Ang II 
regulation of the FAS gene in 3T3-Ll adipocytes. Furthermore, ADDI expression was also up­
regulated by Ang II. With the use of transfections as well as glucose transport assays, we further 
demonstrated that Ang II stimulation of the FAS gene was dependent on glucose. In conclusion, 
this is the first report that Ang II regulates adipocyte FAS gene transcription via insulin response 
sequences in a glucose-dependent manner and that this regulation is mediated at least in part via 
the ADD 1 transcription factor. 
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B. INTRODUCTION
Angiotensin II (Ang II) is a hypertensive hormone classically known to regulate blood 
pressure (1). However, studies from our laboratories and others have shown that this hormone 
also regulates adipocyte differentiation, metabolism and gene expression (2-4). Components of 
the renin angiotensin system have been identified in several tissues, including adipose tissue (2, 
5-7). We and others have provided several lines of evidence for the role of the adipocyte-derived 
Ang II in lipid metabolism (2, 7). First, the Ang II precursor, angiotensinogen, is expressed and 
nutritionally and hormonally regulated in adipose tissue (8-11 ). Secondly, expression of the 
angiotensinogen gene is dependent on differentiation, and treatment of cultured adipocytes with 
Ang II increases the expression of differentiation markers (3). Furthermore, we have shown that 
treatment of cultured adipocytes with Ang II increases triglyceride storage and the activities of 
lipogenic enzymes including fatty acid synthase (FAS) (2). 
FAS is a key lipogenic gene that catalyses the synthesis of the long-chain fatty acid 
palmitate from acetyl-CoA and malonyl-CoA in the presence ofNADPH (12). FAS 
concentrations in adipose tissue are highly sensitive to nutritional, hormonal and developmental 
states (12, 13). Fasting and diabetes in rats lead to diminished synthesis of FAS, whereas obesity, 
a high carbohydrate diet or insulin treatment increases FAS synthesis (14). The gene encoding 
FAS is primarily regulated at the transcriptional level (15-19) and we have previously identified 
an insulin-responsive element (IRE) in the FAS gene that mediates the transcriptional up­
regulation of this gene by insulin in adipocytes (16). Because our previous studies indicate that 
Ang II is a lipogenic hormone that exerts an insulin-like effect on adipocyte gene expression, we 
hypothesized that Ang II and insulin regulate FAS gene expression via similar mechanisms. 
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We report here for the first time that Ang II increases FAS gene transcription in adipocytes 
via an angiotensin-responsive element that is identical with the insulin-responsive region (E box) 
in the proximal FAS promoter. Furthermore, we show that Ang II effect is dependent on glucose 
and we identify adipocyte determination and differentiation factor 1/sterol-regulatory-element­
binding protein le (ADDl/SREBPlc) as a transcription factor involved in the regulation of the 
FAS gene by Ang II. 
C. MATERIALS AND METHODS
1. 3T3-Llcell Culture
3T3-Ll cells were grown and differentiated as described previously (2, 19). In brief, 
cells were grown to confluence in standard DMEM (Dulbecco's modified Eagle's medium) 
supplemented with 10% (v/v) fetal bovine serum. At confluency, cells were induced to 
differentiate by the addition of dexamethasone (250nM) and isobutylmethylxanthine (0.5mM) to 
standard medium for 72h. Cells were maintained for a further 3 days in standard medium, then 
changed to serum-free medium containing 1 % (w/v) BSA for 12h followed by treatment with Ang 
II and/or insulin as indicated in the figure legends. All treatments were performed in serum-free 
medium to test individual and direct hormone effects. However, the responsiveness of the FAS 
gene to both Ang II and insulin can be demonstrated in the presence of both 1 % and 10% (v/v) 
serum (results not shown). Unless otherwise stated, cells were cultured in the presence of a high 
concentration of glucose (25mM). 
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2. RNA Isolation and Northern Analysis
RNA was isolated by the CsCl density gradient method (19). Individual culture dishes 
(100mm) of cells were used for each RNA sample within treatments; three or four samples were 
included in each treatment group and each experiment was repeated two or three times. Total 
RNA (approx. 30µg) for each sample was subjected to electrophoresis in a 0.7% agarose gel, 
transferred to nylon membrane and analyzed by Northern blotting, as described previously (19). 
Membranes were hybridized with 32P-labelled cDNA probes for rat FAS (kindly provided by Dr A. 
G. Goodridge) or ADDI (kindly provided by Dr B. M. Spiegelman) and 18S (purchased from
Promega). Unbound probe was removed by washing membranes in 2xsaline/sodium 
phosphate/EDTA (SSPE) for 45min at 25°C and then in 0.1 xSSPE/0.1 % SDS for 60min at 65°C. 
After being washed, membranes were exposed to X-ray film (Dupont). Autoradiograms were 
analyzed by densitometric scanning; data are expressed as a ratio of FAS to 18S. 
3. Nuclear Run-On Assay
Nuclei were isolated from control or Ang II-treated 3T3-Llcells as described previously 
(19). In brief, cells were homogenized in a buffer containing Nonidet P40, and nuclei were 
isolated by differential centrifugation. Nuclear run-on assays and hybridizations were conducted 
as previously described (19). Labelled RNA was hybridized with plasmids containing cDNA 
species encoding FAS and J3-actin, and with vector alone (pBS) immobilized on nylon 
membranes. Membranes were then exposed to film and the autoradiograms were quantified by 
scanning laser densitometry. FAS transcription rates were normalized to those of J3-actin. 
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4. FAS-Reporter Gene Constructs
A fragment of the FAS 5'-flankng region spanning -2100 to +67 was generated by PCR 
with rat genomic DNA and subcloned into pGL-basic vector (Promega). Various deletions of this 
fragment were subsequently generated by ExoIII/mung bean nuclease deletion (Stratagene, La 
Jolla, CA, U.S.A.) or by PCR with previously published FAS promoter sequences (20). For fusion 
constructs containing two direct repeats of sequences spanning the E box, -70 to -54 wild-type 
(CAGCCCATGTGGCGTGG) and mutant -69 to -54 (AGCC TGT ACGGCGTGG)
oligonucleotides of the specified sequences were synthesized, annealed then subcloned into 
pGL2-SV promoter luciferase plasmid. These FAS-promoter-luciferase fusion constructs were 
used to transfect 3T3-Llcells. To determine the role of this IRE in the context of the native FAS 
promoter, we also used the native FAS promoter fragment -200 to +67 linked to the 
chloramphenicol acetyltransferase (CAT) reporter gene, containing either the wild-type or 
mutated E box (21 ). 
5. Transf ections
3T3-Llcells were transfected with FAS-luciferase gene fusion constructs and pSVneo 
plasmid that confers neomycin resistances using the calcium phosphate-DNA co-precipitation 
method (Gibco BRL, Bethesda, MD, U.S.A.) as described previously (16). Stably transfected 
cells were selected by maintaining transfected cells in 500µg/ml neomycin for 2 weeks. Surviving 
fibroblasts were cultured as described above for 3T3-Llcells. The differentiated stably transfected 
adipocytes were maintained overnight in serum-free medium before being treated with Ang II 
and/or insulin as indicated in figure legends. pGL2-control plasmid, which contains the simian 
virus 40 promoter linked to the luciferase gene, was used as a control to determine the specificity 
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of the effect of Ang II on FAS promoter and did not show responsiveness to insulin or Ang II 
(results not shown). 
6. Reporter Gene Assays
For luciferase assays, the cells were lysed in lO0mM potassium phosphate (pH7.8)/0.2% 
(w/v) Triton X-100/lmM dithiothreitol. The cytosolic extracts were used to measure luciferase 
activities with a luminometer (Berthold, Nashua, NH, U.S.A.) and a kit for luciferase assay 
( Tropix). Luciferase activity was normalized to protein measured with the Bradford assay (22). 
For CAT assays the cells were lysed in a buffer containing 250mM Tris/HCl, pH8, and 5mM 
dithiothreitol; a quantitative non-chromatographic assay was used to measure CAT activity in the 
cell extracts, as described previously (21 ). 
7. Adenovirus-Mediated Overexpression of a Dominant-Negative Form of ADDI in 3T3-Ll
Adipocytes 
An adenoviral vector overexpressing a dominant-negative version of rat ADD 1 under the 
control of the cytomegalovirus immediate-early promoter was previously described (23). The 
adenovirus vector Adnull, whose expression cassette contains the major late promoter with no 
exogenous gene, was used as a control. The adenoviral vectors were propagated in HEK-293cells, 
purified by CsCl density centrifugation and stored. Cells were grown as described above, and 
35mm dishes containing fully differentiated 3 T3-Ll adipocytes were incubated overnight in 
serum-free medium containing BSA. Cells were transduced with 3xl07 plaque-forming units in 
DMEM alone for 4h at 37°C; lnM Ang II was then added. Transduced cells were assayed for 
FAS enzyme activity 48h after viral infection. 
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8. Uptake of 2-Deoxyglucose
3T3-Ll cells were differentiated as described above and incubated overnight in serum­
free medium containing 2% (w/v) BSA. Cells were then washed twice with Krebs-Ringer 
phosphate, pH7.4, and incubated for 30min at 37°C in the presence or absence of insulin (lOnM) 
or Ang II (lnM). 2-Deoxyglucose uptake was initiated by the addition of0.2mM 2-[3H] 
deoxyglucose (500GBq/mmol). After 5min, cells were washed rapidly with ice-cold buffer and 
lysed with NaOH; radioactivity was then counted. 
9. Statistical Analysis
Experiments were repeated two to eight times as indicated in the figure legends. 
Analysis of variance was used to compare overall group means. Student's t test was used for 
comparison between groups. All tests were conducted with 95% confidence intervals. 
D.RESULTS
1. Effects of Ang II on FAS Activity, mRNA Level and Gene Transcription Rate
We have previously reported that Ang II increases FAS gene expression in murine and 
human adipocytes (2). Fig. 1 shows the coordinated effects of Ang II on FAS activity, mRNA 
level and the rate of gene transcription. Ang II increased FAS activity, mRNA level and gene 
transcription by approx. 2.5-fold, 4.5-fold and 2.5-fold respectively. These results demonstrate 
that FAS gene is regulated by Ang II at the transcriptional level. 
2. Effects of Ang II on FAS Promoter Activity: Comparison with Insulin
To investigate further the mechanisms of transcriptional regulation of FAS by Ang II, we 
searched for Ang II-responsive regions in the FAS gene. Ang II significantly increases luciferase 
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Fig. 1 Effects of Ang II on FAS enzyme activity, mRNA level and gene transcription rate.
3T3-Ll adipocytes were treated with lnM Ang II (All). Cells were then harvested after 48h for FAS 
enzyme activity (measured in nmol ofNADPH oxidized/min per mg of protein) or after 24h for mRNA 
analysis and gene transcription assays (measured in arbitrary densitometric units). Results are presented as 
percentages of control. •p < 0.01 compared with controls from a total of eight experiments. 
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activity in 3T3-Llcells transfected with the fusion constructs containing the regions -200 to +67 
(Fig. 2A) and-70 to +67 (Fig. 2B) of the FAS promoter. These fragments contain the IRE 
previously identified in the FAS gene (16). The magnitude of FAS promoter response to Ang II 
stimulation was half of that elicited by insulin but it is clear from Fig. 2 that adipocytes responded 
similarly to Ang II and insulin. In addition we show that Ang II and insulin in combination 
increased luciferase activity in 3T3-Llcells transfected with the plasmids spanning the regions -
200 to +67 and -70 to +67 (Fig. 2A and 2B, respectively) of the FAS promoter. Importantly, the 
increase in luciferase activity in the combined Ang II and insulin treatments was not found to be 
significantly different from insulin treatments alone, suggesting that Ang II and insulin might 
target similar cis-acting elements to regulate FAS gene transcription. 
3. Ang II-Responsive Sequences are the Insulin-Responsive Sequences in the FAS Gene
To determine whether the IRE might mediate the Ang II responsiveness of the FAS gene, 
we tested the responsiveness of this element to Ang II and insulin in the context of a heterologous 
promoter and when linked to the native FAS promoter. Using adipocytes transfected with a 
construct containing only the -70 to -54 (IRE) motif linked to the simian virus 40 heterologous 
promoter, we tested the responsiveness of luciferase to Ang II and to insulin. We demonstrate (Fig. 
3, upper panel) that Ang II and insulin significantly increased luciferase activity. This indicates 
that the -70 to -54 region alone is sufficient to confer Ang II responsiveness on the FAS promoter 
and no additional sequence is needed outside this motif. In addition, this indicates that Ang II and 
insulin both regulate FAS gene transcription through the same responsive sequences in the FAS 
promoter. To confirm this we mutated the insulin-responsive E box in the -70 to -54 region of the 
FAS promoter. Fig. 3 (upper panel) demonstrates that the mutation of this region caused a loss of 
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Fig. 2 Effects of Ang II on /uciferase activity in 3T3-Ll adipocytes transfected with various 
FAS promoter constructs. Adipocytes were transfected with FAS-luciferase constructs containing the -
200 to +67 region (A) or the -70 to +67 region (B) of the FAS promoter and treated for 48h with Ang II 
(All) and/or insulin (Ins). Luciferase activity was then measured (in arbitrary units) and normalized to 
protein levels. Results are means for six different experiments. *P < 0.01 compared with control; #=I>< 
0.01 compared with lnM Ang II. 
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Fig. 3 Insulin-responsive E box mediates Ang II responsiveness of the FAS promoter. Upper 
panel: the IRE (E box) linked to a heterologous promoter mediates the effects of Ang II (AIi) and insulin 
on luciferase activity. Two copies of the insulin-responsive region (-70 to -54) containing the wild-type 
(hatched columns) or mutated (black columns) E box were subcloned into pGL2 SV-luciferase plasmid and 
transfected into 3T3-Ll adipocytes. Cells were then treated with or without lnM Ang II and/or insulin for 
48h; luciferase activity and protein content were then measured. Results are reported in arbitrary units of 
luciferase/mg of protein. This experiment was performed in triplicate. **P < 0.01, Ang II effect compared 
with control; *P < 0.05, insulin effect compared with control; #J> < 0.05, mutation effect compared with 
control. Lower panel: mutation of the IRE (E box) in the native FAS promoter abolishes the effects of Ang 
II (All) on the CAT reporter gene. Fusion constructs containing the wild-type (hatched columns) or mutated 
(black columns) E box within the FAS promoter (-200 to +67) linked to the CAT reporter gene were 
reporter gene activity by Ang II was abolished (Fig. 3, lower panel).Cells were then treated with or without 
lnM Ang II for 48h and harvested for assays. CAT activity was normalized to protein content. *P < 0.01 
compared with control; this experiment was performed in triplicate. 
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stimulation of luciferase activity in response to Ang II treatment as it did for insulin when 
compared with control. Additionally, when IRE within the native -200 to +67 FAS promoter was 
mutated, stimulation of the CAT reporter gene activity by Ang II was abolished (Fig. 3, lower 
panel) 
4. ADDl/SREBPlc is required for Ang II-Regulated FAS Gene Transcription
ADDl/SREBPl c has been proposed as a transcription factor mediating transcriptional 
effects of insulin on lipogenic genes (23, 25). Because Ang II exhibited insulin-like effects on 
FAS gene expression, we next investigated whether ADDI might be the potential transcription 
factor through which Ang II might affect FAS gene transcription: we infected 3T3-Llcells with a 
dominant-negative form of ADD I (ADD 1/DN) designed to induce the formation of 
transcriptionally inactive ADD I dimers that are unable to bind DNA target sequences. Fig. 4 
demonstrates that Ang II-induced FAS enzyme activity was eliminated by the infection of this 
dominant-negative form of ADD 1. This result demonstrates that ADD 1, the insulin-induced 
transcription factor, is also required for the regulation of the FAS gene by Ang II. 
5. Glucose-dependent Effect of Ang II on FAS Promoter: A Proposed Mechanism for
Regulating FAS Gene Transcription 
Because the above results demonstrated that Ang II regulates the FAS promoter activity 
through the same cis-active sequence as insulin, and targets the same transcription factor as 
insulin, we next addressed the question of whether Ang II might exert its effects by mimicking a 
common action of insulin on glucose entry within adipocytes. Because the regulation of lipogenic 
genes by insulin is also dependent on glucose, we next investigated whether the regulation of FAS 
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Null ADDl-DN 
Fig. 4 ADDJ is a potential transcription factor through which Ang II effects FAS gene 
transcription. As described in the Materials and methods section, 3T3-Ll adipocytes were infected with 
adenovirus either encoding or not (null) a dominant-negative form of ADD 1 (ADD 1-DN; multiplicity of 
infection of 100) and treated with lnM Ang II. FAS activity was measured after 48h and normalized to 
protein. *P < 0.01, ADDl/DN compared with null. This figure is representative of four experiments. 
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by Ang II still occurred when glucose was withdrawn from the culture medium and replaced by 
pyruvate as the energy source. 3T3-Ll adipocytes were transfected with the FAS-luciferase fusion 
construct used above (-70 to +67) and treated with or without glucose in the presence or absence 
of lnM Ang II. Fig. 5A demonstrates that glucose alone increased FAS promoter activity by 50%. 
This small effect of glucose alone in adipocytes should be related to the low concentration of 
glucose transporters at the plasma membrane in the absence of insulin, leading to inefficient 
glucose entry. Interestingly, in the absence of glucose, Ang II was almost unable to increase 
luciferase activity (25% stimulation), whereas it elicited a 3-fold increase in the presence of 
glucose. This clearly indicates that the stimulation of FAS activity by Ang II is largely dependent 
on glucose. Because the stimulation of the FAS promoter by Ang II was dependent on the 
presence of glucose in the culture medium, we next investigated whether the effect of Ang II 
might be mediated through the stimulation of glucose uptake into adipocytes. Fig. 5B shows that 
Ang II does indeed stimulate 2-deoxyglucose uptake in 3T3-Ll adipocytes. Even though Ang II 
was less potent than insulin, this effect of Ang II can provide a potential mechanism through 
which Ang II might exert its insulin-like effects on FAS expression in fat cells. 
6. Regulation of ADDI Expression by Ang II and Glucose
Because ADDI mediates the nutritional and hormonal regulation of several lipogenic 
genes (23, 25), we tested whether Ang II modulated ADDI expression (Fig. 6). Adipocytes 
cultured in the absence of glucose expressed very low levels of ADDlmRNA. Consistent with the 
activatory effect of glucose on ADDI expression in cultured hepatocytes (23) was the observation 
that glucose alone was able to induce ADD 1 expression in adipocytes. This effect was further 
potentiated in the presence of Ang II (Fig. 6). This indicates that ADDI expression is modulated 
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Fig. 5 Ang II- and glucose-dependent regulation of the FAS gene and glucose transport. 
(A) The effect of Ang II on promoter activity is dependent on glucose. Adipocytes were transfected with the
SV-luciferase plasmid (described in the legend to Figure 3), which contains the insulin-responsive E box, 
then treated with glucose-free DMEM for 8h before treatment for an additional 48h with (black columns) or 
without (hatched columns) glucose in the presence or absence of Ang II. Luciferase activity was normalized 
to protein and is reported in arbitrary units. *P < 0.05 compared with no glucose; **P < 0.01 compared with 
all other treatments. This experiment was repeated twice. (B) Ang II stimulates 2-deoxyglucose uptake in 
3T3-Llcells. 2-Deoxyglucose uptake was measured for 5min in differentiated 3T3-Llcells in the absence 
(basal conditions) or presence of insulin (Ins) or Ang II at the indicated concentrations. Values are 
presented as the effect of the hormones over basal unstimulated conditions. This experiment was repeated 
three times. 
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Fig. 6 ADDI expression is increased by Ang II and glucose in 3T3-Ll adipose cells. 
Differentiated 3T3-Ll adipocytes were treated with or without Ang II (All, lnM) in the presence or 
absence of glucose (25mM) for 24h; ADDlmRNA expression was analyzed by Northern blotting as 
described in the Materials and methods section. ADDlmRNA levels were normalized to 18S RNA. This 
experiment was repeated twice. 
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by both glucose and Ang II. 
E. DISCUSSION
Insulin is a well-known lipogenic hormone that regulates adipocyte metabolism and 
gene expression. Among these genes, FAS has been well studied for its transcriptional regulation 
by insulin (15-18). We have previously identified an IRE in the FAS proximal promoter (16). 
This IRE is an E box that has been shown to bind ADDl/SREBPl c (23, 25, 26), a member of the 
bHLH family. In established adipose cell lines, ADDI has been shown to promote adipocyte 
differentiation and the expression of genes linked to fatty acid metabolism (24 ). In isolated rat 
adipocytes, FAS expression has been shown to be dependent on ADD 1 through the use of 
infection of a mutated dominant-negative form of ADD 1 (23). Moreover, in the cultured 
hepatocyte system, ADDl/SREBPlc is required for the regulation of lipogenic genes by glucose 
(23) and its expression is nutritionally regulated (23,25) in hepatocytes and fat cells, establishing
it as the strongest candidate for participation in the regulation of the FAS gene by insulin. 
We have shown previously that Ang II acts like insulin as an adipogenic hormone to 
regulate FAS and other lipogenic genes in adipocytes. Here we demonstrate that Ang II regulates 
FAS at the transcriptional level in 3T3 adipocytes and we searched for Ang-II-responsive 
sequences in the FAS gene. By using transfection assays, we mapped the Ang-II-responsive 
region to the IRE. Furthermore, mutation in the E box motif in this sequence abolished Ang II 
responsiveness, as seen in earlier work with the response to insulin when the E box was mutated 
(16,25). This is the first report on the regulation of FAS gene transcription in adipocytes by Ang II 
and the identification of an Ang II-responsive element in the FAS gene. Very few Ang II-
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responsive elements have been identified in other genes. In smooth muscle, responsiveness of the 
a-actin gene to Ang II is partly dependent on modulation of the serum response factor binding to
CC(A!f-rich)6GG regions. The CC(A!f-rich)6GG elements are found in the promoters of several 
immediate-early response genes (27). These response elements have been shown to confer serum­
induced and growth factor-induced transcription activation of these various genes (28-32). In the 
present study the Ang-II-responsive element is an E box (CATGTG) that is distinct from the 
serum response element; there is no evidence that such elements are present in the 2kb promoter 
region located immediately upstream of the transcription start site of the FAS gene. 
As discussed above, the transcription factor ADDl/SREBPlc is critical in the regulation 
of FAS gene transcription in adipocytes. We tested the hypothesis that ADDI might be a 
transcription factor mediating the regulation of FAS by Ang II. Expression of ADDl/DN in 3T3-
Ll adipocytes markedly decreases FAS induction by Ang II, indicating that ADDI is one of the 
transcription factors required for the up-regulation of FAS gene transcription by Ang II. This led 
to the conclusion that the Ang-II-responsive element, which is also the insulin-responsive 
sequence (E box), functions through the same transcription factor (ADDI) as insulin for the 
regulation of FAS gene transcription. This led us to investigate whether Ang II might produce its 
transcriptional effects through insulin-like effects on glucose utilization in adipocytes. Indeed, 
several studies have pointed out that glucose independently was able to regulate lipogenic gene 
expression, including FAS, and that the effect of insulin was in part dependent on glucose. 
Moreover, it has been demonstrated in the hepatic cell system that ADDl/SREBPlc was required 
for the transcriptional effects of glucose on the FAS gene (23). Here we have demonstrated that 
stimulation of the FAS promoter activity with Ang II was largely dependent on glucose. The 
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present results also indicate that Ang II stimulates 2-deoxyglucose uptake in adipocytes, which 
further supports the possibility that the effect of Ang II might be linked to glucose utilization. 
Together, these results provide evidence that, rather than a direct effect of Ang II on 
ADDl/SREBPlc, the induction of the FAS gene by Ang II is linked to increased glucose 
utilization, which in tum up-regulates FAS viaADDl. This led us to propose the following 
scheme for Ang II regulation of FAS transcription, in which the primary action of Ang II is 
exerted at the level of glucose entry within the adipocytes. Once transported within the fat cell, 
glucose can regulate the transcription of the FAS gene throughADDl/SREBPlc, which targets 
the IRE. According to this scheme, insulin is not required for Ang II effects because substantial 
levels of ADDl/SREBPlc are present in differentiated 3 T3 -Ll adipocytes. 
T here are at least two identified types ofreceptor through which Ang II can signal (33). 
M ost studies have focused on the signaling of Ang II through the angiotensin type I receptor 
(ATl ). The primary receptor mediating the regulation oflipogenic genes in adipocytes by Ang II 
identified in our laboratory and in others was the angiotensin type II (AT2) receptor (2, 3); the 
signaling pathway of Ang II through this receptor is largely unknown. Prostaglandin 12 has been 
postulated as a signaling molecule produced by adipocytes in response to Ang II binding to AT2 
receptors (2, 3). One recent study has linked Ang II and glucose transport in vascular smooth cells 
(34). In that experiment, low concentrations of Ang II (0.lnM) stimulated 2-deoxyglucose uptake. 
Although the receptor subtype involved in this effect was not determined, this is reminiscent of 
our present results showing that the effects of Ang II on FAS gene transcription might be related 
primarily to the insulin-like effects of Ang II on glucose metabolism. Because changes in ADD 1 
expression have been involved in the regulation oflipogenic genes by both insulin and glucose 
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(23), we tested whether Ang II also modulates ADDI expression in the presence or absence of 
glucose. The present study demonstrates that Ang II in the presence of glucose markedly induced 
ADDI expression, suggesting that the regulation of the FAS gene in adipocytes by Ang II might 
be mediated by the direct modulation of ADDI in the presence of glucose. 
In conclusion, the present study demonstrates for the first time that Ang II can act on 
gene transcription through insulin-responsive sequences, extending results obtained by others on 
insulin-like mechanisms of intracellular signaling by Ang II. 
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PART IV 
EFFECTS OF HIGH FAT DIET, ANGIOTENSINOGEN GENE INACTIVATION AND 
TARGETED EXPRESSION TO ADIPOSE TISSUE ON LIPID METABOLISM AND 
RENAL GENE EXPRESSION 
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A.ABSTRACT
To address the role of angiotensinogen (agt) in lipid metabolism and its potential 
endocrine effects in vivo, we studied the effects of high fat diets (HFD) on adult, 28-week-old agt 
knockout (KO) mice compared to wild type (WT) mice. Since recent studies by Massiera et al. 
demonstrated that reexpression of agt in adipose tissue of KO mice normalized adiposity, blood 
pressure and kidney abnormalities, we used microarray analysis to investigate changes in gene 
expression profile in kidneys of KO vs. Tg-KO mice, where agt expression is restricted to adipose 
tissue. Body weight, adiposity and insulin levels were significantly decreased (p<0.05) in KO 
mice fed a chow diet (CD) compared to WT mice, while circulating leptin levels were similar. On 
a high fat diet, compared with WT mice, KO mice exhibited significantly lower body weight (p< 
0.05), adiposity (p<0.05), leptin and insulin levels (p<0.05). In agreement with previously 
reported changes in kidney histology, agt KO mice displayed altered expressions of genes 
involved in blood pressure regulation and renal function, but these levels were corrected by 
reexpression of agt in adipose tissue. Collectively, these findings further document important 
endocrine roles of adipocyte agt, in part via regulation of lipid metabolism and kidney 
homeostasis. 
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B. INTRODUCTION
Obesity is a major health problem and a common risk factor for cardiovascular diseases. 
Adipose tissue is a central organ in glucose and lipid metabolism. In addition to its function as the 
major storage depot for triglycerides, adipose tissue is an active organ, sensing metabolic signals 
and secreting hormones that affect whole-body energy homeostasis (1-3). Adipose tissue 
possesses all components of the renin angiotensin system (RAS) that are necessary to generate the 
hypertensive hormone Angiotensin II (Ang II) (4, 5). Angiotensinogen (agt) expression is 
differentiation-dependent, nutritionally and hormonally regulated and differentially regulated in 
adipose tissue of lean vs obese mice and rats ( 6-8). Ang II regulates adipocyte metabolism by 
increasing lipogenic gene expression in a glucose dependent manner (9). The adipocyte 
determination and differentiation factor 1 (ADDI)/ sterol regulatory element binding protein le 
(SREBP 1 c) mediates these effects as a transcription factor binding the Ang II and insulin 
response E box (9). Furthermore, several epidemiological and genetic studies have suggested a 
potential role of adipose Ang II in obesity-related hypertension (10-12). These reports have 
shown an association between genetic polymorphism of human agt gene and variation in body fat 
distribution in men (13, 14). A positive correlation between plasma agt level, BMI and blood 
pressure in humans has also been reported (15). More recently, studies by Massiera et al 
demonstrated that the sole expression of agt in adipose tissue is sufficient to increase blood 
pressure, renal morphology and adiposity in young mice (12-20 weeks ofage) (16,17). Thus, the 
purpose of the present work is to extend these studies to older mice (28 weeks of age) fed a 
standard chow diet or a high fat diet ( 45 % of calories as fat) and determine effects of agt 
inactivation or restricted expression to adipose tissue on lipid metabolism and renal gene 
165 
expression. 
C. MATERIALS AND METHODS
1. Experimental Animals
The agt gene was inactivated in the mouse as previously described (16, 18). Transgenic 
mice (aP2-agt+1") were generated by using transgenic construct containing adipocyte P2 (aP2) 
gene promoter, intron, agt cDNA, polyadenylation site. Mice expressing agt only in adipose 
tissue (Tg-KO) were generated by crossing transgenic mice with agt-deficient mice (16). WT 
(ICR-CDl strain, Harlen, Gannat, France), KO and Tg-KO male mice provided by Dr. Gerard 
Ailhaud (University of Nice, France) were housed 4-6 per cage and fed either a chow diet or a 
high fat diet containing 3% com oil, 21 % lard (representing 45% of calories as fat), 35% 
carbohydrate, 20% protein and 1.2 % minerals (Research diets, NJ, USA), and water ad libitum
in a 12: 12 h light: dark cycle at constant temperature (22 °C). Body weight was measured and 
mice were sacrificed at 28 wk for body compositional analysis. Individual adipose depots were 
removed along with liver and kidney and the epididymal fat pad was weighed. Mice were 
generated at the CNRS 6543, Centre de Biochimie at Nice, France, and then shipped to the 
Department of Nutrition at the University of Tennessee, Knoxville. All experiments described 
were conducted in compliance with the Institutional Animal Care and Use Committee (IACUC) 
at the University of Tennessee. 
2. Plasma Measurements
Following an overnight fast, blood was collected by cardiac puncture for glucose, 
insulin and leptin assay. The plasma was separated by centrifugation at 12,000 rpm for 20 min 
and stored at -80 °c. Plasma leptin and insulin levels were measured by RIA using a mouse leptin 
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and rat insulin RIA kits, respectively, obtained from Linco Research (St. Charles, MO). Blood 
glucose concentrations were measured using a glucose analyzer (LIFESCAN Co, MI, USA). 
3. GeneChip Microarray Assay and Data Analysis
Total RNA from kidneys of KO and Tg-KO mice maintained on a Chow Diet (CD) was 
isolated by the cesium chloride density gradient method and further purified by phenol 
chloroform extraction. Microarray analysis was conducted using the Affymetrix Murine Genome 
U74v2 set that contains probe sets interrogating approximately 36,000 mouse genes and EST 
clusters and was performed at the Genome Explorations Inc. in Memphis, TN. Kidneys from four 
to six KO or Tg-KO mice were used and pooled into 2 sets each; 2 aliquots from the each pool 
for each genotype ( see Appendix Fig 1 ). Total renal RNA (-20µg) from each of these genotypes 
was reverse-transcribed and the phycoerythrin dye was incorporated to the second strand. cRNA 
was synthesized from cDNA and biotinylated and hybridized to a set of Murine Genome 
GeneChips. Following hybridization and washing, the overall fluorescence intensity across each 
chip was scaled to a target intensity of 1500 using Affymetrix GeneChip Microarray Suite 5.0 
software, and pairwise comparisons of mRNA levels were performed. Each experiment was 
performed twice in each genotype and a minimum expression ratio of2-fold differences was 
used as the selection criteria for the differentially expressed genes between the KO (2 sets) and 
Tg-KO mice (2 sets). The fold changes in gene expression were presented as mean of the four 
datasets which are associated with renal function and blood pressure regulation. 
4. Statistical Analysis
All data are expressed as the mean± SEM. Student's test and ANOVA were used to 
compare overall group means. The values were examined by the Bonferroni test for multiple 
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comparison (SAS, Carry, NC) to compare differences among group means after a significant F­
test and statistical significance was defined as p<0.05. 
D.RESULTS
1. Effects of Diet and agt Inactivation on Metabolic Markers
The agt deficient mice fed a chow diet or high fat diet showed significantly decreased 
body weight, adiposity index and epididymal fat pad weight, compared to wild type mice (Fig 1 ). 
The adiposity of high fat diet fed WT and KO mice were increased 83 % and 106 %, respectively, 
compared with that of chow-fed WT and KO mice. Consistent with recent observations (16, 17), 
the epididymal fat pad mass of chow-fed KO mice was 4-fold lower than that of WT mice. 
Similarly, diet-induced fat pad mass was significantly decreased in KO mice (p<0.05). High fat­
fed KO mice exhibited a decreased adiposity index, compared to WT mice fed a high fat diet ( 4.4 
± 0.9% vs 2.0 ± 0.1 %, n=4-6), suggesting that the KO mice were more resistant to dietary obesity. 
Collectively, these results support the hypertrophic effect of Ang II on adipose tissue. Two key 
hormones involved in the regulation of energy homeostasis are insulin and leptin (20, 21 ). 
Plasma insulin levels of KO mice were lower than those of WT animals when fed a chow diet or 
a high fat diet (Fig 2). The high fat diet significantly increased circulating insulin levels as 
expected in the WT mice but not in the KO mice. Similar changes were seen for leptin ( compared 
to insulin); however leptin levels were comparable between the WT and the KO mice but 
significantly increased in response to the HFD in the WT and to a lesser extent in the KO mice. 
Normally, plasma leptin levels closely correlate with body fat (20). However, changes in leptin 
levels did not strictly parallel the changes in adiposity. Circulating leptin levels were similar in 
chow-fed WT and KO mice in spite of the fact that epididymal fat mass of chow-fed KO was 
168 
P<0.05 
8 C d 
5 
i, b C 
l 2 
• 
WT (CD) WT (HFD) 
le:] Adiposity 
[- Fat Pad Weight 
KO(CD) KO (HFD) 
8 
u 
2 :ii, 
A 
uJ 
1 � 
Fig. 1 Effects of agt inactivation and high fat diets on adiposity index and fat pad weight 28-
wk-old mice fed a high fat diet since weaning were used. Body weight and fat fad weight were measured. 
Adiposity index ( x I 00) was calculated for each mouse as the ratio of epididymal fat weight divided by 
body weight minus epididymal fat fad weight. Data are expressed means ± SEM, n=4-6. The Bonferroni 
test was used to compare differences among group means after significant F-test. Means with different 
letters are significant different, p<0.05. 
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Fig. 2 Effects of agt inactivation and high fat diets on plasma leptin and insulin levels. 28-wk­
old mice fed a high fat diet since weaning were used. Plasma parameters were measured as indicated in the 
method section. Data are expressed means ± SEM, n=4-6. The Bonferroni test was used to compare 
differences among group means after significant F-test. Means with different letters are significant different, 
p<0.05. 
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smaller. Further, leptin levels of high fat-fed KO mice were higher than that of chow-fed WT 
mice, although their epididymal fat mass was comparable. Consistent with previous observations 
in 6-week old KO mice (17), 28 week-old KO mice exhibited a lower plasma leptin levels in 
high fat fed animals, compared with high fat fed WT (Fig 2), suggesting that KO mice are less 
sensitive to high fat-induced hyperleptinemia and insensitive to RFD-induced hyperinuslinemia. 
Glucose levels in KO mice remain unchanged when fed a chow or high fat diet, compared with 
WT mice (data not shown). 
2. Effect of Adipose agt on Renal Gene Expression
Previous studies have shown that the plasma agt levels of KO mice were normalized 
by reexpression of agt in adipose tissue (16). These studies have shown that in accordance with 
normalized agt levels in KO mice, the expression of adipose agt reversed hypotension and renal 
abnormalities resulting from agt inactivation (16). Further, agt reexpression in adipose tissue 
corrected increased water intake and urine output of altered renal functions at 12-wk-old mice 
(16). Tg-KO mice exhibited increased body weight and fat pad weight compared with KO mice, 
in agreement with the observation from recent study (16) (data not shown). Reduced leptin levels 
of KO mice were restored by repression ofagt in adipose tissue of KO mice (Fig 3). However, 
while insulin levels were higher in Tg-KO mice versus KO mice, this difference was not 
statistically different (Fig 3). To investigate gene expression profiles of kidneys which are related 
to renal function and blood pressure regulation, we used Affymetrix microarrays to detect 
changes in mRNA expressions in kidneys of KO vs. Tg-KO mice fed a chow diet (Table 1). In 
agreement with increased renin mRNA and protein levels previously reported in KO mice 
compared to WT mice (16), our KO mice displayed increased renin (-11 fold) gene expression 
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Fig. 3 Effect of agt inactivation or agt reexpression in adipose tissue on plasma leptin and 
insulin levels. 28-wk-old mice fed a chow diet were used and total RNA was prepared from kidneys. 
Differential gene expression was analyzed by gene microarray as indicated in the Appendix section. Data 
are expressed means± SEM, n=4-6. Means with different letters are significantly different, p<0.05. 
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Table 1. GeneChip dataset ofmRNAs related to renal function and blood pressure regulation, 
showing �-fold differences in levels between 28 week old KO and Tg-KO mice 
Classification/Function GeneBank Genes Fold changes in 
Accession expre. :sions 
umber (KO vs. Tg-KOJ 
RAS M32352 Renin (Ren-1-d) r <11> 
I
104946 Angiotensin f (2) 
I converting enzy me 
I (A CE) 
I i I,m channels AF047838 Calcium-sensitive ! (1.9)
chloride 
conductance 
protein-I 
(m CLC Al) 
AF029347 Chloride channel ! (2.5)
protein 3 (CLCN3) 
U61085 I Thiazide-sensitive ! (2.4)
i Na- Cl 
cotransporter 
AF012834 I Inwardly rectifying ! (2.8)
potassium channel 
ROMK-2 
I Ang JI signaling X58289 Protein tyrosine ! (3.6)
molecules I phosphatase
I receptor type B I 
D84376 I m RN Afor !(2) 
I 
I phosphatidic acid 
i phosphatase 
t: Increase,!: Decrease, ():Fold changes expressed as Mean 
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compared to Tg-KO mice. Along with upregulated renin expression in kidneys of KO mice, two­
fold increased expression of angiotensin converting enzyme (ACE), which is one of renin 
angiotensin system (RAS) components, was found in KO mice. In addition to altered RAS 
component gene expressions, differences in ion transport/ channel gene expressions were 
observed between KO and Tg-KO mice. Calcium-sensitive chloride conductance protein-I, 
thiazide sensitive Na-Cl cotransporter, chloride channel protein 3 and potassium channel ROMK.-
2 expressions were down regulated by 2-3 folds in KO mice compared with those ofTg-KO mice. 
As anticipated, changes in Ang II signaling molecule gene expression were also observed in KO 
mice; protein tyrosine phosphatase receptor type B and mRNA for phosphatidic acid phosphatase 
gene expressions which are documented to mediate AT2 receptor signaling pathways (26), were 
decreased by -4 folds and 2 folds in KO compared with Tg-KO mice, respectively. We were not 
able to detect expression of AT 1 gene in these studies and no changes in AT2 receptor expression 
were observed. Taken together, these results confirm that adipose tissue agt contributes to kidney 
homeostasis via endocrine mechanisms that affect renal gene expressions. 
E. DISCUSSION
In the present study, the endocrine roles of adipose agt were studied using agt null and 
transgenic mice. Several studies have suggested various roles of Ang II in adipose tissue: 1) 
control of local blood flow 2) stimulation of PGI2 synthesis 3) lipogenesis 4) gene expression 5) 
cell cycle regulation 6) estrogen production (7, 27-30). Studies on agt knockout and transgenic 
mice have revealed that adipose agt acts as a trophic factor in body fat mass and a modulator in 
blood pressure, emphasizing the potential role of adipose agt as an endocrine effector of obesity-
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associated hypertension ( 16). Subsequent comparison experiments of agt knockout and control 
wild-type mice have supported that adipose agt regulates adipose tissue development in young 
mice ( 6 week of age) by modulating endogenous lipogenesis as well as locomotor activity ( 17). 
Our studies also confirmed that agt is involved in the regulation of fat accretion in adipose tissue 
of older mice (28 weeks of age). In addition to decreased body fat mass in agt deficient mice, 
plasma concentrations for key metabolic hormones, leptin and insulin levels were reduced along 
with decreased body fat mass, indicating a trophic effect of adipose agt. However, in previous 
studies, similar levels of leptin and insulin in agt KO and control WT mice were observed in both 
chow-fed and high-fat fed animals (17). It is possible that this is an age-related resistance to diet­
induced hyperleptinemia and hyperinsulinemia since younger mice ( 6 weeks of age) were used in 
these studies ( 16, 31 ). Further, the direct role of adipose agt in blood pressure regulation has been 
proposed ( 16). In the present study, as an approach to understand mechanisms, which account for 
changes in kidney homeostasis, we used microarray analysis to investigate differential gene 
expression in kidneys for KO and Tg-KO mice. Upregulated renin and ACE expressions in KO 
mice were in accordance with the observations of altered renin expression and protein levels in 
KO mice (16). Consistent with renal dysfunction observed in mice lacking agt, ion channel­
related gene expressions in kidneys were suppressed in KO mice. These ion channel related genes 
have been identified as important blood pressure regulatory genes that are responsible for renal 
function and also associated with Bartter 's syndrome which is a hyperkalemic alkalosis with 
dehydration, hypotension and severe polyuria and caused by null mutations in any ofNa+-K+-2cr 
cotransporter, ROMK potassium channel and CLC-KB chloride channel (22-25). Additionally, 
Ang II signaling molecule expressions were also downregulated by agt inactivation. However, agt 
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deficiency-induced renal abnormalities and hypotension were restored by adipose agt 
reexpression, reflecting that adipose agt is released into the blood stream and mediates blood 
pressure regulation (16, 32). Ang II also modulates other physiological functions such as 
fibrinolysis, via upregulation of PAI-1 expression (33). Ang II receptors are expressed in several 
tissues including adipose tissue and kidney that express both AT 1 and AT2 subtypes (28, 34 ). 
Future studies will determine Ang II receptor subtypes mediating the paracrine and endocrine 
effects of adipose Ang II in both adipose tissue and kidney. Collectively, our results confirm a 
critical role of agt in adipose tissue metabolism and further directly support a regulatory role of 
adipose agt in body blood pressure as well as kidney homeostasis. 
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PARTV 
CROSSTALK BETWEEN ANGIOTENSIN II AND INSULIN SIGNALING IN 3T3-Ll 
ADIPOCYTES 
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The manuscript is being prepared for publication with Co-authors Jones Voy, B., Huang, T.Y., 
Koontz, J. and Moustaid-Moussa, N for the Biochem J 
A.ABSTRACT
In adipocytes, Angiotensin II (Ang II) exerts actions on lipogenesis by increasing fatty 
acid synthase (FAS) gene transcription in a paracrine/autocrine manner. This effect was mediated 
by glucose and the transcription factor ADD 1/SREBP le. In the present study, we have elucidated 
the potential signaling mechanisms mediating FAS promoter and enzyme activity regulation by 
Ang II in adipocytes. Since Ang II was shown to mimic insulin actions in regulation of FAS gene 
and simultaneous stimulation of both hormones did not induce an additive effect on FAS 
transcription, we have proposed that the lipogenic hormone Ang II may act on the same signaling 
molecules as those used by insulin in adipocytes. Inhibition of phosphatidylinositol 3-kinase (PI3-
K) abolished the Ang II-dependent increase in FAS enzyme and promoter activities whereas
repression of the mitogen-activated protein kinase (MAPK) cascade was without effect or had a 
stimulatory effect. Ang II caused rapid activations of insulin receptor (IR)f3 subunit and insulin 
receptor substrate- I (IRS-1) which are initial components in the insulin signaling cascade and 
induced the association ofp85 with tyrosine-phosphorylated IRS-1, an indicator of PI3-K 
activation. Furthermore, Ang II stimulated the phosphorylation of the major PI3-K downstream 
effector, Akt at Ser 473, the critical site for the kinase activation. This action of Ang II was 
completely abrogated by the ATl receptor antagonist and only partially by the AT2 receptor 
antagonist. In summary, this study provides a new mechanistic insight by which Ang II may 
display its lipogenic effects in adipocytes through the activation of insulin signaling molecules 
including 1Rf3, IRS-1, PI3-K and Akt. 
182 
B. INTRODUCTION
Ang II, the dominant effector peptide of the systemic renin-angiotensin system (RAS) is 
a pleiotrophic hormone which plays a critical role in blood pressure regulation and fluid volume 
balance (!).Various tissues possess their own RAS, which seems to influence local tissue 
functions. Human and rodent adipose tissues have a functional RAS. The locally generated Ang II 
exerts its physiological effects via at least two G-protein coupled receptors (GPCR) subclassified 
as AT 1 and AT2. Adipose Ang II has been shown to directly participate in adipose tissue growth 
and development by significantly increasing triglyceride stores as well as indirectly in adipogenic 
differentiation concomitant with stimulating release of the autocrine adipogenic effector 
prostacyclin (2, 3). Earlier studies from our lab have demonstrated that the lipogenic mechanisms 
of Ang II are linked to increasing activity and gene expression of the two key lipogenic enzymes, 
fatty acid synthase (FAS) and glycerol-3 phosphate dehydrogenase (GPDH) in an AT2 receptor­
dependent manner, accumulating triglyceride content and ultimately increasing adiposity in 
human and 3T3-Ll adipose cells (2, 4). Of significance, Ang II exhibits insulin-like action in the 
regulation of FAS gene transcription in adipose cells. The molecular mechanisms underlying 
these effects by Ang II stimulation in 3T3-Ll adipocytes were dependent on glucose and a 
transcription factor ADDI (adipocyte determination and differentiation factor 1) that binds to the 
insulin-responsive element (E-box) within the proximal FAS gene promoter (5). Further, the 
signaling mechanism for insulin regulation of FAS transcription has been shown to involve 
activation ofphosphoinositide 3-kinase (PI3-K)-Akt pathways in 3T3-Ll adipose cells (6). 
Accordingly, we hypothesized that given the insulin-like effect of Ang II in adipocytes, this 
hormone is likely to mediate its effects on the activation of FAS transcription via insulin signaling 
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molecules such as PI3-K and mitogen-activiated protein kinase (MAPK), which play important 
roles as mediators in insulin-induced glucose transport, lipogenesis and mitogenesis. To test this 
hypothesis, we first investigated the effects of the inhibitors for well-documented insulin­
stimulated kinases like PI3-K and MAPK on Ang II-induced FAS promoter and enzyme activities. 
Next, we examined the action of Ang II with signaling molecules (e.g. IR, IRS-I, PI-3K and Akt), 
which involve an early step of PI3-K cascade or MAPK cascade in insulin receptor signaling. Our 
results suggest that Ang II regulates adipocyte metabolism by positive crosstalk with the PI-3K 
mediated pathway of the insulin signaling cascade. This Ang II effect was mediated by both Ang 
· II receptors (ATl and AT2).
C. MATERIALS AND METHODS
1. Reagents and Antibodies
Human Ang II was purchased from Sigma (St. Louis, MO).Rabbit polyclonal anti-IR, 
rabbit polyclonal anti-IRS-I, phosphospecific anti-Akt/PKB, anti-Akt/PKB and secondary 
antibodies as well as protein A/G-Sepharose were purchased from Santa Cruz Biotechnology, Inc. 
(Santa Cruz, CA). Monoclonal anti-phosphotyrosine antibody (clone 4G10) was from Upstate 
Biotechnology (Lake Placid, NY). Polyclonal antibody against the p85a. regulatory subunit of 
PI3-K was purchased from BioSource International (Camarillo, CA). Phosphospecific-ERKl/2, 
also known as p42/44 MAPK and anti-ERKl /2 were from Cell Signaling Technology (Beverly, 
MA). PI3-K inhibitor, LY294002 was purchased from Sigma (St. Louis, MO) and MEKl/2 
inhibitor, PD 98059 was from New England Biolabs (Beverly, MA). 
184 
2. Cell Culture
3T3-Ll fibroblast cells (American Type Culture Collection, Rockville, MD) were grown 
and differentiated as described previously (7). In brief, cells were grown to confluence in standard 
DMEM (Dulbecco's modified Eagle's medium) supplemented with 10% (v/v) fetal bovine serum. 
At confluency, cells were induced to differentiate by the addition of dexamethasone (250nM) and 
isobutylmethyxanthine (0.5mM) to standard medium for 72h. Cells were maintained for 
additional 3 days in standard medium, then changed to serum-free medium (SFM containing 1 % 
(v/v) BSA) for 12h followed by treatment with Ang II ( l 0nM), insulin ( lOnM) and various 
inhibitors of insulin signaling molecules as indicated in the figure legends. All treatments were 
performed in SFM to test individual and direct hormone effects. FAS enzyme activity was 
measured after 24h and normalized to protein content. 
3. Transient Transfections
3T3-Ll adipocytes were transfected with FAS-luciferase gene fusion constructs 
(2µg/well) containing two direct repeats of sequences spanning the E box, -70 to -54 
(CAGCCCATGTGGCGTGG) and pGL2-control plasmid (2µg/well) using the calcium 
phosphate-DNA co-precipitation method (Gibco BRL, Bethesda, MD) as described previously (8). 
Transfection efficiency was monitored by cotransfection of J3-galactosidase expression vector 
pSV-J3gal (0.2µg/well) (Promega). The differentiated transiently transfected adipocytes were 
maintained overnight in SFM. Before adding 1 0nM of Ang II or I 0nM of insulin, cells were 
pretreated with SFM supplemented with vehicle (0.1 % Mg2SO; DMSO), 50µM LY294002 (Pl-
3K inhibitor) or I00µM PD98059 (MAPK Kinase inhibitor) for l h  and a second batch of 
inhibitors was added after 12h of Ang II or insulin treatment. Luciferase activity was assayed 
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after 24h of transfection in transient transfection experiments. 
4. FAS Enzyme Activity Assay
Cells were harvested by scraping into 250ul of0.25M sucrose buffer (pH 7.4) containing 
0.1 mM phenylmethysulfonyl fluoride (PMSF), 1 mM dithiothreitol and 1 mM EDTA. Cell 
homogenates were sonicated for 5 sec and ultracentrifuged (12,000 x g) for 30 mins at 4 °C. FAS 
enzyme activity in crude cytosolic extracts of adipocytes was measured spectrophotometrically 
by monitoring the oxidation rate of NADPH at 340 nm. The enzyme activity was normalized to 
per mg protein as previously described (8). 
5. Reporter Gene Assays
For luciferase assays, the cells were lysed in l 00mM potassium phosphate (pH 
7.8)/0.2% (w/v) Triton X-100/ lmM dithiothreitol. The cytosolic extracts were used to measure 
luciferase as well as galactosidase activities with a luminometer (PerkinElmer, Boston, MA) and 
a kit for luciferase assay (Tropix). Luciferase activity was normalized to protein content measured 
with the Bradford assay (9). 
6. Immunoprecipitation
After various stimulation times (5mins, 10mins, 30mins, l h), cells were lysed in ice-cold 
lysis buffer (20mM Tri-HCl, pH 7.4, lO0mM NaCl, lmM EDTA, lmM EGTA, 2mM NaNO4, 
20mM Na2P2O7, l mM NaF, 1 % Trition X-100, 10% glycerol, 0.1 % SOS, 0.5% deoxycholate, 
lmM PMSF, 5% (v/v) protease inhibitor cocktail (Sigma) and 1 % Nonidet P-40) at 4 °C for 30
mins. The cell lysates were centrifuged at 10,000 x g for 30mins at 4 °C to remove cell debris and 
nuclei. Protein was determined in the cleared supernatant using the Bradford assay reagent. For 
immunoprecipitation, equal amounts of protein (-1000 µg) were incubated with appropriate 
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antibodies overnight with gentle agitation at 4 °C, followed by addition of 50ul protein A/G­
Sepharose beads into immune complexes and further incubation at 4 °C for 5h on a rotating 
device. The immunoprecipitates were gentle washed five times in cold lysis buffer and 
solubilized in 50ul of 2 X SOS/PAGE sample buffer and then boiled for 5mins. The soluble 
supernatants were further analyzed by SOS/PAGE. The antibodies and their concentrations used 
in immunoprecipitation were anti-phosphotyrosine antibody (5µg/ml) and anti-IRS antibody 
(5µg/ml). 
7. Immunoblot Analysis
Cells were prepared as described above for the immunoprecipitation method. For 
immunoblotting, protein sample (25-50µg) were resolved by 8-10 % SOS/PAGE and 
electronically transferred onto nitrocellulose membrane. The membranes were blocked with Tris­
buffered saline-0.05% Tween 20 (TBST) containing 5% non fat dry milk for overnight at 4 °C or 
BSA for 3hrs at 23 °C. The blots were then incubated with an appropriate dilution of primary 
antibody, washed six times in TBST and further incubated with the appropriate secondary 
antibody conjugated to horseradish peroxidase and then washed another six times in TBST. 
Bound peroxidase was visualized by a high sensitive chemiluminescence system (ICN 
Biomedicals, Inc., Costa Mesa, CA). The bands obtained in the western blots were scanned and 
quantified using Zero-Oscan software (Scanalytics Inc., Fairfax, VA). The antibodies and their 
concentrations used in immunoblotting are phosphospecific anti-ERK.1/2 (20ng/ml), anti-IR 
antibody (2µg/ml), anti-IRS antibody (2µg/ml), anti-p85a antibody (5µ1/ml), phosphospecific­
anti-Akt/PKB antibody (0.4µg/ml) and anti-Akt/PKB antibody (0.4µg/ml). 
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8. Statistical Analysis
Data comparison was performed using one-way or two-way ANOVA and presented as 
mean± SEM. IfF-ratio was significant, further comparisons were made using the Bonferroni test. 
Values of p<0.05 were considered significantly different. 
D.RESULTS
1. PI3-K mediates Ang II-induced FAS enzyme and promoter activities
Ang II has previously been shown to act via an insulin-like mechanism in the regulation 
of FAS activity, mRNA level and rate of gene transcription in adipocytes (5). Recently, it has been 
shown that PI-3K and Akt/PKB play roles as mediators in insulin-induced FAS promoter 
activation in adipose cells (6). To define potential signaling mechanisms responsible for the Ang 
II-induced FAS transcription in adipocytes, we first examined the effects of inhibitors for Ang II 
and insulin signal transduction pathways on Ang II-stimulated FAS enzyme and promoter 
activities. As shown in Fig I& 2, Ang II and insulin significantly induced FAS enzyme and 
promoter activities in non-transfected 3T3-Ll and transiently transfected adipose cells (p<0.05), 
consistent with previous data from our lab (5). A PI3-K inhibitor, LY 294002, significantly 
suppressed Ang II-dependent increases in FAS enzyme and promoter activities (p<0.05). In 
contrast, the responsiveness to Ang II was essentially unaffected or increased by PD 98059, an 
inhibitor ofMAPK Kinase (MEK). Consistent with previous data, with this MEK inhibitor 
treatment, insulin-stimulated FAS enzyme and promoter activities were also enhanced (6). In 
accordance with previous results, insulin responsiveness was significantly decreased by 50µM of 
LY 294002 treatment (p<0.05) (6). In addition, no interactions between both hormones and 
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Fig. 1 Ang II stimulation of FAS enzyme activity is dependent on PI3K. Differentiated adipocytes 
were pretreated with or without vehicle (0.1 % DMSO), 50µM LY 294002 (PI3K inhibitor) or 1 00µM PD 
98059 (MEK inhibitor) for lh and stimulated with or without 1 OnM Ang II or 1 OnM insulin for 24h. A 
second aliquot of the inhibitors was added after 12h treatment with Ang II or insulin. FAS activity was 
measured after 24h and normalized to protein content. a,b,c,d Values with different letters are significantly
different (p<0.05). Results are representative of four separate experiments (n=6). Control, C; Ang II, A; 
Insulin, I; LY 294002, LY; LY 294002 plus Ang II plus, LA; LY 294002 plus insulin, LI; PD98059, PD; 
PD98059 plus Ang II, PA; PD98059 plus insulin, PI 
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Fig. 2 Ang II stimulation of FAS promoter activity is dependent on PI3K. Adipocytes were 
transfected with FAS-luciferase constructs containing E box, -70 to +67 of FAS promoter or empty vector. 
The differentiated transfected adipocytes were pretreated with or without vehicle (0.1 % DMSO), LY 
294002(50µM) or PD98059 ( l00µM) for l h  and stimulated with or without lOnM Ang II or lOnM insulin 
for 24h. A second aliquot of the inhibitors was added after 12h treatment with Ang II or insulin. Luciferase 
activity was normalized to protein. a,b,c,d Values with different letters are significantly different (p<0.05). 
Results are representative of four separate experiments (n=6). Control, C; Ang II, A; Insulin, I; LY 294002, 
LY; LY 294002 plus Ang II plus, LA; LY 294002 plus insulin, LI; PD98059, PD; PD98059 plus Ang II, PA; 
PD98059 plus insulin, PI 
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inhibitors were observed. This result suggests involvement of PI3-K  not MAPK in both 
hormone-induced FAS transcription in adipose cells. To confirm the above results, we examined 
the effect of Ang II stimulation on dual phosphorylation levels ofMAPK (ERK.1/2) at different 
time points, which reflects the activation of MEK and indirectly MAPK cascade. As expected, 
insulin treatment led to a marked increase in the dual phosphorylation ofERK.1/2 by about 4-fold 
at 5 min, compared with control (Fig 3, upper panel) (10). Conversely, Ang II did not modify 
basal activities ofERK.1/2 for 10 min of incubation and then blunted basal ERK.1/2 
phosphorylation after 30 min (Fig 3, upper panel), suggesting that MAPK pathway is not likely to 
be involved in FAS transcription activation in response to Ang II. The amount of total cytosolic 
ERK.1/2 was similar (Fig 3, lower panel). 
2. Ang II stimulates phosphorylation of IRP, IRS-1 and p85a association with IRS-1
To further elucidate possible mechanisms of crosstalk between Ang II and insulin 
receptor signaling in adipocytes, we studied the effect of Ang II on tyrosine phosphorylation of 
major upstream mediators of PI3-K in the process of insulin signaling. As expected, lOnM insulin 
treatment for 5 min caused rapid tyrosine phosphorylation ofIRJ3 (Fig 4, upper panel) and IRS-I 
(Fig 4, lower panel). Compared with the response to insulin, IRJ3 (Fig 4, upper panel) and IRS-I 
(Fig 4, lower panel) activations were delayed in the presence of Ang II. These stimulatory effects 
by Ang II on IRJ3 were peaked at 10 min but reduced by 30 and 60 min of incubation, 
representing approximately 2-fold and 3-fold decreases compared with those produced by 10 min 
Ang II stimulation, respectively (p<0.05). Similar to Ang II-induced IRJ3 activation, IRS-I 
phosphorylation was observed at 10 min Ang II treatment and this phosphorylation also was 
reduced by longer treatment of Ang II. The tyrosine-phosphorylated IRS-I is essential for its 
191 
C Im Angil 
TUM (nun,) 5 5 5 10 30 60 
Phospho- p44 MAPK 
Phospho- p42 MAPK 
::�=� ,�-•-•i 
0 CantmJ. � Angll(.IOmim) 
• lOnM lnrulin. � Ancll�) 
� I.OnMAlig II�) � Angll(fiDminl) 
Fig. 3 The inhibitory effect of Ang II on p42/44 MAPK phosphorylation. Fully differentiated 
adipocytes were stimulated with or without 1 OnM Ang II or 1 OnM insulin as a positive control for the 
indicated times. The cell lysates were analyzed by immunoblotting with anti-phospho-p42/44 MAPK 
antibody (Thr183 /Tyr185) and anti-p42/44 MAPK antibody for loading control. A representative
autoradiograph ofphosphorylated ERK.1/2 and bar graph of quantitation of two experiments are shown. 
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Fig. 4 Ang II-induced phosphorylation of insulin receptor p (IRP) or insulin receptor substrate­
] (IRS-1 ). Fully differentiated adipocytes were stimulated with or without 1 OnM Ang II or 1 OnM insulin 
(positive control) for the indicated times. The cell lysates were immunoprecipitated with 
antiphophotyrosine antibody and immunoblotted with anti-IR� subunit antibody or anti-IRS-1 antibody. A 
representative autoradiograph ofphosphorylated IR� and IRS-1 and bar graph of quantitation (mean± 
SEM) from three separate experiments are shown. a,b,c,d Values with different letters are significantly 
different (p<0.05). 
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association with tyrosine phosphorylated IRS-I as an indicator of PI3-K activation. As shown in 
binding to SH2 domains of the p85 regulatory subunit of PI3-K and its activation of PI3-K 
enzymatic activity (10). We next investigated the effect of Ang II on p85a. 
Fig 5 (upper panel), a low level of IRS-1/p85a. association was present in the basal state and this 
was markedly stimulated by insulin (5min of incubation) and Ang II. The maximal increase of 
Ang II-induced IRS-1/p85 docking was observed at IOmin but the effect was diminished after 30 
min of incubation. The amount ofIRS-1 immunoprecipitated was similar (Fig 5, lower panel). 
This implies that PI3-K is a signaling molecule involved in Ang II action in 3T3-Ll adipocytes 
3. Ang II stimulates serine phosphorylation of Akt
Akt (protein kinase B, PKB) is a major downstream target of PI3-K in the insulin 
receptor signaling pathway. Akt activation is associated with insulin-stimulated glucose transport, 
glycogen synthesis and expression of genes such as FAS (6, 10). Specifically, a recent study has 
shown that Akt activation was involved in insulin-stimulatedADDl /SREBPlc  gene expression in 
the liver ( 11 ). To further investigate whether Akt mediates the effect of Ang II in adipocytes, we 
assessed serine phosphorylation of Akt in the absence or presence of Ang II. As shown in Fig 6 
(upper panel), insulin and Ang II induced significant increases in serine phosphorylation of Akt 
by about 3-fold and 2.8-fold, respectively, in adipose cells, compared with basal values (p<0.05). 
The longer stimulation of 3T3-Ll adipose cells by Ang II showed slight decrease inAkt 
activation. The amount of total cytosolic Akt was similar (Fig 6, lower panel). This demonstration 
indicates that PI3-K-Akt pathway mediates Ang II signaling to the lipogenic response in 
adipocytes. 
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Fig. 5 Ang II-induced p85a association with tyrosine-phosphorylated insulin receptor 
substrate-] (IRS-1). Fully differentiated adipocytes were stimulated with or without lOnM Ang II or 
1 OnM insulin as a positive control for the indicated times. The cell lysates were immunoprecipitated with 
anti-IRS-1 antibody and immunoblotted with anti-p85a antibody or anti-IRS-1 antibody as loading control. 
A representative autoradiograph ofIRS-l/p85a association and cytosolic IRS-1 and bar graph of 
quantitation (mean ± SEM) from three separate experiments are shown. a,b,c,d Values with different letters
are significantly different (p<0.05). 
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Fig. 6 Ang II-induced Ser473 phosphorylation of Akt/PKB. Fully differentiated adipocytes were 
stimulated with or without lOnM Ang II or lOnM insulin (positive control) for the indicated.times. The cell 
lysates were analyzed by immunoblotting with anti-phospho-Ser473 -Akt/PKB antibody or anti-Akt/PKB 
antibody as a loading control. A representative autoradiograph of phosphorylated Akt/PKB and Akt/PKB 
and bar graph of quantitation (mean± SEM) from three separate experiments are shown. a,b,c,dValues with 
different letters are significantly different (p<0.05). 
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4. Ang II receptors mediates Ang II-induced insulin singling molecules
Since Ang II has been shown to increase FAS activity in an AT2-dependent manner (2), 
we determined whether Ang II-induced phosphorylation events are receptor-mediated. Fig 7 
shows that pharmacological inhibitor of AT 1 receptor activity, losartan, completely blocked 
stimulatory effect of Ang II on IRS-I (Fig 7, upper panel) and Akt activation (Fig 7, lower panel) 
but PD-186, an AT2 receptor antagonist only partially altered this Ang II action, indicating that 
Ang II-stimulated IRS-I and Akt activations are primarily mediated via ATI receptors and partly 
through AT2 receptors. 
E. DISCUSSION
We have previously reported Ang II exerts several biological effects in adipocytes 
including lipogenic actions and prostaglandin secretion (5). We showed that Ang II increased 
activity and mRNA level and gene transcription of FAS, a key lipogenic enzyme (5). Furthermore, 
we have recently defined the Ang II-responsive element (E box motif) to the proximal promoter 
region and have demonstrated that transcription factor ADD 1 is functionally required for Ang II 
regulation of the FAS gene (5). Likewise, the well-known lipogenic hormone insulin increases 
triglyceride accumulation via FAS gene activation in adipocytes. Both hormones did not 
synergize in the context of stimulation of the FAS gene (5, 6). With respect to signaling 
mechanisms for insulin-mediated gene regulatory effects, a considerable number of studies have 
found that insulin positively regulates the expression of specific genes such as FAS, GLUT I, 
glucose kinase (GK) and SREBPlc via activation of the PI3-K/Akt branch of insulin signaling 
pathways in insulin-responsive tissues ( 6, 12-14 ). However, the Ang II signaling mechanisms 
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Fig. 7 Angiotensin receptor inhibitors inhibit Ang II-induced IRS-1 and Akt/PKB activations. 
Fully differentiated adipocytes were pretreated with vehicle or 1 00nM losartan (ATI receptor antagonist) or 
lO0nM PD-186 (AT2 receptor antagonist) for lh and stimulated for lOmin in the absence or presence Ang 
II. Immunoprecipitates (IP) of anti-phosphotyrosine antibody were analyzed by immunoblotting with anti­
IRS-1 antibody or total cell lysates were immunoblotted with anti-phospho-Ser473 -Akt/PKB. An
autoradiograph of phosphorylated IRS-I and Akt/PKB and bar graph of quantitation of two experiments are
shown. Control, C; Ang II; Losartan, LO; Losartan plus Ang II plus, LA; PD-186, PD; PD-186 plus Ang II,
PA.
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which mediate Ang II action in adipocytes are largely unknown: In the present study, we explored 
Ang II signaling adipocytes, focusing on the potential intracellular interactions between Ang II 
and insulin signaling that may lead to regulation of adipocyte metabolism. The results from PI-3K 
and MAPK inhibitor experiments suggest that the Ang II effect on FAS gene and enzyme 
activities was virtually unaffected or enhanced by the MEK inhibitor, PD98059, suggesting that 
Ang II-stimulatory effect on FAS gene does not appear to require activation of the MAPK 
cascade. By contrast, data from LY294002 clearly implies the involvement of the PI-3K signaling 
pathway in Ang II regulation of FAS gene. Furthermore, the collective results from 
immunoblotting analysis for IR�, IRS-1, IRS- l/p85� association and Akt indicate that Ang II 
signaling in adipose cells is linked to PI-3K cascade via functionally positive crosstalk with 
important mediators involved in key intermediate steps within insulin signaling pathways. 
Accordingly, this study provides the first evidence that the Ang II-activated IR�/PI-3K/Akt 
pathway is responsible for Ang II regulation of FAS gene expression in adipocytes. 
In both in vivo and in vitro studies, Ang II has shown to positively or negatively 
interact with insulin signaling pathways at multiple levels via ATl and AT2 receptors in Ang II­
responsive tissues such as the vasculature (15-20). These intracellular interactions of Ang II with 
insulin-mediated pathways have been strongly implicated in pathophysiologic states, e.g. insulin 
resistance in hypertension, cardiovascular diseases such as atherosclerosis and cardiac myopathy 
in type 2 diabetes (15-21). In terms of molecular mechanisms of Ang II-induced peripheral 
insulin resistance, Ang II has been demonstrated to interfere with insulin signaling pathways 
though inactivation of insulin signaling molecules in Ang IT-responsive tissues such as vascular 
smooth muscle cells and cardiac myocytes (16, 17, 21), although the precise mechanism remains 
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elusive. Further, fat insulin receptor knockout mouse models have shown that insulin signaling 
interruption in adipocytes is associated with decreased fat mass and altered adipocyte size rather 
than insulin resistance, indicating that insulin signaling in adipose cells is not critical for the 
maintenance of euglycemia but is required for triglyceride storage in adipocytes (22). 
Here, our data show that like insulin, acute Ang II treatment is sufficient to promote IR� 
subunit and IRS-I kinase activities. These activations may be dependent on activity of JAK2 
which was shown to serve as an important linker protein involved in mediating AT 1 receptor­
mediated IRS-I and IRS-2 phosphorylation by Ang II in cardiac tissues (19, 23). As a 
consequence ofIRS-1 activation, Ang II-induced IRS-1/PI-3K association is significantly 
increased. This, in tum, stimulates serine phosphorylation of Akt. Thus, Ang II exhibits its 
lipogenic actions by enhancing insulin signaling pathways in adipocytes, suggesting that the 
mechanism underlying Ang II-induced lipogenesis in adipocytes differs from that previously 
associated with peripheral insulin resistance. In PI-3K-dependent Akt activation, arachidonic acid 
(AA)/ reactive oxygen species (ROS) pathways have currently been identified to play important 
roles in Akt activation in Ang II signaling pathway ofmesangial cells (24). In the present study, it 
cannot be ruled out that both PI-3K and other factors (e.g. ROS) could also contribute to Ang II­
stimulated Akt activation in adipocytes. Insulin-activated Akt has been shown to mediate several 
biological actions including stimulation of glucose transport, glycogen synthesis and lipogenesis 
in insulin-responsive tissues (6, 10) whereas the exact role of PI-3K and Akt in Ang II signaling 
pathways is still unknown. Recently, Akt was shown to phosphorylate several transcriptional 
activators of the forkhead family including AFX and FKHR (25-27). Further, insulin-induced 
ADD 1/SERBP 1 c expression was mediated through Akt activation in the liver ( 11 ). Taken 
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together, despite the fact that further targets of this signaling pathway remain unknown, it is 
reasonable to speculate that Akt activation induced by positive interaction of Ang II with insulin 
signaling might participate in SERBPlc gene expression via phosphorylation of transcriptional 
activators involved in transcriptional regulation of SEREPlc. Our previous data, showing that 
Ang II shows direct effects on ADD 1 gene expression in a glucose-dependent manner, support 
this hypothesis. Furthermore, the transcription factor SERBP 1 c has been shown to be regulated 
by phosphorylation/dephosphorylation mechanisms (13). Accordingly, it is plausible that 
ADD 1/SERBP 1 c activation by Ang II-mediated Akt binds to Ang II-responsive element of the 
FAS promoter region and thus enhances transcriptional activity of FAS and FAS enzyme activity, 
consequently contributing to accumulation of triglyceride storage in adipocytes. 
ATI and AT2 receptors have been shown to exert counteracting effects on cellular 
growth and differentiation in a variety of cell types (1). In our previous study, both receptors 
showed similar functions in lipogenesis of adipocytes by preventing Ang II induction of FAS 
activity, however, only AT2 antagonist was able to potently inhibit Ang II binding to 3T3-Ll 
adipocytes. In this study, the AT2 receptor was partially involved in this Ang II regulation of 
insulin signaling. This is inconsistent with our previous demonstration that AT2 receptor mainly 
mediates Ang II-stimulated FAS enzyme activity and gene expression (2). Previously, we 
observed significant attenuation of FAS activity by inhibition of ATl receptor eliciting lower 
binding affinity to this cell line, implying that ATI receptor also may play a role as a critical 
mediator in this Ang II-mediated FAS gene regulation in adipocytes. Other numerous studies on 
the regulation of Ang II receptor expression and Ang II receptor-mediated physiological effects in 
murine and human adipocytes have shown inconclusive results (28-30). Additionally, another 
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report showed that activated AT2 receptor has recently negatively interacts with insulin signaling 
pathway in cardiac tissue thereby inhibiting insulin-induced cell growth and proliferation (15, 20), 
although the exact signaling pathways and the functional roles of AT2 receptor remain unclear. 
These observed contradictory data could possibly be due to different species and different cell 
lines and culture conditions used. 
In addition to the function of Ang II in lipogenesis, another potential role of adipose Ang 
II in obesity-associated insulin resistance was recently proposed (28). The inhibitory effect of 
Ang II on human preadipocyte recruitment ultimately induces redistribution of fat accumulation 
to nonadipose tissues such as liver and muscle, thereby resulting in insulin resistance (28). Our 
present study provides another possible mechanism for insulin resistance in obesity. Adipose Ang 
II appears to develop insulin resistance arising from fat mass increase though positively 
modulating insulin signaling mechanism in adipocytes. One possible mechanism is that Ang II
stimulates lipogenesis through the transactivation of insulin signaling molecules that further 
promotes adipocyte hypertrophy, thereby leading to enlargement of adipocyte mass, a 
characteristic feature of obesity. As a consequence, the secretion of cytokine tumor nuclear factor 
a ( TNFa), free fatty acids (FFA) and resistin which are important linkers between obesity and 
insulin resistance is elevated, thereby contributing to the development of insulin resistance and 
increased risk of diabetes in obesity. Thus, adipose Ang II may play a lipogenic role in adipocyte 
physiology and hence be a major candidate linking obesity and insulin resistance. 
In conclusion, our findings indicates that Ang II regulates fat cell metabolism by 
increasing lipogenic activity via activation of insulin signaling transduction; primarily linked to 
activation of the IRf3/PI3-K/Akt cascade in adipocytes. This effect appears to be mediated through 
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both Ang II receptor subtypes. Additional studies are warranted to determine the mechanisms 
linking Ang II binding to its receptors to activation of insulin receptor and signaling molecules. 
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PART VI 
IN VIVO ENDOCRINE EFFECTS OF ADIPOSE ANGIOTENSINOGEN ON ADIPOSE 
AND RENAL TISSUES 
208 
The manuscript is being prepared for publication with co-authors Jones Voy, B. and Moustaid­
Moussa, N. for the Journal of Hypertension 
A.ABSTRACT
Using knockout and transgenic strategies, recent studies provided evidence for the 
contribution of adipose angiotensinogen ( agt) to regulation of fat mass, systemic blood pressure 
and kidney homeostasis. However, mechanisms that account for the physiological effects of 
adipose RAS are poorly defined. In the current study, we have used agt knockout (agt-1-, KO) mice
and transgenic (Tg) mice harboring adipose tissue-specific expression of rat agt (Tg-KO) or rat 
agt overexpression in adipose tissue (Tg-Wn. We examined changes in adipose tissue 
metabolism and further dissected endocrine effects of adipose agt on regulation of RAS 
components of adipose tissue and kidney in these mice. Total body weight, epididymal fat pad 
weight, and circulating leptin and insulin levels were significantly decreased (p<0.05) in KO mice 
compared to wild type (WT) mice. Higher fat pad weight and plasma leptin and insulin levels 
were observed in Tg-WT mice compared to WT mice. In particular, agt knockout mice had 
significantly increased plasma adiponectin (an insulin sensitivity marker) and decreased 
circulating resistin (an insulin resistance marker) levels whereas mice carrying the other three 
genotypes (WT, Tg-KO and Tg-WT) showed comparable circulating adiponectin and resistin 
levels. Subsequently, western blot analysis of total kidney protein extracts demonstrated that 
markedly elevated agt and AT I receptor protein levels were observed in Tg-WT mice compared 
with WT animals, implying that adipose agt may regulate systemic blood pressure at least partly 
mediating the stimulation of renal RAS. Moreover, oligonucleotide microarray analysis illustrated 
that targeted reexpression of agt only in adipose tissue was able to restore altered expression of 
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genes associated with renal function and development seen in KO mice in an endocrine manner. 
Taken together, the results from this study provide possible mechanisms responsible for the 
endocrine effects of adipose agt. These effects appear to be mediated in part via activation of 
renal RAS and correction in altered expression of genes associated with renal function or 
development in combination with hypertrophic actions on adipose tissue. 
B. INTRODUCTION
The renin-angiotensinogen system (RAS) plays a central role in blood pressure 
regulation and fluid-electrolyte homeostasis and may also contribute to essential hypertension ( 1 ). 
In addition to its vascular effects, the RAS has been shown to be an important regulator in renal 
growth, development and function (1). Angiotensin II (Ang II), the major effector of the RAS, is 
produced by the successive enzymatic cleavage of the hepatic glycoprotein agt by kidney-derived 
renin and lung-derived angiotensin-converting enzyme (ACE). Ang II exerts its actions by 
binding to G-protein coupled angiotensin receptors, ATl and AT2 (2). Most well-documented 
biological actions of Ang II are primarily mediated by ATl receptors. In addition to this 
circulating RAS, accumulated evidence from studies of angiotensin's physiological properties has 
suggested that distinct local tissue RAS with different regulatory mechanisms from endocrine 
RAS may exist and function in the brain, heart, adrenal gland, kidney, vessel wall and adipose 
tissue (3). Previous studies showed that a variety of stimuli including blood pressure, sodium 
intake, inflammation, and sympathetic nerve activity modulate the expression of the local RAS 
mRNA and proteins in physiological and pathophysiological conditions ( 4). Of note, adipose 
tissue in rodents and humans possess physiologically active RAS components (2). In adipocytes, 
Ang II has been implicated in induction of differentiation of preadipocytes into adipocytes via an 
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adipogenic factor, prostacyclin, and key genes for lipogenesis via a paracrine/autocrine 
mechanism (5, 6). Currently, increasing evidence has suggested that alterations in adipocyte 
production of RAS components contribute to metabolic disorders including obesity, obesity­
associated hypertension and diabetes (2). Several studies have reported RAS hyperactivity in 
obese rodents and humans (7, 8). Additionally, subcutaneous and omental adipose agt expression 
have been shown to be positively associated with increased body mass index (BMI) and waist-to­
hip ratio (9, 10). A very recent agt transgenic study also presented that high fat-induced obesity 
was highly related to increased expression of both mAGT and hAGT genes in visceral adipose 
depots such as omental, reproductive and perirenal fat ( 11 ). Other RAS components, renin and 
ATl receptor genes in adipose tissue were upregulated exclusively in obese hypertensive subjects 
and angiotensin converting enzyme (ACE) was increased in obesity, with highest expression 
levels in obese hypertensive women (12). Of note, recent studies with agt knockout and 
transgenic mice expressing agt selectively in adipose tissue have suggested a significant role for 
adipose agt in obesity-associated hypertension. Agt inactivation was associated with the 
resistance to high fat diet-induced obesity, reduced adipose tissue mass, increased locomotor 
activity, profound hypotension and renal abnormalities (13, 14). Adipose tissue-specific 
restoration of agt partially rescued these phenotypes seen in KO mice whereas moderate 
overexpression of agt in adipose tissue led to a significant increase in fat pad mass and a doubling 
in FAS activity. Interestingly, T g-WT mice exhibited systemic hypertension coupled with elevated 
plasma agt levels, suggesting that adipocytes are a significant source of circulating agt (14, 15). In 
addition, the growing body of evidence from experimental, epidemiological and genetic studies 
have also addressed a potential role for adipose Ang II in obesity-related hypertension ( 16-19). 
Accordingly, in this study, we examined changes in adipose tissue metabolism in these 
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agt knockout and transgenic mice and metabolic parameters. Further, we determined endocrine 
effects of adipose agt on expression of RAS components in adipose and renal tissues as well as 
global expression profile of genes associated with renal regulation in these mice exhibiting 
distinct phenotypes with respect to adiposity, insulin sensitivity, systemic blood pressure and 
renal function/morphology. 
C. MATERIALS AND METHODS
1. Experimental Animals
The agt gene was inactivated in the mouse as previously described (15, 20). Transgenic 
mice (aP2-agt+1) were generated by using a transgenic construct containing adipocyte P2 (aP2) 
gene promoter, intron, agt cDNA and a polyadenylation site (15). Mice expressing agt only in 
adipose tissue (Tg-KO) were generated by crossing transgenic mice with agt-deficient mice (agf'-, 
KO), whereas mice overexpressing agt selectively in adipocytes were generated by crossing 
transgenic mice with wild type mice (agt +t+, WT) (15). WT (ICR-CDl strain, Harlen, Gannat, 
France), KO, Tg-KO, Tg-WT male mice provided by Dr. Gerard Ailhaud (University of Nice, 
France) were housed 4-6 per cage and fed a chow diet (Research diets, 20 Jules Lane New 
Brunswick, NJ) and water ad libitum in a 12:12 h light: dark cycle at constant temperature (22 °C). 
Body weight was measured and mice were sacrificed at 28 weeks for body composition analysis. 
Individual adipose depots (perirenal and inguinal depots) were removed along with liver and 
kidney; the epididymal fat pad was weighed. Mice were bred at the CNRS 6543, Centre de 
Biochimie at Nice, France, and shipped to the Department of Nutrition at the University of 
Tennessee, Knoxville. All experiments described were conducted in compliance with the 
Institutional Animal Care and Use Committee (IACUC) at the University of Tennessee. 
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2. Plasma Measurements
Following an overnight fast, blood was collected by cardiac puncture for glucose, insulin, 
leptin, adiponectin and resistin assays. The plasma was separated by centrifugation at 12,000 rpm 
for 20 min and stored at -80 °C. Plasma leptin and insulin levels were measured by RIA using 
mouse leptin and rat insulin RIA kits, respectively, obtained from Linco Research (St. Charles, 
MO). Blood glucose concentrations were measured using a glucose analyzer (LIFESCAN Co, 
MI). Plasma adiponectin and resistin levels were analyzed by enzyme immunoassay kits obtained 
from B-Bridge International, Inc. (San Jose, CA) and Phoenix Pharmaceuticals, Inc. (Belmont, 
CA), respectively. 
3. Western Blot Analysis
Proteins were extracted from epididymal fat depot and total kidneys of WT, KO, Tg-KO 
and Tg-WT mice after homogenization with protease inhibitor cocktail and quantitated by the 
method of Bradford et al (21). Total kidney protein extracts (50 µg) and epididymal fat pad 
protein extracts (-25 µg) were electrophoretically separated by SDS/PAGE on 8-10% running gel, 
respectively. Proteins were subsequently transferred to nitrocellulose membranes in transfer 
buffer (20% methanol, l 2mM Tri base, 96mM glycine, at pH 8.3), blocked overnight and 
incubated with primary polyclonal antibody Angiotensin I/II detecting agt (52 kDa), ATI (47 
kDa) and AT2 (46 kDa) receptors (Santa Cruz Biotechnology Inc., Santa Cruz, CA) at 1:100, 
1 :200, 1 :200 dilution, respectively for 3h at room temperature. Signals were detected using 
enhanced chemiluminescence (ICN Biomedicals, Inc., Costa Mesa, CA). Duplicate gels were 
prepared and stained with 0.1 % Coomassie blue R250 and then distained in 7% acetic acid-5% 
methanol to visualize protein bands for total protein quantification and confirmation of equal 
protein loading. The bands obtained in the western blots were scanned using Digital Imagining 
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and Analysis Systems (Zero-Dscan software, Scanalytics Inc., Fairfax, VA). In addition to protein 
analysis in these mice, Affymetrix Microarray was conducted to investigate gene expression 
changes of RAS components as well as global gene expression profile in adipose tissue and 
kidney of these knockout and transgenic mice (see Appendix section) 
4. Statistical Analysis
All data are expressed as the mean± SEM. ANOVA was used to determined between­
group differences in measured parameters. The values were examined by the Bonferroni test for 
multiple comparisons (SAS, Carry, NC) to compare differences among group means after a 
significant F-test and statistical significance was defined as p<0.05. 
D.RESULTS
1. Effect of Adipose agt on Fat Pad Weight and Metabolic Parameters
The four groups of mice were fed a chow diet from weaning up to 28 weeks of age. The 
effects of adipose agt on body weight and fat pad mass are shown in Table 1. Consistent with 
previous results ( 14, 15), total body weight and epididymal fat pad mass of agt knockout mice 
(KO) were significantly lower than those of wild type (WT) mice. Compared to KO mice, Tg-KO 
mice reexpressing agt only in adipose tissue showed a slight increase in total body weight and 
adipose tissue weight of epididymal fat. Although Tg-WT mice overexpressing agt in adipose 
tissue exhibited almost normal body weight, an approximate 1.5-fold increase in the weight of 
epididymal fat pads was observed compared with WT mice (p<0.05). This observation directly 
supports that adipose agt plays a hypertrophic role in adipose tissue metabolism (5). 
We evaluated effects of adipose agt on plasma leptin and insulin levels, as these 
hormones have been known to be involved in regulation of energy homeostasis (22). As shown in 
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Table 1. Body weight, fat pad weight and blood parameters in 28-wk-old WT, KO, 
Tg- KO and Tg-WT mice 
WT KO Tg-KO Tg-WT 
(n=lO) (n=8) (n=9) (n=9) 
Body weight (g) 50 ± 2.4b 35 ± 0.9° 38 ± 1.09° 52 ± 2.8b 
Epididymal fat (g) 1.1 ±0.18 b ' 0.4 ± 0.02° 0.5 ± 0.18° 1.6 ± 0.15c ' 
Leptin (ng/mL) 5.7 ± 0.1 b" 4.0 ± 0.05°" 5.5 ±0.06 b" 8.3±0.l c " 
Insulin ( ng/mL) 1.2 ± 0.03b• 0.6 ± 0.03°· 0.8 ± 0.03°· 2.3 ± o.1c•
Resistin {ng/mL) 43.4 ± o.1b·· 8.7 ± 1.3a•• 42.0 ± 1.6b•• 44.3 ± 0.1 b••
Adiponectin {ng/mL) I.I ±0.11°••• 1.9 ± o.1b··· I.I± 0.2°••• I.I ±0.2°•••
Values with different letters are significantly different (p<0.05). Values with the same letter are not 
significantly different. Results are the mean ± SEM, n, number of animals. 
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Table 1, the plasma level of leptin was significantly decreased in KO mice compared to that in WT 
mice, in contrast with previous data showing no difference in plasma leptin concentrations 
between KO and WT animals (14). KO mice elicited a significant decrease in the plasma level of 
leptin, although KO and Tg-KO mice showed comparable fat pad mass. In contrast with previous 
observations in 6-week old Tg-WT mice, a significant increase (about 1.5-fold) was found in the 
level ofleptin in 28-week old Tg-WT mice compared with that in WT animals. The level of 
insulin was similar in KO and Tg-KO mice while Tg-WT mice showed higher insulin levels 
(about 1.9-fold) compared with WT mice, suggesting that agt overexpression in adipose tissue 
could contribute to insulin resistance associated with a parallel increase in fat mass. Subsequently, 
we examined potential roles of adipose agt in obesity-associated insulin resistance by measuring 
circulating levels of adiponectin and resistin, which are adipocyte-derived plasma hormones (23). 
It has recently been documented that adiponectin has anti-insulin resistance and anti-atherogenic 
properties while resistin is highly associated with insulin resistance (24-27). No statistically 
significant difference among three genotypes (WT, Tg-KO and Tg-WT) was observed with 
respect to plasma adiponectin and resistin levels although Tg-WT mice seemed to exhibit insulin­
resistance. Strikingly, a reversed ratio of these hormones was found in the KO mice; a significant 
(approx.1.9-fold) increase in the level of adiponectin and a substantial decrease (approx 4.8-fold) 
in the level of resistin were observed in agt knockout mice compared with those in WT mice. 
Similar plasma concentrations of glucose were also found in these four mouse genotypes ( data 
not shown). 
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2. Effects of Adipose agt on the Regulation of RAS Components in Adipose and Renal
Tissues 
Since agt inactivation was associated with reduced adiposity and lower blood pressure 
whereas targeted overexpression of agt in adipose tissue led to the development of hypertension 
along with increased adiposity (14, 15), we further analyzed endocrine effects of adipose agt on 
the regulation of RAS proteins in adipose and renal tissues. Fig. 1 shows a representative western 
blot of adipose agt, ATl and AT2 receptor proteins from these four mouse genotypes. As expected, 
the adipose agt protein was not detected in agt knockout mice. Total agt protein levels were 
similar between WT and Tg-KO mice selectively expressing agt in adipose tissue. Tg-WT mice 
exhibited a moderate increase in adipose agt protein expression compared with WT mice, 
confirming previous northern blot analysis in these mice (15). The KO mice had approximately 
1.7-fold and 1.8-fold higher levels of ATI and AT2 receptor proteins in adipose tissue than WT 
mice, respectively, whereas WT, Tg-KO and Tg-WT mice exhibited comparable adipose level of 
ATl receptor protein. A 1 .4-fold increase in AT2 receptor protein expression was observed in Tg­
KO mice as compared to that of WT mice. By contrast, a considerable decrease in AT2 receptor 
protein expression was found in Tg-WT mice compared to that of WT mice. 
In the total kidney (Fig. 2), the agt protein was expressed in WT mice but not in KO and 
Tg-KO mice as previously reported. Further, marked increases in agt and ATI receptor protein 
expression were found in Tg-WT mice overexpressing agt in adipose tissue with resultant 
increases in systemic agt concentration (22-44% higher than that of WT mice) (p<0.05). This 
overexpression agt in kidney was tissue-specific, compared to hepatic agt expression in these 
transgenic animals (data not shown). Tg-KO mice targeted reexpression ofagt only in adipose 
tissue exhibited a partial restoration of circulating agt levels (20-30% of agt levels of WT mice) 
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Fig. 1 Protein expression of agt, ATJ & AT2 in adipose tissue of WT, KO, Tg-KO and Tg-WT 
mice. Representative immunoblots of agt, ATl and AT2 proteins are shown in the upper, middle and lower 
panels, respectively. Bars depict means of the quantitated agt, ATl and AT2 bands, independently obtained 
in duplicate. nd, not detectable. 
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Fig. 2 Protein expression of agt, ATJ & AT2 in kidney of WT, KO, Tg-KO and Tg-WT mice. 
Representative immunoblots of agt, AT 1 and AT2 proteins are shown in the upper, middle and lower panels, 
respectively. Bars depict mean± SEM of the quantitated agt, ATl and AT2 protein bands, independently 
obtained in triplicate. Values with different letters are significantly different (p<0.05). nd, not detectable. 
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and had significantly lower protein expression of AT l receptor than did KO mice. Compared with 
WT mice, a decreased ATl protein expression was observed in KO mice (p<0.05). Tg-WT mice 
showed similar AT2 receptor protein expression to that of WT mice whereas KO and Tg-
KO mice displayed-8-fold and-7.6-fold increases in AT2 protein levels compared to those of 
WT mice, respectively. 
E. DISCUSSION
The present study has addressed potential mechanisms by which adipose agt 
influences systemic blood pressure and renal regulation in an endocrine manner, using agt 
knockout and transgenic mice. First, we examined changes in adipose tissue metabolism and 
metabolic parameters. Agt deficient mice elicited markedly diminished fat pad mass and body 
weight gain along with significant decreased circulating insulin and leptin levels compared with 
WT mice. Clearly, Tg-WT mice overexpressing adipose agt were hyperinsulinemic and 
hyperleptinemic with a significant increase in fat pad mass compared to WT mice despite the fact 
that Tg-KO mice reexpressing agt only in adipose tissue exhibited comparable fat pad weight to 
KO mice. These results support previous in vivo and in vitro findings showing a hypertrophic 
function of Ang II in adipocytes through activation of key lipogenic enzymes, FAS and GPDH (5, 
13, 15). In contrast with our findings, it was reported that transgenic mice (20 wk of age) 
ubiquitously overexpressing agt in multiple tissues including adipose tissue, liver, heart and 
kidney showed comparable plasma leptin and insulin levels to WT mice ( 11 ). 
Of significance, KO mice displayed markedly increased circulating adiponectin and 
decreased plasma resistin concentrations while the other three genotypes showed comparable 
plasma levels of these proteins. Both adiponectin and resistin are recently discovered adipocyte-
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derived proteins and their plasma levels have been shown to be highly associated with insulin 
sensitivity and resistance (23-26). Thus, these protein levels seen in KO mice may reflect the 
increased insulin sensitivity. This observation supports the previously defined inhibitory roles of 
Ang II in insulin signaling transduction in vascular tissue (28, 29). This result is also in agreement 
with a recent clinical report demonstrating that inhibition of the RAS improves insulin sensitivity 
in subjects with essential hypertension, with parallel elevation in plasma adiponectin 
concentrations (30). 
Using western and oligonucleotide microarray analyses (see Appendix), the current 
study extends previous findings and specifically demonstrates adipose agt regulation of adipose 
and renal RAS components in these agt knockout and transgenic mice. Ang II has been shown to 
exert various effects on the expression of major component genes of the RAS by positive and 
negative feedback mechanisms (31-33). In addition, several studies of regulation of the RAS 
components in experimentally and genetically hypertensive animals as well as hypotensive 
animals have reported significant abnormalities of RAS gene expression in some tissues (34-36). 
In the present study, compared with WT mice, we showed higher ATl and AT2 receptor protein 
levels in adipose tissue of KO mice which have no detectable plasma agt and lower blood 
pressure. These results support the previous well-documented feedback inhibition of Ang II on 
angiotensin receptors (34). Thus, complete loss of Ang II-mediated negative feedback caused by 
genetic deficiency of Ang II endogenous production in agt knockout mice may be involved, in 
part in upregulation ofboth receptors in adipose tissue (31-34). In the kidney, western and 
microarray analyses of KO mice demonstrated markedly increased renin and ACE mRNA levels, 
as previously described in the kidney of agt knockout mice (31, 34 ). Similar to the regulation of 
adipose AT2 receptor, increased total kidney AT2 receptor protein and mRNA expression were 
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detected in these null mice. In contrast with AT2 receptor, we found a significant repressed level 
of total kidney AT l receptor protein. One possible explanation for altered renal RAS regulation in 
agt deficient mice may be remarkable renal defects at the function and structure levels including 
marked vascular hypertrophy, atrophic changes in the tubules and papilla, increased urine output 
and decreased urine osmolality, as previously reported in the kidney of agt null mutant mice (37, 
38). Thus, these pathological changes could participate in altered gene and protein expression in 
renin, ACE, ATl and AT2 in the kidney in agt knockout mice. In particular, Taumra et al proposed 
that abnormal renal structure such as reduced renal medullas seen in agt deficient mice may 
contribute to increased mRNA level of ACE which is mainly produced by the renal cortex (34). 
Another possibility is that the higher renin, ACE, and AT2 expression in the kidney of agt 
knockout mice compared to WT mice may be in part due to complete disruption of the negative 
feedback of Ang II on renin, ACE, and AT2-expressing cells in the kidney of agt deficient mice, 
as seen in adipose tissue of KO mice (31-33). Alternatively, alterations of hormone levels, 
including vasopressin and aldosterone which are known to modulate ATl and ACE gene 
expression and signaling pathways as well as compensatory mechanisms induced by agt gene 
ablation, could change regulation of RAS genes and proteins in a tissue-specific manner (39). 
Microarray data demonstrating altered expression of genes associated with transcription 
regulation and signal transduction cascades in the kidney of KO mice provided additional 
evidence for altered renal gene regulation in these mice. Moreover, our result of reduced renal 
AT 1 expression seen in agt knockout mice is in contrast to a previous report showing 
upregulation ofrenal ATl mRNA and protein expression in KO mice, raising the possibility that 
differences in RAS regulation in agt null mice may also be associated with genetic background 
used (34, 40). 
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In contrast with the observations in KO mice, Tg-WT mice overexpressing agt in 
adipose tissue displayed prominent systemic hypertension along with circulating agt level 
increased by 22-44 % compared with WT mice (15). These observations, along with several 
reports demonstrating that introduction of human agt and renin genes or rat agt into different 
tissues of agt knockout mice using tissue or cell specific promoters induced higher plasma Ang II 
levels, support that increased circulating agt level is a causative factor in the development of 
systemic hypertension (40-44). In the present study, the western blot analysis ofTg-WT mice 
showed slightly decreased adipose AT 1 receptor protein expression with markedly reduced 
adipose AT2 receptor protein level compared with WT mice. In contrast with KO mice, the 
repressive protein levels of both receptors in Tg-WT mice suggest that the complete restoration of 
circulating agt and predictably Ang II stimulates a negative regulation of expression of both 
receptor genes in the adipose tissue (34). A marked increase in agt and ATl receptor protein levels 
was evident in the kidney ofTg-WT mice. However, similar hepatic agt and slightly increased 
ATl protein contents were noted in Tg-WT mice compared with WT mice (data not shown). Our 
results from this study suggest that adipose agt overexpression induces overproduction of agt in 
the circulation, which enhances renal RAS activity in a tissue-specific manner and further 
activated renal RAS increases intrarenal Ang II level, thereby contributing to the development of 
hypertension in Tg-WT mice. Our results support previous studies demonstrating that specific 
targeting of RAS overexpression in the kidney was able to elevate systemic blood pressure 
independent of endocrine RAS, suggesting that intrarenally-derived Ang II is a potent regulator of 
systemic blood pressure (43, 45, 46). Consistent with this, double transgenic mice (R+/A J 
overexpressing human renin and agt in the renal proximal tubule exhibited increased arterial 
pressure(47). Recently, studies on Ang II-induced hypertensive rats have emphasized that 
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elevated intrarenal Ang II levels play a pivotal role in the development and maintenance of 
hypertension (48, 49). In Ang II-induced hypertension (80ng/min, 2 wk), chronically elevated 
circulating Ang II was actively taken up through an ATl receptor-mediated process and thus 
augmented intrarenal Ang II. This, in turn, exerts a sustained influence on tubular reabsorption 
and subsequently induces hypertension without any increase in the plasma levels of Ang II (45, 
50). Of importance, the enhanced intrarenal Ang II has been shown to exert a positive feedback 
action to augment intrarenal levels of agt mRNA and protein, which likely contributes to the 
progressive increases in intrarenal endogenous production of Ang II in hypertensive states ( 48, 
49). Thus, it is conceivable that specific targeting of agt overexpression in adipose tissue leads to 
increased circulating agt concentrations, which are potentially responsible for elevated systemic 
Ang II production. This, in tum, is taken up by the kidney via an ATl receptor-mediated 
endocytosis and subsequently enhances intrarenal Ang II. Renal agt mRNA and protein levels in 
T g-WT mice in this study may be stimulated by elevated intrarenal Ang II via a positive feedback 
mechanism, thereby increasing Ang II-mediated tubular transport and consequently causing 
systemic hypertension in these transgenic mice. This is also supported by microarray results of 
Tg-WT mice showing significantly upregulated expression of genes related to ion exchange and 
ion channels which are involved in tubular sodium reabsorption and renal volume expansion, 
thereby resulting in systemic increases in arterial pressure compared with WT mice. Additionally, 
since insulin increases agt expression and production in vascular smooth muscle and adipose 
tissue, our data do not exclude the plausibility that elevated renal agt expression in Tg-WT 
showing hyperinsulinemia may result from the additive effects of insulin and potential 
overproduction of intrarenal Ang II (51, 52). Moreover, significantly increased renal ATl protein 
level was evident in T g-WT mice compared with WT mice, which was in contrast to the 
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observations from studies of Ang II-induced hypertension animals which showed a common 
phenotype, namely hypertension, with Tg-WT mice (48). In genetic hypertension models, tissue­
specific activation of ATI-mediated hypertension mechanisms has been reported (3, 40, 53-55). 
Further, Ang II-induced tubular sodium transporter activation through increased renal ATl 
receptor number and function was observed in obese zucker rats which are characteristically 
hypertensive and hyperinsulinemia, similar to those seen in Tg-WT mice although results on renal 
ATI receptor mRNA and protein expression in hypertensive animal models remain elusive (53). 
Additionally, microarray data ofTg-WT mice exhibited marked upregulation of renal H+-ATPase 
transports and potassium channels, which have been shown to be stimulated by ATI receptor 
mediation. Taken together with microarray results (see Appendix), this result suggest that 
potential overproduction of renal Ang II increases renal ATI receptor activity and subsequently 
stimulates AT I-mediated ion transport and channel activation, thereby elevating blood pressure in 
Tg-WT mice. In addition, in Ang II-induced hypertension, markedly suppressed renal renin 
mRNA and content but increased renal ACE mRNA levels, activity and binding were recently 
reported. It has been suggested that this differential regulation of RAS components may help 
maintain enhanced endogenous Ang II formation in the kidney. In our study, increased renal renin 
gene expression and comparable renal ACE mRNA level were observed in Tg-WT mice 
compared with WT mice despite the fact that both Ang II-infused rats and Tg-WT mice displayed 
significantly increased renal agt protein levels and systemic hypertension. It is possible that the 
adipose agt ectopic expression-induced compensation in Tg-WT mice and other regulatory 
mechanisms may be involved in these differences, in part. In renal AT2 receptor expression ofTg­
WT mice, in spite of a significant increase in renal AT2 mRNA levels, comparable protein content 
was observed. Along with renal AT2 function, little is known about regulation of the renal AT2 
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gene in hypertensive models. Our results was consistent with previous study showing that renal 
AT2 receptor protein expression was not altered in hypertension models (34). Altogether, blood 
pressure effects of adipose agt overexpression observed in Tg-WT mice appears to be in part 
mediated by elevated systemic agt and activation of renal RAS, providing potential mechanisms 
responsible for obesity-associated hypertension. It is important to point out that with respect with 
blood pressure mechanisms, adipose RAS differs from kidney or brain RAS; kidney or brain­
induced blood pressure regulation is independent of endocrine RAS (45, 55). We also cannot 
preclude the possibility that blood pressure effects of adipose agt overexpression may also result 
from the combined effects of intrarenal Ang Il, activation of other local RAS such as brain and 
systemic RAS. 
Massiera et al showed that Tg-KO mice reexpressing agt only in adipose tissue exhibit 
1.5-fold fat mass increase and have intermediate blood pressure. Notably, targeted agt expression 
on adipose tissue was able to reverse renal structural abnormalities and dysfunction as well as 
altered blood pressure seen in KO mice with partial restoration of systemic agt concentrations at 
20%-30% of those ofWT mice (15). In Tg-KO mice, maintained AT! and increasedAT2 protein 
levels were observed in adipose tissue compared with WT mice. On the basis of previous studies, 
this observation may be in part due to partial restoration of the negative feedback effect oflocally 
produced Ang II in adipose tissue ofTg-KO mice. Of note, in comparison with Tg-WT mice, Tg­
KO mice displayed significantly decreased renal ATl protein levels despite the fact that sole 
reexpression of agt in adipose tissue was sufficient to correct altered systemic blood pressure seen 
in KO mice. This finding reflects that adipose agt influence of blood pressure in these animals 
may be at least partly mediated via partial restoration of systemic agt levels rather than 
stimulation ofrenal ATl-mediated hypertensive effects observed in Tg-WT mice although exact 
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mechanisms need further investigation. Further, increased renal AT2 gene and protein levels as 
well as increased renal renin mRNA and ACE mRNA were observed in these mice compared with 
WT mice. Of note, altered renin gene expression in KO mice was nearly normalized by 
reexpression agt only in adipose tissue. In addition, microarray results also presented evidence 
that adipose tissue-specific agt restoration can partially normalize altered expression of genes 
associated with renal function and development in KO mice. These results support previous 
studies showing that reexpression of adipose agt was capable of correcting renal abnormalities 
such as hydronephtosis (14). Evidence from other genetic models of hypertension has 
demonstrated that brain-specific restoration of human Ang II, multi-tissue restoration of human 
agt or systemic expression of human agt and renin genes in numerous tissue except targeted 
restoration of agt only in the kidney prevent renal anomalies observed in agt-deficient mice, 
suggesting that extra-renal tissue RAS activation is required for renal development and function 
(40-42, 45, 46). Taken together, our results support that adipose RAS play pivotal roles in renal 
function and development in an endocrine manner. 
In summary, using agt knockout and transgenic models, we confirmed the positive 
association of systemic blood pressure with increased fat mass. Further, we provided potential 
mechanisms responsible for endocrine effects of adipose agt using knockout and transgenic 
animal models. Adipose agt overexpression potentiates argumentation of systemic Ang II which 
further activated renal RAS in a tissue-specific manner, thereby contributing to the development 
of hypertension in T g-WT mice whereas adipose tissue-specific restoration of agt may affect 
renal function and development through restoring altered expression of genes associated with 
renal regulation. Collectively, adipose RAS plays pivotal roles in renal and adipose function and 
potentially development as well as obesity-associated hypertension via an endocrine mechanism. 
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PART Vil 
SUMMARY AND CONCLUSION 
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The findings of this dissertation provide new insights into possible mechanisms 
responsible for paracrine and endocrine actions of Ang II in modulating adiposity and 
hypertension associated with obesity. Previously, the components of the RAS were shown to be 
expressed in the adipose tissue and appear to be upregulated in obesity which is associated with 
enhanced plasma agt levels. Genetic and biochemical studies demonstrate functional roles of 
local adipose RAS in adipocyte differentiation and possibly in body-fat accumulation. Further, 
precious data from our lab indicate a pivotal role of Ang II in lipid metabolism in adipose tissue. 
However, no studies have evaluated the molecular or signaling mechanisms mediating Ang II 
regulation of adipocyte gene expression. We demonstrated that Ang II plays a paracrine role in 
regulation of adipocyte metabolism by upregulating a lipogenic gene, namely FAS iir a glucose 
and ADDl/SERBPlc-dependent manner. This effect of Ang II in adipocytes was mediated by its 
receptor-mediated crosstalk with insulin signaling molecules. These results illustrate the 
involvement of adipose RAS in the development of obesity. Using agt knockout and transgenic 
mouse models, our in vivo findings confirmed the lipogenic effect of adipose agt on adipose 
tissue metabolism and also demonstrated endocrine actions of adipocyte agt on kidney function. 
Obesity is an increasingly prevalent condition associated with a large number of 
comorbid diseases, one of the most important of which is obesity-related hypertension. Weight 
gain was shown to be a significant factor in elevating arterial pressure in many essential 
hypertensive patients although precise mechanisms for obesity-induced hypertension remain 
elusive. Taken together with clinical studies showing upregulation of RAS genes in adipose tissue 
of obese hypertensive subjects, genetic manipulation approaches of RAS have provided the 
evidence for a possible role of adipose RAS in altering systemic blood pressure; an associated 
elevation in blood pressure combined with increased fat mass in the transgenic mice 
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overexpressing agt in adipose tissue. Our data further demonstrate that reexpression of adipose 
. agt reverses the pattern of expression of genes associated with blood pressure regulation and renal 
function in agt knockout mice and support important endocrine functions of adipose RAS. 
Importantly, our findings indicate that adipose agt contributes to the development of hypertension 
in obesity by activation of local renal RAS in Tg-WT mice (Fig 1 ). 
On the other hand, obesity predisposes to insulin resistance and further type 2 diabetes. 
There has been some evidence to support a potential link of agt polymorphism to insulin 
resistance. In line with this, clinical trial studies show that inhibition of RAS improves insulin 
sensitivity. Our result demonstrating that adipose agt inactivation improves insulin sensitivity 
supports this notion. This implicates a possible role of adipose RAS in the development of insulin 
sensitivity and diabetes. To further ascertain and confirm the above paracrine and endocrine 
actions of the adipose agt, it would be important to engineer mouse models where agt is 
specifically inactivated in adipose tissue (such as using ere-lox recombinase tissue specific 
systems) and determine the impact of the inactivation on adiposity, blood pressure and insulin 
sensitivity. 
The significance of this research is to help to develop treatments of obesity and 
hypertension in obese patients. Accordingly, blockade of RAS components (e.g. antagonists of 
AT 1 receptor and ACE) might be an effective therapeutic approach to prevent the development of 
obesity and obesity-associated metabolic alternations including insulin resistance and diabetes. In 
addition, this present study unraveling the mechanisms by which weight gain raises blood 
pressure provides a better understanding of human essential hypertension. Further studies are 
needed to more fully elucidate the quantitative importance of these mechanisms that influence the 
risk of hypertension in obese subjects. 
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Fig. 1 Mechanisms of paracrine and endocrine actions of Ang IL In paracrine effects of Ang II,
Ang II binds to AT1/AT2 receptors and increases ADDl and FAS gene expression via activation of PI-3K­
Akt signaling pathways. In endocrine effects of Ang II, adipose agt is secreted into the circulation, thus 
increasing systemic agt levels as well as acts on kidney and elevates renal agt and AT 1 expression, 
activating renal RAS and thus increasing systemic blood pressure 
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A. GeneChip Microarray assay and Data Analysis
Total RNA from kidneys of KO and Tg-KO mice maintained on a Chow Diet (CD) was 
isolated by the cesium chloride density gradient method and further purified by phenol 
chloroform extraction. Microarray analysis was conducted using the Affymetrix Murine Genome 
U74v2 set that contains probe sets interrogating approximately 36,000 full-length mouse genes 
and EST clusters and was performed at the Genome Explorations Inc. in Memphis, TN. Kidneys 
from four to six KO or Tg-KO mice were used and pooled into 2 sets of each genotype (Fig 1 ). 
Total renal RNA (-20µg) from each of these genotypes was reverse-transcribed and the 
phycoerythrin dye was incorporated to the second strand. cRNA was synthesized from cDNA and 
biotinylated and hybridized to a set ofMurine genome GeneChips. Following hybridization and 
washing, the overall fluorescence intensity across each chip was scaled to a target intensity of 
1500 using Affymetrix GeneChip Microarray Suite 5.0 software, and pairwise comparisons of 
mRNA levels were performed. Each experiment was performed twice in each genotype and a 
minimum expression ratio of 2-fold differences was used as the selection criteria for the 
differentially expressed genes between the KO (2 sets) and Tg-KO mice (2 sets). The fold 
changes in gene expression are presented as the mean of four datasets which are associated with 
renal function and blood pressure regulation. 
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+ 
Check each RNA quality and quantity(4-6 samples for each gemtype) 
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Degraded RNA samples discarded 
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2 datasets/ each genotype 
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�
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{
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Group Dataset 2: Ml vs K02 Dataset2: Wrl vs Tg-K02 Dataset2: Wrl vs Tg-WT2 
Comparisons Dataset 3: Wf2 vs Kot Dataset3: M'2 vs Tg-KOl Dataset3: Wf2 vs Tg-M'2 
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+ 
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duplicates/genotype) 
Fig. 1 Flow chart for GeneChip microarray experiments and data analysis. 
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B. GeneChip Microarray assay and Data Analysis
Total RNA from kidneys of WT, KO, Tg-KO and Tg-WT mice maintained on a chow 
diet was isolated by the cesium chloride density gradient method and further purified by phenol 
chloroform extraction. Microarray analysis was conducted using the GeneChip® Mouse 
Expression Set 430A that contains probe sets interrogating approximately 14,484 full-length 
mouse genes and EST clusters and was performed at the Genome Exploration Inc. in Memphis, 
TN. Kidneys from four to six WT, KO, Tg-KO or Tg-WT mice were used and pooled into 2 sets 
each genotype (Fig 1). Total renal RNA (-20µg) from each of these genotypes was reverse­
transcribed and the phycoerythrin dye was incorporated to the second strand. cRNA was 
synthesized from cDNA and hybridized to a set of Murine genome GeneChips. Following 
hybridization and washing, the overall fluorescence intensity across each chip was scaled to a 
target intensity of 1500 using Affymetrix GeneChip Microarray Suite 5 .0 software. Each 
experiment was performed twice in each genotype and a minimum expression ratio of2-fold 
differences was used as the selection criteria for the differentially expressed genes between WT 
mice (2 sets) and KO (2 sets), Tg-KO mice (2 sets) and Tg-WT mice (2 sets). The fold changes in 
gene expression were presented as the mean for the four datasets in each comparison which are 
associated with renal function and blood pressure regulation. 
Microarray data of four genotype mice were analyzed using GeneSifter.Net™ (VizX Labs LLC, 
Seattle, WA, www.vizxlabs.com). Only genes with a fold change greater than 2 that passed spot 
quality filtering were included in the analysis. The resultant gene list was further analyzed by 
partition clustering using PAM (partitioning around medioids) to separate genes into similar 
expression profiles. Gene ontology reports (Biological Process, Cellular Component, and 
Molecular Function) were also generated using GeneSifter.Net™. The three distinct clusters were 
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selected to analyze endocrine effects of adipose agt in renal gene regulation; I) the cluster is 
composed of genes which are downregulated by agt inactivation but corrected by agt reexpression 
in only adipose tissue 2) the cluster is composed of genes which were upregulated in the KO mice 
but normalized toward wild-type levels by reexpression of agt in only adipose tissue 3) the cluster 
reveals genes which were upregulated by overexpression of agt in adipose tissue compared with 
Wf mice. Microarray data for these knockout and transgenic mice are explained by the following 
section. 
1. Effects of Adipose agt on mRNA Expression Levels of Renal RAS Components
Using affymetrix micro array analysis, we also examined the effects of adipose agt on 
gene expression of renal RAS. A minimum differential expression ratio of2-fold was used as 
selection criterion for differentially expressed genes between the KO, Tg-KO, Tg-WT and Wf 
mice, respectively (Table 1). In comparison with expression pattern ofrenal agt protein, Tg-WT 
mice showed an increased agt gene expression by approximate 1.6-fold compared with Wf mice, 
although this value was not statistically significant ( data not shown). Consistent with previous 
studies demonstrating abnormalities of RAS component gene expression in hypotensive agt null 
mutant mice (1-3), KO mice had significantly higher renal renin, ACE andAT2 mRNA 
expression levels than WT mice. Tg-KO mice reexpressing adipose agt exhibited similar 
expression levels of ACE and AT2 genes compared with KO mice, but higher mRNA levels of 
renin,ACE andAT2 than WT mice. In Tg-Wf mice, renin andAT2 receptor gene expression 
were significantly increased compared with Wf mice but ACE expression was similar to that of 
WT mice. 
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Table 1. Gene expression of RAS components in the renal tissue, showing� 2-fold differences 
in levels between 28 week-old KO, Tg-KO, Tg-WT and WT mice, respectively 
G'"" Accession Foul Clsangt1S in Exprm.Jion 
Numher 
KOnWT T1:-KOnWT T&-WTt'sWT 
Renin 1 NMD31192 
structural 
t (20.8) t (2.3) t (l.5) 
An&iotensin M55333 t (2.6) t (2.5) -(Ll) 
conTertin& 
enzyme 
An&iotensin II, MN007429 
type 2. receptor 
t (2.2) t (l.6) t (4.6)
l : Increase, ! : Decrease, ( ): Fold changes expressed as Mean
2. Effects of Adipose agt on Global Renal Gene Expression
We and others previously demonstrated that transgenic replacement of adipose agt 
was able to correct renal structural abnormalities and altered expression of genes associated 
with blood pressure regulation and renal function ( 4, 5). To further define endocrine effects of 
adipose agt on the global expression profile of renal genes involved in renal function, 
development and blood pressure homeostasis, expression analysis was first performed with 
total RNA isolated from renal tissue of these four mouse genotypes using oligonucleotide 
microarray analysis. Resulting data were analyzed by GeneSifter.Net™ software including 
cluster analysis, which groups genes with similar expression pattern and gene ontology, which 
is then used to assign the regulated genes into functional categories. Three distinct clusters were 
selected to elucidate the endocrine influence of adipose agt on renal gene regulation in these 
mice. 
The results from cluster analysis showed that two clusters were composed oftwenty­
one genes that were dysregulated threefold or more in agt null mice, which are specifically 
corrected toward wild-type levels by restoration of adipose agt (Fig 2 & 3). Fig 2 shows that the 
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i�rsa·-- .. - ..... . . ·... 
! .. '=" . .. 
� Wf KO Tg-KO 
0 
:.:: 
� � � 
-- Catalytic activity (36.311%) 
RJKEN cOOA S730583K22 gene (NM01!5164} 
<ild&hyda dehydrogenas8 faniy 1, sli>famiy A (NM013461} 
protein mase C, n, fNM008Bt!i8J 
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maim� 19 �Ffl53mJ 
Fig. 2 The cluster of genes specifically suppressed in KO renal tissue and functional 
classification of the downregulated genes. We investigated adipose agt effects on the kidney gene 
expression profile using oligonucleotide microarray analysis. The resulting data were further analyzed by 
GeneSifter.Net™ software including cluster analysis and gene ontology which is used to assign the 
regulated genes into functional categories. The results showed that genes suppressed in agt knockout renal 
tissue were normalized by sole reexpression of agt in adipose tissue. These genes are involved in binding 
and catalytic processes or transcription regulation. Gene names are given along with Genebank accession 
numbers 
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Fig. 3 The cluster of genes specifically upregulated in KO renal tissue and functional 
classification of the up regulated genes. We investigated adipose agt effects on the kidney gene 
expression profile using oligonucleotide microarray analysis. The resulting data were further analyzed by 
GeneSifter.Net™ software including cluster analysis and gene ontology, which is used to assign the 
regulated genes into functional categories. The results showed that genes upregulated in renal tissue of KO 
mice were normalized by sole reexpression of agt in adipose tissue. These genes are involved in binding 
and catalytic processes, transcription regulation, signal transduction cascade or ion transport. Gene names 
are given along with Genebank accession numbers. 
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seven genes that were downregulated 3.5-fold in agt knockout mice were corrected in Tg-KO 
mice to levels approaching those in WT mice. As anticipated, alterations in expression of Ang II 
signaling molecules were observed in agt knockout mice. Particularly, expression of protein 
kinase C, which was shown to play a role as an important mediator in Ang II-induced 
hypertrophic action associated with vascular remodeling, was significantly decreased in KO 
mice characterized by renal structural and vascular abnormalities (e.g. hypoplastic renal papilla) 
but adipose agt reexpression restored this expression level to that of wild-type mice ( 6). This 
supports the previous study demonstrating that Ang II plays a critical role in renal function and 
development. Of these 7 genes with known functions, the majority corresponded to genes 
coding proteins involved either in binding (45.4 %), catalytic activity (36.3%) or transcriptional 
regulation (18.1 %). Fourteen of the 21 genes were upregulated approximately 3-fold in KO mice 
and significantly corrected toward wild-type expression levels by reexpression of adipose agt 
(Fig 3). Similar to results of previous studies, a substantial increase in the levels of renin mRNA 
in the kidney was found in agt deficient mice (1, 3). This altered renin expression was partially 
normalized in Tg-KO mice. Of interest, upregulation of hepatic nuclear factor 4 (HNF 4) gene, 
which was demonstrated to be one of the transcription factors involved in the regulation of agt 
gene transcription, was observed in KO mice but targeted restoration of agt only in adipose 
tissue in these mice returned this altered expression to the level observed in WT (7, 8). The 
expression of other transcription factors like POU domain, class 2, transcription factor 2 and 
zinc finger protein 40 was also significantly increased by agt inactivation and their altered 
expression levels were corrected by targeted adipose agt reexpression. Expression in genes 
associated with development such as paired-like homeobox 2b and protein tyrosine phosphatase, 
non-receptor was increased in agt null mice but these levels was nearly equivalent to those of 
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WT mice by restoration of adipose agt. Gene ontology reports revealed that this cluster 
contained genes which are involved in transcription regulation (19.23 %), signal transduction 
(7.69%), binding (34.6%), catalytic activity (30.7 %) or transport (3.85%). Another cluster 
consisted of genes that were upregulated approximately 5-fold by overexpression of adipose agt 
compared with those of WT mice. Table 2 presents forty-five out of eighty-eight genes, which 
have known functions. An analysis of the genes in this cluster demonstrated that adipose agt 
overexpression specifically increased the expression of genes responsible for ion transport and 
channel, signal transduction, transcription regulation, cell growth and apoptosis in renal tissue of 
Tg-WT mice. Specifically, Tg-WT mice displayed upregulation ofrenal ion channel and 
exchanger genes like W-ATPase and K channel which was known to be involved in blood 
pressure homeostasis (9, 10). Consistent with previous findings that Ang II stimulates the 
expression and production of plasminogen activator inhibitor- I (P AI-1; serine proteinase 
inhibitor, clade B, member 2) in vascular and adipose tissues, thereby emphasizing its potential 
prothrombotic effects, a significant increase in PAI- lgene expression was also observed in renal 
tissue of Tg-WT mice (11-13). This supports additional functional roles for Ang II in 
hypertension-associated renal disease progression (6). 
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Table 2. Effects of adipose agt overexpression on renal regulation We invest
tigated adipose agt effects on the kidney gene expression profile using oligonucleotide microarray analysis. 
The resulting data were further analyzed by GeneSifter.Net™ software including cluster analysis and gene 
ontology, which is used to assign the regulated genes into functional categories. The presented genes are 
upregulated in renal tissue ofTg-WT mice compared with WT mice and associated with renal function and 
blood pressure regulation. Gene names are given along with Genebank accession numbers 
.. 
I I.F1,1,11cJj_on,. , > Acce$sion Number Gene .·.· .: ' i ·.· I·• . 
Metabolic function AI195046 RIKEN cDNA 2410027J01 gene 
M30774 Thymidylate synthase 
NM010455 Homeo box A7 
AB032770 Myeloid/lymphoid or mixed lineage-leukemia 
translocation to 7 homolog 
BB284199 Thioredoxin reductase 1 
NM023894 Placenta specific homeobox 2 
B8166592 Topoisomerase (DNA) II beta 
NM009548 Zinc finger protein 179 
NM009990 Cytoplasmic linker 2 
BC018323 D site albumin promoter binding protein 
BC014718 Deoxyribonuclease I 
AW741575 Histone 1, Hie 
NM028094 RIKEN cDNA 2010321J07 gene 
NM009171 Serine hydroxymethyl transferase !(soluble) 
AK.017701 Karyopherin (importin) beta 3 
AK.008023 Protease, serine, 3 2 
AK.017573 Mitochondrial translation optimization 1 
homolog 
NM0l l l l l  Serine ( or cysteine) proteinase inhibitor, clade 
B, member 2 
BE553261 RIKEN cDNA 2810457M08 gene 
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Table 2. Continued 
Fun,:don 
'.�-. . �; ,,,.,,. ,,,: ,l ii', 
,,, 
�1, ·" ; Accession iRr; Gene 
Number ,, · .... t\zt;,;;] \,'®: .,.,,, ,  ,, , 
Metabolic AA543265 Heat shock protein A 
function AI327006 Cytochrome P450, family 4, subfamily a, polypeptide 14 
BM117916 Xeroderma pigmentosum, complementation group A 
NM008792 Proprotein convertase subtilisin/kexin type 2 
Cell growth 8B19683 Sarcoglycan, gamma { dystrophin-associated glycoprotein) 
(Skeleton and B8538661 RIKEN cDNA El30012P22 gene 
adhesion) NM007605 Capping protein alpha 3 
AV341395 Calsyntenin 3 
Transport AV238793 Apoptosis, caspase activation inhibitor 
NM008218 Hemoglobin alpha, adult chain 1 
AK004157 ATPase, H+ transporting, Vl subunit C, isoforms 2 
NM011395 Solute carrier family 22 {organic cation transporter), 
member3 
BC018335 Solute carrier family 15 {H+/peptide transporter), member 
1 
AV309591 ATP-binding cassette, sub-family F {GCN20), member 1 
NM023782 Solute carrier organic anion transporter family, member 
la6 
BC001995 ATPase, H+ transporting, lysosomal V 0 subunit a isoforms 
1 
AF319542 Potassium channel, subfamily K, member 5 
NM0019640 Phosphotidylinositol transfer protein, beta 
Signal NM007557 Bone morphogenetic protein 7 
transducer NM020490 Leukotriene B4 receptor 2 
and BC011215 Histocompatibility 2, Q region locus 10 
transcription BE852312 RIKEN cDNA 1700001C14 gene 
regulator NM009491 Vomeronasal 2, receptor 16 
NM008883 Plexin A3 
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Table 2. Continued 
T <Fi'11ctioh :; . .... .... Accession N.umbt!� ··•···· f .. l;efte :.t: i l0\ �: 11jj iti·0; j<
Signal transducer NM007429 Angiotensin II receptor type 2 
and transcription NM009548 Zinc finger protein 179 
regulator NM011746 Makorin, ring finger protein, 3 
BB024536 Growth hormone releasing hormone 
receptor 
Stress response AA543265 Heat shock protein, A 
AF349142 Immunoglobin heavy chain 4 (serum 
IgGl) 
Apoptosis AV238793 Apoptosis, caspase activation inhibitor 
NM007544 BH3 interacting domain death agonist 
BC 014718 Deoxyribonuclease I 
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